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Abstract 
 
 The Nuclear Receptor Coactivator 4 (NCOA4) gene (also known as 
RFG/ELE1/ARA70) is frequently targeted by chromosomal rearrangements in 
papillary thyroid carcinoma (PTC). These events join the N-ter (exons 1-5, 
encoding amino acids 1-238) of the NCOA4 gene to the DNA sequence encoding 
the tyrosine kinase (TK) domain of the receptor tyrosine kinase RET, generating 
the RET/PTC3 chimeric gene, whose protein product displays oncogenic activity. 
The NCOA4 N-ter mediates homodimerization of the RET TK domain, followed 
by RET kinase activation and, in turn, gain of transforming activity. Disruption of 
NCOA4 gene might contribute to the neoplastic phenotype as well, however to date 
no cellular phenotype has been associated with NCOA4 deficiency. To gain insight 
into the physiological function of NCOA4, we disrupted NCOA4 in mice. NCOA4-
deficient mice did not exhibit any apparent phenotypic alteration. However, when 
grown at 20% O2, NCOA4-/- mouse embryonic fibroblasts (MEFs) undergo 
premature senescence, characterized by block of cell proliferation and BrdU 
incorporation, as well as SA(senescence-associated)-β-galactosidase positive 
staining. This phenotype is associated with accumulation of DNA damage and 
activation of a DNA damage response (DDR). Using a fiber stretching assay, that 
monitors DNA replication fork progression, we show that NCOA4-depleted cells 
accumulate replication fork stalling lesions and feature increased DNA replication 
origin activation. In addition, NCOA4-/- MEFs, grown at 3% O2 concentration, 
feature increased sensitivity to genotoxic stress, particularly that induced by S-
phase specific DNA damaging agents. In conclusion, these findings highlight a 
novel role for NCOA4 in the prevention of replication stress, DNA damage, and 
premature senescence and, thus, in the maintenance of genome stability. Loss of 
such NCOA4 function may contribute to thyroid cancer formation. 
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1. Background  
 
 
1.1 Thyroid cancer 
 
 Thyroid cancer is the most frequent endocrine malignancy and represents 
around 1% of newly diagnosed cancers (Hundahl et al. 1998; Gimm 2001), with an 
incidence stably increasing over the last decades (Jemal et al. 2010). It comprises a 
broad spectrum of neoplasms classified according to distinct clinical and 
pathological features (Kondo et al. 2006; DeLellis and Williams 2004; DeLellis 
2006) (Table 1). The great majority of thyroid tumors (∼ 95%) derive from 
follicular cells that synthesize and secrete thyroid hormones. The remainder derive 
from the parafollicular or C-cells that synthesize calcitonin. Thyroid follicular cell-
derived carcinomas are classified into: well differentiated thyroid carcinoma 
(WDTC), [which comprises papillary (PTC) and follicular (FTC) thyroid 
carcinoma], poorly differentiated (PDTC), and anaplastic (ATC) thyroid carcinoma. 
Medullary thyroid carcinoma (MTC) derives from parafollicular cells and 
represents a rare thyroid malignancy (3-5%). 
 PTC comprises 80-85% of all thyroid carcinomas and is characterized by a 
branching (papillary) architecture and specific nuclear features. Several PTC 
variants are recognized, including solid-follicular, follicular, tall-cell and hurthle 
cell with different pathological and clinical features (DeLellis 2006). PTC generally 
has an indolent behaviour, metastasizes prevalently at the local lymph nodal 
stations and has a survival rate greater than 90% (Schlumberger 1998; Sherman 
2003). However, some PTC cases lose the ability to concentrate iodine and become 
resistant to radio-iodine mediated ablation. 
 FTC is defined as a tumor with follicular cell differentiation in the absence 
of the nuclear diagnostic features of PTC (DeLellis 2006). ATC is the rarest tumor 
of the thyroid gland (2-3%). Despite this, ATC represents the first cause of death 
for thyroid cancer. Morphologically, it is defined as a malignant tumor composed 
entirely or partially of undifferentiated cells (DeLellis 2006). PDTC is defined as a 
neoplasm of follicular origin, with limited evidence of follicular cell differentiation 
(DeLellis 2006); PDTC is considered, morphologically and clinically, as an 
intermediate lesion between WDTC and ATC. MTC comprises both sporadic (∼ 
75%) and familial (∼ 25%) cases in the context of the autosomal dominant MEN2 
syndromes (Marx, 2005). 
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Table 1: Classification of thyroid carcinomas (modified from Kondo et al. 2006) 
 
 
 
 
 
1.2 Genetic alterations in thyroid carcinoma 
 
 In the last two decades, some genetic lesions that underlie thyroid follicular 
cell transformation have been unveiled, including genetic alterations that initiate 
WDTC and those responsible for the progression to PDTC and ATC (Table 2). 
Around 70% of PTC is associated with two kind of genetic lesions:  oncogenic 
rearrangements involving RET (REarranged during Transfection) and NTRK1 
(Neurotrophic Receptor-Tyrosine Kinase 1) and point mutations in BRAF gene 
(Table 2). Importantly these genetic lesions are mutually exclusive and activate a 
common signal transduction pathway, the MAPK (Mitogen-Activated Protein 
Kinases) one, that leads to cellular proliferation, survival and motility (Melillo et al. 
2005). NTRK1 is a tyrosine kinase receptor that binds NGF (Nerve Growth Factor); 
in PTC, NTRK1 undergoes chromosomal rearrangements leading to its oncogenic 
activation (Greco et al. 2010). Such rearrangements involve principally three fusion 
partners (TPR, TPM3 and TFG) (Greco et al. 1993; Greco et al. 1995; Greco et al. 
1997). BRAF is a serine-threonine kinase that transduces regulatory signals through 
the MAPK pathway. In PTC, BRAF can be activated by point mutations within the 
kinase domain, the most frequent being a transversion from thymine to adenine at 
nucleotide 1799 (T1779A), resulting in the substitution of a glutamic acid for a 
valine at position 600 (V600E). BRAF mutations are found in 29-69% of PTCs 
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(Ugolini et al. 2007). Transgenic mice expressing BRAFV600E develop thyroid 
carcinomas that closely recapitulate PTC features in humans, showing an 
aggressive behaviour and progression to PDTCs (Knauf et al. 2011). Thus, BRAF 
mutations correlate with tumor recurrence, reduced radioiodine concentration and 
decreased overall survival (Lupi et al. 2007; Elisei et al. 2008; Xing 2010). 
 FTC develops through two main different pathways, involving either RAS 
or PPARγ (Peroxisome Proliferator-Activated Receptor gamma) (Table 2). RAS 
family members are small GTP-ases activating the MAPK pathway and are 
frequently mutated in cancer. RAS point mutations in codons 12, 13 and 61 are 
found in FTCs, in the follicular variant of PTC (Zhu et al. 2003; Kondo et al. 2006) 
and in PDTC and ATC suggesting a role for RAS mutations in thyroid tumor 
progression (Garcia-Rostan et al. 2003; Volante et al. 2009). PPARγ is a member of 
the nuclear-hormone-receptor superfamily and forms heterodimers with the retinoid 
X receptor. Some FTC harbour a rearrangement (PPFP: PAX8-PPARγ) mediated 
by a translocation between PAX8, a thyroid specific transcription factor, and 
PPARγ (Eberhardt et al. 2010). In PPFP, the DNA binding domain of PAX8 is 
fused to the A-F domains of PPARγ. The resulting chimeric protein acts as a 
dominant negative PPARγ and displays oncogenic properties (Kroll et al. 2000; 
Castro et al. 2006). PI3KCA mutation or gene amplification have been also 
reported in some FTCs (Garcia-Rostan et al. 2005; Liu et al. 2008).  
 PDTC and ATC share genetic lesions with WDTC, consistent with the 
hypothesis of a multi-step carcinogenesis model for thyroid cancer. Some PDTC 
and ATC present BRAF mutations, particularly samples with morphological 
evidence of pre-existing PTC (Nikiforova et al. 2003; Soares et al. 2004; Begum et 
al. 2004). In PDTC and ATC are also frequently detected point mutations of RAS 
(Garcia-Rostan et al. 2003; Volante et al. 2009) as well as amplifications or point 
mutations of PI3KCA (Garcia-Rostan et al. 2005; Liu et al. 2008). However, 
differently from WDTC, around 70% of ATC and a significant fraction of PDTC 
shows point mutation of TP53 (Nikiforov 2004, Kondo et al. 2006) or p53 
disfunction induced by other mechanisms, including upregulation of  negative p53 
regulators like HMGA1, ∆Np73 or HDM2 (Pierantoni et al. 2007; Malaguarnera et 
al. 2007). Furthermore, ATC and to a lesser extent PDTC are associated with point 
mutation in exon 3 of the CTNNB1 gene encoding  β-catenin (Garcia-Rostan et al. 
2001), suggesting a role for this gene in the loss of differentiation of thyroid 
tumors. 
 MTC, as previously mentioned, can be sporadic (75%) or familial in the 
context of the autosomal dominant cancer syndromes MEN2 (Multiple Endocrine 
Neoplasias 2) (MEN2A, MEN2B and FMTC) (Marx 2005). RET point mutations 
are associated to both sporadic (50%) and familial (virtually 100%) MTC cases 
(Elisei et al. 2008). In MEN2A, mutations target extracellular cysteine residues of 
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RET, while MEN2B is associated predominantly with the Met918Thr intracellular 
substitution involving  the tyrosine kinase domain (Leboullex et al. 2004). 
Recently, RAS mutations have been described in RET-negative sporadic MTC 
(Moura et al. 2011). 
 
 
Table 2: Genetic alterations in follicular cell-derived thyroid carcinomas (modified 
from Kondo et al. 2006) 
 
 
 
1.3 RET/PTC rearrangements 
 
 The REarranged during Transfection (RET) gene was discovered in 1985 by 
Takahashi and coworkers as a proto-oncogene activated by DNA rearrangements 
(Takahashi et al. 1985). RET is located on the long arm of chromosome 10 
(10q12.2) and encodes a transmembrane receptor tyrosine kinase that binds to 
growth factors of the glial-cell line-derived neurotrophic factor (GDNF) family 
(Manie' et al. 2001). RET protein is composed by 4 functional domains: an 
extracellular ligand-binding portion with four cadherin like and a juxtamembrane 
cysteine rich domain, a hydrophobic transmembrane segment, an intracellular 
tyrosine kinase domain and a COOH-terminal tail. Binding of the ligand induces 
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receptor dimerization, autophosphorylation of target tyrosine residues which 
function as binding sites for signalling molecules cointaining phosphotyrosine-
binding motifs (SH2 or PTB), and the activation of several signalling pathways 
(Santoro et al. 2004). RET is normally expressed in the central and peripheral 
nervous system and is required for renal organogenesis, enteric neurogenesis and 
spermatogenesis (Schuchardt et al. 1994). RET is normally expressed at high levels 
in C-cells, but not in follicular cells (Santoro and Carlomagno 2006). 
 About 30% of PTC harbour oncogenic rearrangements, induced by 
chromosomal inversions or translocations, in which the tyrosine kinase domain of 
RET is fused in frame with the 5'-portion of several gene partners leading to the 
formation of the chimeric RET/PTC oncogenes (Fusco et al. 1987; Grieco et al. 
1990). The presence in the gene partners of coiled-coil domains causes a 
constitutive dimerization and kinase activation of the rearranged RET/PTC 
oncoprotein. In addition, RET/PTC becomes ectopically expressed in thyrocytes, 
loses RET protein domains that negatively regulate its kinase activity  (like the 
extracellular domain) and relocalizes to the cytoplasm. RET/PTC rearrangements 
are particularly common in PTC from patients exposed to ionizing radiation and in 
pediatric PTC (Nikiforov et al. 1997). More then ten different RET/PTC 
rearrangements have been reported differring in the RET fusion partner (Figure 1). 
RET/PTC1 and RET/PTC3 involving genes CCDC6, previously known as 
H4(D10S170) (Grieco et al. 1990), and NCOA4 (also known as 
RFG/ELE1/ARA70) (Santoro et al. 1994; Bongarzone et al. 1994) respectively, 
constitute more then 90% of the total.  
 RET/PTC3 is formed by the fusion of the tyrosine kinase domain of RET with 
the first 238 aminoacids of the NH2 portion of NCOA4. RET/PTC3 results from a 
paracentric inversion of the long arm of chromosome 10 and it has a high 
prevalence in post-Chernobyl pediatric PTC (Nikiforov et al. 1997). Furthermore, 
RET/PTC3 is associated with more aggressive PTC variants like the solid-follicular 
and tall-cell ones (Basolo et al. 2002). 
 Oncogenic activation of RET in RET/PTC rearrangements represents a major 
mechanism explaining the tumorigenic properties of this chimeric oncoprotein. 
However, it cannot be excluded that the genetic alteration of the  partner genes 
might contribute to the transformation as well. For instance, in the case of 
RET/PTC2 rearrangement that involves the regulatory subunit type 1-α of the 
protein Kinase A (RIα) it is possible that loss-of-function of RIα is involved in 
tumorigenesis (Bongarzone et al. 1993). Indeed, RIα is a bona fide tumor 
suppressor since its germline inactivating mutations are responsible for an inherited 
neoplastic syndrome, the Carney complex, featuring predisposition to develop 
several neoplasias comprising thyroid cancer (Bossis and Stratakis, 2004). 
Furthermore, RIα depletion in mice induces the formation of thyroid tumors 
(Griffin et al. 2004).  
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 Along this line, multiple evidences suggest that other RET partner genes in 
RET/PTC rearrangements might play a role in tumorigenesis. In particular, CCDC6 
(Coiled-coil domain-containing protein 6), which is involved in the formation of 
RET/PTC1, has been recognized as a target of the DNA Damage Response (DDR) 
kinase ATM and to function as a apoptosis mediator. ATM-mediated 
phosphorylation of CCDC6 in response to DNA damage, promotes its nuclear 
accumulation and leads to apoptosis. Its alteration in RET/PTC1 transformed cells 
may, therefore, contribute to PTC development by impairing apoptotic response to 
DNA damage (Merolla et al. 2007).  Furthermore, CCDC6 has also been shown to 
interact with and repress the activity of the pro-proliferative transcription factor 
CREB1 by recruiting HDAC1 (Histone Deacetylase 1) and PP1 (Protein 
Phosphatase 1) at CRE (CREB responding elements) sites (Leone et al. 2010). 
Thus, CCDC6 disruption  may contribute to thyroid cell transformation mediated by 
the RET/PTC1 oncogene. Finally, other genes less frequently involved in RET/PTC 
rearrangements have beeen suggested to play a role in cancer development like 
HTIF1 (also known as TRIM24) (Khetchoumian et al. 2007) and TRIM27 (Dho & 
Kwon 2003). 
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Figure 1: RET/PTC rearrangements in papillary thyroid carcinoma 
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1.4 The NCOA4 (RFG/ELE1/ARA70) gene 
 
 The NCOA4 gene encodes an ubiquitously expressed 70-KDa protein. 
Initially identified as a gene rearranged with the tyrosine kinase receptor RET in 
PTC (Santoro et al. 1994; Bongarzone et al. 1994) and named RFG (Ret-fused 
gene) or Ele1, it was subsequently discovered as a co-activator of the androgen 
receptor (Yeh et al. 1996). NCOA4 is able to interact and promote the 
transcriptional activity of other nuclear receptors: the LXXLL motif (aa 92-96) and 
the FXXLF motif (aa 328-332) mediate its interaction with the peroxisome-
proliferator activated receptor γ (PPARγ) (Heinlein et al. 1999) and the androgen 
receptor (AR) (Hu et al. 2004) and estrogen receptor (ER) (Lanzino et al. 2005), 
respectively (Figure 2). Several evidences suggest a role for NCOA4 in 
tumorigenesis. NCOA4 expression is reduced in prostate cancer as well as in 
prostate cancer cell lines and its adoptive overexpression in prostate cancer cells 
reduces cellular proliferation and colony formation (Li et al. 2002; Tekur et al. 
2001). Moreover, its expression is also reduced in a subset of breast carcinomas, 
particularly in HER2+ samples (Kollara et al. 2001). Finally, genome mapping 
association studies linked the presence of SNPs at the 10q11 locus, harbouring 
NCOA4, with an increased susceptibility to prostate cancer (Chang et al. 2009; 
Pomerantz et al. 2010).  
 The NCOA4 protein contains a coiled-coil domain (aa 17-125) that 
mediates protein oligomerization (Monaco et al. 2001). Thus, one functional 
consequence of NCOA4-RET fusion (RET/PTC3) is NCOA4 mediated 
homodimerization of the RET tyrosine kinase domain followed by constitutive 
autophosphorylation and oncogenic activation. This is probably a major mechanism 
of the tumorigenic role of RET/PTC3 rearrangement in thyroid cancer (Monaco et 
al. 2001). 
 However, disruption of the NCOA4 gene, as well as its inhibition by a 
dominant negative effect of RET/PTC3 oncoprotein may have a role in RET/PTC3-
mediated tumorigenesis. To study NCOA4 function in our laboratory a yeast-two-
hybrid screening was performed to identify new NCOA4 protein interactors. Using 
as a bait the N-terminal 238 aa of NCOA4, corresponding to the portion fused to 
RET gene in the RET/PTC3 rearrangement, two clones encoding the C-terminal 
portion of the MCM7 gene were isolated (Carlomagno et al. personal 
communication).  
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Figure 2: Structure of NCOA4 protein; domains mediating interaction with PPARγ 
(peroxisome-proliferator activated receptor γ), AR (androgen receptor) and ER 
(estrogen receptor) are shown. A vertical arrow indicates the breakpoint site in 
RET/PTC3 rearrangement. 
 
 
 
1.5 DNA replication 
 
 DNA replication is a complex multistep process whose accuracy is essential 
for the maintenance of genome stability (Bell and Dutta 2002; Branzei and Foiani 
2010) (Figure 3). DNA replication involves the stepwise formation of several 
protein complexes. Initially, the Pre-Replication Complex (Pre-RC) is assembled at 
replication origins in early G1 to license them (Chong et al. 1995; Kubota et al. 
1995; Tanaka et al. 1997; Yan et al. 1993). The pre-RC assembly starts with the 
binding of the six-subunit complex ORC (origin recognition complex) that allows 
the sequential binding of the licensing factors Cdc6 and Cdt1, necessary for the 
recruitment of the MCM2-7 complex and its stable loading onto chromatin as 
double hexamers (Remus et al. 2009). At this point, chromatin is "licensed" to be 
replicated (Chevalier and Blow 1996). Several mechanisms restrain these events to 
the G1 phase of the cell cycle, inhibiting MCM2-7 loading onto chromatin in S and 
G2 phases to avoid re-replication (Blow and Dutta 2005; Arias and Walter 2007). 
The principal one involves the activity of Geminin which inhibits Cdt1 by directly 
binding to it, protecting it from degradation and leaving it in an inactive form 
unable to further promote licensing (Wohlschlegel et al. 2000). Replication 
initiation depends on activation of the helicase function of MCM2-7 by 
phosphorylation of several components of the Pre-RC by Cyclin E/A-CDK2 (cyclin 
dependent kinase 2) and Cdc7/DDK (Dbf4 and Drf1 dependent kinase) during G1 
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to S phase transition (Pasero and Schwob 2000; Sclafani 2000). This event is 
referred to as “origin firing”. Cdc6 is then phosphorylated, released from chromatin 
and extruded from nucleus (Delmolino et al. 2001) while Cdt1 is subsequently 
degraded by a PCNA-coupled degradation pathway involving the Cul4-Cdt2 
ubiquitin ligase (Arias & Walter 2005; Jin et al. 2006) and by a Skp2-containing 
SCF complex after CDK-dependent phosphorylation (Li et al. 2003). Other 
replication factors, such as CDC45 and the GINS complex [Go(5)-Ichi(1)-Ni(2)-
San(3); tetrameric complex composed of Sld5, Psf1, Psf2, Psf3], bind to licensed 
origins to form the so called Pre-IC (Pre-initiation complex) or CMG (Cdc45-
MCM2-7-GINS) complex that represents the processive helicase that unwinds 
double strand DNA during replication. Subsequently, the CMG complex opens the 
replication bubble, allowing loading of the single-strand binding protein RPA, that 
stabilizes the single strand DNA and promotes the binding of DNA polα-Primase. 
In turn, DNA polα produces a short RNA/DNA primer recognized by the clamp 
loader, RFC. Finally, RFC recruits PCNA, the processivity factor of DNA 
polymerases. PCNA is a homotrimeric ring protein that encircles double strand 
DNA with a 3' free end allowing polymerase activation. DNA polα is replaced by 
DNA polδ and DNA polε, which display greater processivity and possess a 3'-5' 
proofreading exonuclease activity (Ritzi and Knippers 2000). At each replication 
bubble, the replication starts and proceeds bidirectionally, with helicase moving 
onto leading strand (Fu et al. 2011) to generate single strand and DNA polymerases 
elongating the nascent strand in 5’-3’direction. The MCM2-7 proteins gradually 
dissociate from chromatin as S-phase proceeds (Krude et al. 1996) and replication 
forks merge, consistent with their predicted function as a DNA helicase (Ishimi 
1997). 
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Figure 3 : A schematic representation of the main steps of DNA replication  
 
 
 
1.6 DNA damage, genome instability and cellular senescence 
 
 The primary objective for every life form is to deliver its genetic material, 
intact and unchanged, to the next generation (Jackson & Bartek 2010). Eukaryotes 
have to deal constantly with endogenous and exogenous sources of DNA damage 
that can affect genome integrity. An evolutionary conserved pathway senses DNA 
damage and relays this information by activating a signal transduction pathway, 
known as DNA damage response (DDR) (Figure 4). DDR halts cell cycle 
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progression to prevent the transmission of altered genetic material and coordinates 
cellular efforts to repair DNA and maintain genome integrity. DDR is robustly 
activated by double strand breaks (DSBs) or by RPA-coated single-stranded DNA.  
 DSBs are sensed by the Mre11-Rad50-Nbs1 (MRN) complex which 
recruits, through the C-terminus of Nbs1, the Ataxia-Teleangectasia mutated 
(ATM) kinase leading to its autophosphorylation and activation (Falck et al. 2005). 
Activated ATM phosphorylates the histone variant H2AX on Ser 139 (also known 
as γH2AX) at sites of damage to help recruitment of additional checkpoint proteins 
including MDC1 (Mediator of the DNA damage Checkpoint 1), which directly 
binds to phosporylated H2AX (Stucki et al. 2005), and 53BP1 (p53 Binding Protein 
1). MDC1 binds to and help recruitment of further MRN complexes that by 
spreading onto chromatin induce a positive loop that fosters DDR. Furthermore, 
MDC1 and 53BP1 induce the transient loading of the checkpoint kinase Chk2 
which is phosphorylated by ATM and then rapidly released from chromatin to 
activate the checkpoint.  
 On the other hand, RPA-coated single-stranded DNA leads to the 
recruitment of the ATR (ATM-related)-ATRIP (ATR-Interacting Protein) dimer 
(Zou and Elledge 2003), whose activity is boosted by the loading of the RAD9-
HUS1-RAD1 and Rad17-RFC complexes onto replication stalling lesions. ATR 
activity is also stimulated by its own target TOBP1, while Claspin is necessary for 
ATR-mediated phosphorylation of Chk1, which is then released to activate the 
intra-S-phase checkpoint (Smits et al. 2006).  
 Chk2 and Chk1 represent the checkpoint proteins responsible for the 
spreading of the DDR signalling cascade into the nucleus far away from the initial 
DNA-damage site. Finally, p53 and Cdc25 phosphatases are the ultimate effectors 
of this pathway and connect DDR signalling to the cell cycle machinery. In 
particular, p53 activates transcription of the cell cycle inhibitor p21 which halts cell 
cycle progression by inhibiting CDKs (Cyclin Dependent Kinases). Cdc25 family 
phosphatases, which normally activate CDKs during cell cycle progression, are 
inactivated either by degradation or nuclear extrusion induced by DDR. This cell 
cycle arrest can be transient and upon DNA damage repair cells can resume 
proliferation. However, if DNA damage is particularly severe cells may undergo 
apoptosis or enter a protracted DDR-induced cell cycle arrest known as cellular 
senescence (d'Adda di Fagagna 2008). 
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Figure 4: The DNA Damage Response (DDR). A schematic representation of the 
main players involved in the recognition of DNA damage and the transmission of 
the signal throghout the cell to activate effectors that halt cell cycle progression and 
favour DNA repair (modified from d'Adda di Fagagna 2008). 
 
 
 Senescent cells have been observed in vivo in mammals in association with 
normal ageing and with the first stages of tumorigenesis (Collado and Serrano 
2010; Bartkova et al. 2005; Braig et al. 2005; Gorgoulis et al. 2005). Indeed, 
cellular senescence is induced (in vivo and in vitro) by oncogene activation 
(Serrano et al. 1997) because of the induction of a hyperproliferative stress 
associated with replication stalling lesions and DDR activation (Di Micco et al. 
2006; Bartkova et al. 2006). Recently Kerem and colleagues suggested that 
oncogene-induced hyper-replication leads to a reduction in the nuclear nucleotides 
pool that causes replication failure inducing genetic instability (Bester et al. 2011). 
Whatever the mechanism, the so called oncogene-induced senescence (OIS) 
represents one of the principal barriers that restrain cancer development in vivo 
(Bartkova et al. 2006; Halazonetis et al. 2008). It has been suggested that breaches 
to this barrier, arising from mutational or epigenetic inactivation of DDR 
components, are subsequently selected for during tumor development, thus 
allowing malignant progression. This model for the DDR as an anti-cancer barrier 
helps explaining the high frequency of DDR defects in human cancer (Halazonetis 
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et al. 2008). Furthermore, oncogene-induced hyper-replication and DNA damage 
could explain the main hallmark of human cancer: e.g. genetic instability (Negrini 
et al. 2010) (Figure 5). 
 
 
 
 
Figure 5:  An oncogene-induced DNA damage model for cancer development.  
Oncogene-induced replication stress causes DNA damage and DDR activation to 
restrain tumor development. However, by favouring genetic instability, it promotes 
a selective pressure for p53 inactivation and further tumor progression (modified 
from Halazonetis et al. 2008). 
 
  21 
 
2. Aim of the study 
 
 In papillary thyroid carcinoma (PTC), RET TK domain is fused to 
heterologous genes to form the RET/PTC oncogenes. RET/PTC3, one of the most 
common variant, is generated by a chromosomal inversion leading to the fusion of 
the NCOA4 gene 5’ portion to the 3'-ter of the RET gene, coding for the tyrosine 
kinase domain. NCOA4 drives RET/PTC3 expression in thyroid follicular cells and 
induces its constitutive dimerization, switching on RET kinase activity. However, 
inactivation of NCOA4 function may contribute to tumorigenesis as well. Aim of 
this study has been to verify this hypothesis by characterizing the physiological 
function of mammalian NCOA4. To this aim, we:   
 
1. generated a NCOA4 gene knock-out mouse and analysed its phenotype; 
 
2. generated Mouse Embryo Fibroblasts (MEFs) from E13.5 embryos wild 
type (WT), heterozygous (HT) and knock-out (KO) for NCOA4 and 
analysed their proliferation rate; 
 
3. studied replication properties and DNA damage accumulation of NCOA4-/- 
cells by different molecular approaches. 
 
Additional aims of this study were to address: 
- the role exerted by the beta-catenin mitogenic pathway in thyroid cancer;  
- FOXM1-mediated control of cell cycle progression in ATC 
These further studies are described in the manuscripts attached at the end of 
Dissertation. 
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3. Materials and methods 
 
 
3.1  Murine NCOA4 gene targeting 
 
 Several overlapping genomic clones were isolated from a λφIXII phage 
library of a 129SVJ mouse strain (Stratagene) using standard procedures. Exons II-
VII of the murine NCOA4 gene were replaced by a neomycin-resistant (neo) 
cassette. The targeting construct was transfected by electroporation into embryonic 
stem (ES) AB2.1 cells. Genomic DNA from each G418-resistant clone was 
digested with StuI and hybridized by southern blot to an external 3' genomic 
sequence that detects 9 Kbp and 4 Kbp fragments corresponding to the wild-type 
(WT) and knock-out (KO) alleles, respectively. Two correctly targeted ES cell lines 
were injected into C57BL/6 blastocysts at BIOGEM facility (Ariano Irpino, Italy). 
Both gave rise to germ line chimeras that were backcrossed to C57BL/6 females to 
obtain heterozygous NCOA4-KO offsprings. Heterozygous NCOA4-KO mice were 
inter-crossed with each other to yield homozygous NCOA4-KO animals. Mice 
were maintained under specific pathogen-free condition in our laboratory animal 
facility and all studies were conducted with respect to the Italian regulation for 
experimentations on animals. 
 
 
3.2 Preparation of MEFs and cell culture conditions 
 
 NCOA4+/- mice of C57BL/6 genetic background were mated. Pregnant 
females at 13.5 d of gestation were sacrificed under anesthesia, followed by uterine 
dissection to isolate individual embryos. Each embryo was washed in PBS (pH 
7.2), followed by removal of head (used for embryo genotyping) and internal 
organs (hearth and liver). The embryo body was minced and then forced through a 
5ml syringe with a 18-gauge needle. Cell suspension was incubated in a 10 cm 
plate (now considered passage 0) and cultured in Dulbecco’s modified Eagle’s 
medium (DMEM) supplemented with 10% FBS (HyClone), 50µg/ml penicillin-
streptomycin, 2mM L-glutamine. Once cells became subconfluent, we  followed a 
3T3 subculture schedule  by counting the total number of cells using a 
hemocytometer and plating 5x105 per 100-mm dish. Every 3 days, cells were 
trypsinized and counted to determine the numer of population doublings, and then 
plated onto a new dish. The accumulation of population doubling level (PDL) was 
calculated by using the formula ΔPDL=log(nh/ni)/log2, where ni was the initial 
number of cells and nh is the final number of cells at each passage. 
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3.3 Protein studies 
 
Protein extractions and immunoblotting experiments were performed according to 
standard procedures. Briefly, cells were harvested in lysis buffer (50 mM HEPES, 
pH7.5, 150 mM NaCl, 10% glycerol, 1% Triton X-100, 1 mM EGTA, 1.5 mM 
MgCl2, 10 mM NaF, 10 mM sodium pyrophosphate, 1 mM Na3VO4, 10 μg of 
aprotinin/ml, 10 μg of leupeptin/ml) and clarified by centrifugation at 10,000 x g 
for 30 min. Protein concentration was estimated with a modified Bradford assay 
(Bio-Rad, Munich, Germany). Immune complexes were detected with the enhanced 
chemiluminescence kit (ECL, Amersham). Anti-human-NCOA4 antibody is a 
rabbit polyclonal antibody raised against the last 376 C-terminal residues of human 
RFG (Monaco et al. 2001). Secondary anti-mouse and anti-rabbit antibodies 
coupled to horseradish peroxidase were from Bio-Rad. 
 
 
3.4 Senescence-associated β-galactosidase (SAβ-gal) staining 
 
 SAβ-gal stain was performed according to Dimri et al. (1995). Briefly, cells 
were washed twice with PBS, fixed with 2% formaldehyde and 0.2% 
glutaraldehyde in PBS, and washed twice with PBS. Then, cells were stained 
overnight in X-gal staining solution (1mg/ml X-gal, 40 mM citric acid/sodium 
phosphate (pH 6.0), 5mM potassium ferricyanide, 5 mM potassium ferrocyanide, 
150 mM NaCl, 2 mM MgCl2). Photographs were taken using a Canon CCD camera 
mounted on a Zeiss phase contrast microscope. 
 
 
3.5 Immunofluorescence staining 
 
 For indirect immunofluorescence, cells were fixed in 4% paraformaldehyde 
and permeabilized with Triton 0.2% X-100 (5 minutes on ice), and then incubated 
with  α-H2AX phosphorylated on Ser139 (γH2AX) (R&D Systems) or α-53BP1 
(Cell Signalling) for 1h at room temperature. Coverslips were washed and 
incubated with an Alexa-488 goat anti-rabbit antibody (Invitrogen) for 30 minutes 
at room temperature. After 5 minutes of Hoechst counterstaining, coverslips were 
mounted in Glycerol/PBS (1:1) and observed with a Zeiss LSM 510 META 
confocal microscope (Carl Zeiss). At least 300 cells were counted in triplicate. 
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3.6 DNA fiber analysis 
 
 MEF cells were pulse-labeled with 10 µM CldU for 20 min, washed once 
with medium and subsequently pulse-labeled with 150 µM IdU for 20 min. 
Labelled cells were harvested, resuspended in PBS (106 cells/ml) and 2.5 µl were 
spotted onto the top of cleaned glass slides and lysed with 7.5 µl of 0.5% SDS in 
200 mM Tris-HCL, pH 7.4, 50 mM EDTA (10 min, 20°C). Slides were tilted (15° 
to horizontal), allowing a stream of DNA to run slowly down the slide, air dried 
and then fixed in methanol/acetic acid (3:1). CldU was detected by incubating acid-
treated fiber spreads with rat anti-BrdU monoclonal antibody (1:1000; AbD 
Serotec) O.N. at  +4°C. IdU was detected using a mouse anti-BrdU monoclonal 
antibody (1:500; Becton Dickinson) for 1h at R.T. Slides were finally incubated 
with a mix of secondary antibodies cointaining AlexaFluor 594-coniugated goat 
anti rat IgG (1:500; Molecular probes) and AlexaFluor 488-coniugated goat anti 
mouse IgG (1:500; Molecular Probes) for 30 min at R.T. Fibers were examined 
using a Zeiss microscope with 60x oil immersion objective. For quantification of 
replication structures at least 200 structures were counted per experiments. The 
lengh of red (AF 594) or green (AF 488) labeled patches were measured using the 
ImageJ software (National Insitute of health; http://rsbweb.nih.gov/ij/) and arbitrary 
lenght values were converted into micrometers using the scale bars created by the 
microscope. Kb values were finally obtained by multiplying micrometers for 2.5, a 
constant stretching factor. 
 
 
3.7 Alkaline sucrose gradient sedimentation.  
 
 Cells were labeled in MEF medium containing 5 µCi/mL of  3H-thymidine 
for 15 min at 37°C, harvested and resuspended in PBS at 5 x 106/mL. A 1 ml 
syringe was cut at the top and 300 µl of alkaline lysis solution (0.5M NaOH, 0.02M 
EDTA, pH 12.5, 0.1% NP-40) was added to the bottom. Subsequently, 50 µl of the 
cell suspension cointaining 2.5 x 105 cells was gently layered onto the lysis 
solution. The syringe was sealed to prevent evaporation and incubated at room 
temperature for 3h. Then, the cell lysate  (350 µl) was layered on the top of a 5-
20% alkaline sucrose gradient by inverting the cut syringe and slowly moving the 
piston while touching the top of the gradient. Sealed buckets were placed into the 
swing out rotor (SW40 TI-rotor) and centrifuged at 26,100 rpm for 90 min at 20°C 
using low acceleration setting and allowing the rotor to stop without brakes. After 
centrifugation, gradients were fractionated in 1-mL fractions starting from the top 
and collected into 1.5 ml eppendorf tubes. Each fraction was then spotted onto a 
piece of GF/C glass microfiber filter. After 3 washing in 10% TCA and deionized 
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water, filters were allowed to dry and transferred into scintillation vials. Two ml of 
0.5 M NaOH was added to each vial and allowed to incubate at 60°C for 12 h. After 
the addition of 2ml of 0.5 M HCL to neutralize NaOH, 10 ml of scintillation fluid 
was added to each vial, vortexed vigorously and 3H-activity was counted using a 
liquid scintillation counter. To obtain a sedimentation profile, the cpm values were 
plotted as percent of total 3H-thymidine activity per fraction starting from the top 
fraction containing the shorter DNA fragments to the bottom containing the longer 
ones. 
 
 
3.8 Pulsed field gel electrophoresis 
 
 Subconfluent cultures of KO and WT MEFs were irradiated with 40 Gy of 
Rx. Cells were harvested by trypsinization at different time points after irradiation, 
and agarose plugs of 106 cells were prepared with a CHEF disposable plug mold 
(BioRad). Plugs were incubated in lysis buffer (100 mM EDTA, 1% (w/v) sodium 
laurylsarcosyne, 0.2% (w/v) sodium deoxycholate, 1 mg ml-1 proteinase K) at 37°C 
for 48 h and then washed four times in TE buffer (10 mM Tris-HCl (pH 8.0), 100 
mM EDTA) before loading onto an agarose gel. Electrophoresis was performed for 
23 h at 13°C in 0.9% (w/v) agarose containing 250 mM Tris-Borate with EDTA 
(TBE) using a CHEF MAPPER apparatus (BioRad) with the following parameters: 
voltage 180-120 V log; angle from 120° to 110° linear; interval 30 s to 5 s log. In 
these conditions, high molecular weight genomic DNA (more then 20 million base 
pairs (Mbp)) remains into the well, whereas low molecular weight DNA fragments 
(10 Mbp to 500 kbp) migrate into the gel as a compact single band. The gel was 
stained with Ethidium bromide and analysed using a Typhoon 9200 scanner 
(Amersham). Band intensities were quantified using the ImageJ software (National 
Insitute of health; http://rsbweb.nih.gov/ij/). The amount of broken DNA was 
calculated as the intensity of the DNA in the migrated fraction over the intensity of 
DNA in the well plus the migrated fraction (total DNA intensity). 
 
 
3.9 Statistical analysis 
 
 The two-tailed unpaired Student's t test was used for statistical analysis. All 
P values were two sided and differences were significant when P was less then 
0.05. All statistical analysis were carried out using the GraphPad Instat software 
program (version 3.06.3). 
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4. Results 
 
 
4.1 Generation of a Knock-out mouse for the NCOA4 gene. 
 
 To examine the in vivo role of NCOA4, we used a gene targeting technique 
in ES cells to generate a null mutation at the murine NCOA4 genomic locus 
(Figure 6A). Heterozygous progeny of chimeric animals was identified by 
Southern Blot analysis of StuI-digested tail DNA and matings were established 
to produce mice heterozygous or homozygous for the NCOA4-null allele 
(Figure 6B). The knock-out allele was transmitted in a mendelian fashion and 
both heterozygous and homozygous mice were viable and fertile. 
Immunoprecipitation of cell lysates from mouse embryonic fibroblasts (MEFs) 
with an anti-NCOA4 antibody followed by Western blot for NCOA4 confirmed 
that homozygous mouse cells did not express the NCOA4 protein (Figure 6C).  
We followed mice growth and performed macroscopic and microscopic 
analysis of the principal mouse organs and tissues and no significant differences 
were detected between knock-out (KO) and wild-type (WT) mice (data not 
shown).  
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Figure 6: Targeted disruption of the murine NCOA4 gene. (A) Schematic 
representation of the genomic locus surrounding the targeted NCOA4 exons, 
the targeting vector and locus. (B) Southern blot analysis of tail DNA from wild 
type (WT), heterozygous (HT) and knock-out (KO) mice. Genomic DNA was 
digested with StuI and hybridized to a 3' external probe as shown in A. The 
wild type band is ∼ 9 Kb while the disrupted allele generates a ∼ 4 Kb band. (C) 
Protein extracts from wild type (WT), heterozygous (HT) and knock-out (KO) 
MEFs were imuunoprecipitated with anti-NCOA4 antibody, run on SDS PAGE 
and incubated with anti-NCOA4 antibody. 
 
 
4.2 MEF homozygous for NCOA4 deletion show reduced growth rate  
 
 To determine whether NCOA4 is important for cell cycle progression in 
mice, mouse embryo fibroblasts (MEFs) from NCOA4 wild-type (WT), 
heterozygous (HT) and knock-out (KO) animals were cultured according to a 
standard 3T3 protocol. Cells seeded at a fixed density were cultured for 3 days, 
counted and then re-seeded at the same initial density. Cell confluence was 
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avoided by seeding cells at a relatively low confluence (500,000 cells/10 cm 
plate). The number of population doublings was calculated as described in 
Materials and Methods. 
 As shown in Figure 7, NCOA4-/- cells showed a decreased accumulation of 
population doublings compared to the WT cells. Heterozygous cells showed an 
intermediate phenotype. In particular, after 3 to 4 population doublings NCOA4 
-/- cells accumulated into the plates with a flattened and enlarged morphology 
and no increase in cell number was obtained despite serial passaging.  
 We rarely succeeded in establishing spontaneously immortalized cell lines 
from NCOA4-/- embryos (data not shown). However, after prolonged passages 
in culture (more then 2 months) we could isolate from 20-30% of KO embryos 
a few proliferating cell clones. In contrast, 100% of WT and HT embryos gave 
rise to immortalized cells. Such immortalized NCOA4-/- MEFs displayed a 
slow proliferation rate compared to both HT and WT immortalized cells lines 
(data not shown) suggesting that the proliferative defect seen in primary cells is 
conserved also in immortalized cell lines. 
 
 
 
Figure 7: NCOA4-/- cells show impaired cell proliferation. Growth of NCOA4 
WT, HT and KO MEFs was examined by using a 3T3 protocol. The data are 
presented as the accumulated population doublings (PDL) during six passages 
in culture. The bars represent standard deviation of triplicate experiments. 
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4.3 NCOA4 depleted cells undergo premature senescence as a consequence 
of DNA damage accumulation 
 
 In response to genomic stress, murine primary cells undergo a cellular 
response known as DDR (see Introduction) that restrains cellular proliferation 
leading to a permanent cell cycle arrest known as cellular senescence. Despite 
being alive, senescent cells are unable to re-enter cell cycle in the presence of 
serum and display a typical morphology and gene expression pattern. After 3-4 
population doublings, NCOA4-/- cells stopped growing and acquired an 
enlarged and flattened morphology suggesting premature senescence. To 
address this possibility, we performed a senescence associated β-galactosidase 
assay (SAβ-gal assay). As shown in Figure 8, compared to  WT cells, a greater 
number of NCOA4-/- cells stained positively for β-gal both at passage 3 and 4, 
with more then 50% of cells being positive in the latter.  
 
 
 
Figure 8: Senescent phenotype of NCOA4-/- cells. (A) Bar-graphs showing the 
percentage of senescent cells in WT, HT and KO MEFs at the described 
passages ± SD (standard deviation). (B) Representative images of passage 4 
WT and KO cells stained for the β-galactosidase. 
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 Primary cells undergo cellular senescence as a consequence of DNA 
damage accumulation. This event impedes the transmission of altered genetic 
information and represents a fundamental mechanism to prevent genetic 
instability and cancer development (D'adda di Fagagna  2008). To address the 
hypothesis that NCOA4-/- cells undergo premature senescence as a 
consequence of DNA damage accumulation, we looked for markers of DDR 
activation at single cell level by immunofluorescence. Cells rapidly recognize 
DNA damage and activate a signalling pathway that restrains cell cycle 
progression and activates DNA repair. One of the first event in this cascade is 
the phosphorylation of the histone variant H2AX on Serine 139 (known as 
γH2AX). This event is fundamental to allow the sequential recruitment of 
checkpoint and repair proteins, like 53BP1 and MDC1, and to activate the Chk2 
kinase to spread the signal into the nucleus and activate the checkpoint 
response. We performed a confocal immunofluorescence analysis of NCOA4 
WT and KO cells using an antibody that specifically recognizes γH2AX. As 
shown in Figure 9, we found a statistically significant (p< 0.0001) increased 
number of cells positive for the presence of γH2AX foci in NCOA4-/- MEFs 
compared to wild type controls. 
 
Figure 9: NCOA4-/- cells accumulate γH2AX foci. (A) Representative 
immunofluorescence staining for γH2AX in KO and WT cells (B) Bar-graphs 
showing the percentage of γH2AX positive WT and KO cells ± SD (standard 
deviation).  
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4.4 NCOA4 depleted cells display a normal DSBs repair ability 
 
 The accumulation of DNA damage in NCOA4-/- cells could be the 
consequence of a defect in the repair of DNA damage induced by the exposure 
to a stressfull environment (in particular high O2 concentration). To verify 
whether NCOA4 exerts a role in DNA damage repair, we studied the efficiency 
of DNA repair after double strand breaks (DSBs) induction in WT and KO 
MEFs. Cells where subjected to 40 Gy Rx to induce cell cycle independent 
DSBs and DNA repair was followed by Pulsed field gel electrophoresis 
(PFGE). Cells where harvested at different time points after the irradiation, 
included in agarose plugs and processed for PFGE to detect broken DNA. 
Broken to intact DNA ratio was calculated by analysing bands intensity using 
the Image J software. As shown in Figure 10, NCOA4-/- MEFs showed a DSBs 
recovery curve overlapping to the wild type one. These data strongly suggest 
that NCOA4 is not involved in DSBs repair and exclude the possibility that 
DDR activation in KO cells is due to the inability to repair endogenous DNA 
DSBs. 
 
 
Figure 10:  PFGE analysis of DSBs recovery after IR. (A) Cells irradiated with 
40 Gy Rx were harvested at different time points and included into agarose 
plugs. PFGE was performed and gel stained with Etidium Bromide to detect 
intact DNA and double stranded molecules (fragmented DNA). (B) 
Quantification of recovery from DSBs formation in NCOA4 WT and KO MEFs 
shown as percentage of broken to intact DNA. 
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4.5 NCOA4-/- cells undergo replication stress  
 
 DNA damage accumulation in NCOA4-/- MEFs could be explained by 
replication stress due to unscheduled DNA synthesis. DNA replication 
represents the most challenging phase of cell cycle, since native single strand 
DNA is particularly fragile. Furthermore, primary cells show a peculiar 
sensitivity to high proliferation rate induced by high serum concentration. This  
suggests that serum-induced hyper-replication could promote genetic instability 
(Di Micco et al. 2008; Woo et al.  2004). Similarly, oncogene activation in 
primary cells induce senescence due to unscheduled DNA synthesis and 
replication stress (Di Micco et al. 2006).  
 Recently different research groups established the role of a mediator of the 
DNA damage checkpoint, 53BP1, in marking sites of DNA damage arising 
from replication stress (Lukas et al. 2011; Harrigan et al. 2011). Thus, following 
an immunofluorescence-based approach, we looked for evidence of 53BP1 
nuclear bodies accumulation in NCOA4 WT and KO cells. As shown in Figure 
11, we found an incresead number of 53BP1-foci positive cells as well as an 
increased number of foci/cell in NCOA4-/- MEFs. These data suggest that 
increased DDR activation in NCOA4-/- cells could be the consequence of a 
replication stress. 
 
  33 
 
 
 
Figure 11: 53BP1 nuclear bodies accumulation in NCOA4-/- cells. (A) 
Representative immunofluorescence staining of NCOA4-/- and +/+ for 53BP1. 
(B) Bar-graphs showing the percentage of WT and KO cells with 1-2 ; 3-9 and 
>10 53BP1 foci/cell ± SD (standard deviation).  
 
 
 Replication stress is not only the consequence of hyper-replication induced 
by oncogene activation or high serum concentration but can also be caused by 
agents that perturb the activity of the MCM2-7 helicase complex (cisplatin and 
mitomycin C) or the processive polymerases (UV irradiation). To investigate 
the hypothesis that replication stress in NCOA4-/- cells is the consequence of 
unscheduled origin activation or replication fork dynamics we studied 
replication forks progression in NCOA4 WT and KO MEFs. First, we studied 
the sedimentation profile of newly synthesized DNA molecules labelled with 
3H-Thimidine. As shown in Figure 12, through an alkaline sucrose gradient 
assay, we discovered that NCOA4-/- cells accumulate shorter radiolabelled 
DNA fragments compared to WT cells. The accumulation of shorter replicons 
in KO cells suggests the presence of fork stalling and increased origin firing. 
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Figure 12: Alkaline sucrose gradient profiles of NCOA4 WT and KO MEFs. (* 
p< 0.05; ** p< 0.001) 
 
 
To confirm these data, we took advantage of an immunofluorescence-based 
approach known as fiber stretching or DNA fiber assay that allows the study of 
replication fork progression. A detailed explanation of the experimental 
procedure is described in materials and methods, while a representation of 
replication fork patterns and the measurable variables is represented in Figure 
13. 
 
 
 
 
 
Figure 13: Fiber stretching assay. A representative picture of DNA replication 
patterns recognized through fiber assay and of the measurable DNA replication 
parameters. 
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 Briefly, NCOA4 WT and KO cells were pulse-labelled sequentially with 
CldU and IdU and nucleotides incorporation was followed on DNA fibers by 
using specific primary and secondary antibodies that allow the detection of 
CldU and IdU as red and green tracks respectively. Through this approach, we 
could study the execution of DNA replication and its abnormalities in NCOA4 
WT and KO cells. First, to confirm the data obtained with the alkaline sucrose 
gradient we studied the lenght of newly synthesized DNA. We evaluated more 
then 200 replication tracks from NCOA4 WT and KO cells and to obtain the 
fork velocity (a parameter directly dependent on the lenght of the tracks) we 
divided double tracks (red+green) for pulse duration (40 minutes) to have a 
distribution of fork velocities in those groups. As show in Figure 14, the 
distribution of fork velocities between NCOA4-/- and +/+ cells was highly 
divergent with the first group accumulating slower (and therefore shorter) tracks 
(p < 0.0001). 
 
 
 
Figure 14: Reduced fork speed in NCOA4-/- cells. (A) Representative image of 
a replicon observed on a stained DNA fiber after a consecutive pulse labelling 
with CldU and IdU, detected as red and green tracks respectively. (B) 
Representative images of replication tracks of NCOA4+/+ and NCOA4-/- 
MEFs. (C) Bar-graphs showing replication fork speed distribution in NCOA4-/- 
and NCOA4+/+ cells. The bars represent standard deviations deriving from 
experiments performed in triplicate. 
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 From each origin, replication forks normally proceed bi-directionally in a 
symmetric way. Oncogene activation as well as fork perturbation induced by 
stalling agents (UV, cisplatin) are associated with replication fork asymmetry 
which is directly correlated with fork stalling. Using the fiber stretching assay 
we studied the symmetry of anti-directional replicated traits from newly firing 
DNA replication origins in NCOA4+/+ and -/- MEFs. This can be obtained by 
the calculation of the ratio between the two arms that move away from the open 
replication bubble (the green tracks in Figure 15A). As shown in Figure 15 B-C, 
NCOA4-/- cells accumulate an increased amount of asymmetric replication 
forks compared to WT cells, suggesting that the absence of NCOA4 induces 
extensive fork stalling. 
 
 
 
Figure 15: NCOA4 depleted cells accumulate replication fork stalling lesions. 
(A) Representative images of DNA replication tracks upon pulse labelling with 
CldU (red) and IdU (green). (B) Representative images of newly firing 
replication origins in wild type and knock-out cells. (C) Bar-graphs showing the 
percentages of asymmetric replication forks in NCOA4-/- and +/+ MEFs. The 
numbers of asymmetrical replication bubbles was divided by the total number 
of replication bubbles ± SD (standard deviation). 
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 Oncogene activation induces replication stress by activating 
simultaneously an excessive number of replication origins and therefore 
inducing fork stalling because of nucleotide depletion. This has been suggested 
to be a primary source of genomic instability during the initial phases of cancer 
development (Bester et al. 2011). Furthermore, the stalling of a replication fork 
prompts the activation of dormant origins to prevent the transmission of 
unreplicated genomic regions. Therefore, increased origin density and 
consequently reduced inter-origin distance (IOD) are bona fide indicators of 
replication stress. By measuring the distance between newly firing origins 
(IOD), we could detect the density of activated origins in WT and KO cells 
(Figure 16). We found a reduced IOD in NCOA4 KO compared to WT cells 
suggesting extensive origin activation in NCOA4 depleted cells (p< 0.0001). 
These data could be explained by an increased activity of replication origin 
induced by a reduced inhibition of MCM2-7 activity as well as by an increased 
use of dormant origins activated by fork stalling. 
 
Figure 16: Reduced inter-origin distance in NCOA4-/- cells. (A) 
Representative image of two adiacent replicons observed on individual DNA 
fibers. Cldu is detected in red and IdU in green. The distance between the two 
origins (double arrow) correspond to the interorigin distance. (B) Bar-graphs 
showing average IOD (inter-origin distance) values in NCOA4 KO and WT 
MEF ± SD (standard deviation).  
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All together, these data indicate the failure of NCOA4-/- cells to maintain a 
normal replication rate. 
 
 
4.6 NCOA4-/- cells cultured in 3% O2 concentration are hypersensitive to 
agents inducing replication stress 
 
 Campisi's group recently showed that primary murine cells are highly 
susceptible to culture stress induced by elevated oxygen concentrations. In 
particular, MEFs cultured in 3% O2 do not show evidence of cellular senescence 
and undergo spontaneous immortalization (Parrinello et al. 2003). However, 
murine cells grown in the absence of serum are resistant to senescence even if 
cultured in 20% O2 concentrations (Loo et al. 1987; Woo & Poon 2004). One of 
the mechanism responsible for DDR-dependent oncogene-induced senescence 
(OIS) in primary cells is linked to an increased production of ROS (Reactive 
oxygen species) (Di Micco et al. 2006). This suggests that growth factors (in 
high O2 concentrations) and oncogenes (by increasing ROS production) induce 
a replication stress that impairs faithful transmission of the genome. The exact 
contribution exerted by ROS in this process is still unclear. ROS could 
accelerate replication rate as well as directly damage DNA, increasing the 
activity of repair systems working in the context of the intra-S-phase 
checkpoint.  
 When cultured at 3% O2 concentrations, NCOA4-/- cells showed a growth 
rate similiar to WT cells at least for the initial 8-9 passages (data not shown). 
This discrepancy in the growth rate of NCOA4-/- MEFs when kept at 3% or 
20% oxygen concentration could be explained by the efficiency of the cellular 
DNA repair machineries. One possibility is that DNA repair mechanisms could 
be sufficient to counteract low levels of DNA damage at low oxygen 
concentration but not high levels of DNA damage induced by high oxygen 
concentration. To address this hypothesis, we mimicked a replication stress at 
3% O2, by treating WT and KO cells with agents able to perturb replication fork 
progression. To this aim, we treated WT and KO cells, grown at 3% O2, with 
increasing doses of different DNA damaging agents. To address specifically a 
role for NCOA4 in preventing replication stress, we used agents known to 
induce DNA lesions that alter replication fork progression and activate the 
intra-S-phase checkpoint, such as cisplatin and UV. The former induces the 
formation of intra-strand and inter-strand crosslinks that alter the progression of 
the replicative helicase during the unwinding phase of DNA replication, while 
the latter causes the formation of pyrimidine dimers inducing polymerases to 
stall. As shown in Figure 17, KO cells showed an increased sensitivity to both 
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agents compared to WT cells. As a control, we used ionizing radiations that are 
known to induce prevalently DSBs in a cell cycle-independent manner. 
NCOA4-/- cells displayed only a moderately increase of sensitivity to IR 
compared to WT cells. This is not surprising since IR have been shown to 
induce the formation of replication stalling lesions (Harper et al. 2010). These 
data suggest that NCOA4 ablation is normally tolerated in the absence of an 
exogenous stress because of the activation of an intra-S-phase checkpoint that 
allows the execution of a normal replication program. The addition of a O2 
induced stress, probably by saturating DNA repair machineries, increases the 
sensitivity of cells to the stress induced by NCOA4 ablation. These data can 
also be reconciled with the apparent normal phenotype of NCOA4-/- mice, 
because they show that a genotoxic stress is required to unveil the DNA damage 
accumulation in cells lacking NCOA4. 
 
 
 
Figure 17: Increased sensitivity of NCOA4-/- cells to S-phase damaging 
agents. Two WT and KO MEF cell lines where treated with increasing doses of 
IR, UV or Cisplatin and their survival rate was measured after 48 hours. 
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5. Discussion 
 
 
5.1 NCOA4 ablation leads to replication stress and premature senescence in 
cultured cells.  
 
 Maintenance of genome integrity is a primary objective for mammals to allow 
the transmission of a correct genetic information to progeny and to restrain genetic 
instability and cancer formation. Several conserved mechanisms have adapted 
during evolution to deal with damaging forces that affect faithful genome 
duplication. During replication, DNA is particularly vulnerable because of the 
generation of unprotected single strand DNA. Thus, DNA replication and 
oncogene-associated genome instability allows cancer cells to continously 
rearrange their genome favouring cancer progression, and providing the chance to 
escape anticancer barriers, such as senescence. Here, we show that NCOA4 is a 
novel player of the control of genome stability during replication. Indeed, we show 
that primary murine cells lacking the NCOA4 gene show genetic instability and 
premature senescence as a consequence of replication stress and DNA damage. 
 As far as the mechanism of NCOA4-mediated control of DNA replication, 
our group has recently shown that NCOA4 protein binds to MCM7 protein, a 
component of the MCM2-7 helicase complex involved in DNA unwinding during 
replication (Carlomagno et al, personal communication). Through the use of an in 
vitro model of DNA replication that recapitulates all the step of vertebrate DNA 
replication, the Xenopus laevis egg extracts, our group demonstrated that NCOA4 
inhibits DNA replication by hindering the helicase activity of the whole MCM2-7 
complex (Carlomagno et al, personal communication). Thus, NCOA4 may be 
normally required to keep under check MCM2-7 complex activity and NCOA4 
ablation may release MCM2-7 control allowing unscheduled DNA replication and 
replication stress.  
 Our findings provide strong evidence of the key role played by the control of 
MCM2-7 activity to maintain genome stability during DNA replication. 
Accordingly, we show that NCOA4-/- cells accumulate replication stalling lesions 
that prompts DDR activation and cellular senescence. Two mechanisms, not 
mutually exclusive, may explain replication stress in NCOA4-/- cells.  
 On one hand, inappropiate origin firing due to unscheduled MCM2-7 
activation may trigger replication stress. Nucleotide depletion induced by increased 
origin firing and DNA lesions generated by oxidative damage during replication 
may be the driving forces able to increase number of stalled lesions ultimately 
leading to a saturation of the intra-S-phase repair mechanisms, DNA damage 
accumulation and premature senescence.  
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 On the other hand, unchecked MCM2-7 activity by increasing replication fork 
speed and single strand DNA exposure may lead to fork stalling and increased 
damage accumulation.  
 Whatever the mechanism, we show that lack of control of MCM2-7 activity 
leads to genome instability in mammalian cells. This findings could be important to 
understand the mechanisms that allow faithful DNA replication and maintenance of 
genome integrity. 
 
 
5.2 NCOA4 gene is dispensable for mouse viability and development. 
 
Despite its essential function in regulating MEFs proliferation, NCOA4 appears 
dispensable for mouse viability and development. It should be noted, however, that 
mouse targeting studies have shown that many genes that are important for cell 
cycle progression are dispensable for mice viability (Sherr and Roberts, 2004). 
Redundancy of mechanisms that control cell cycle progression and in particular 
DNA replication is a possible explanation for this observation. In the case of 
NCOA4, our data show that primary mouse cells (MEFs) accumulate DNA damage 
when grown under stressed conditions produced by a combination of high serum 
concentration and O2 pressure (Sherr & DePinho 2000; Parrinello et al. 2003), both 
conditions absent in mouse tissues. Future work will be required to explore the 
viability of NCOA4 KO mice upon treatment with genotoxic agents. To this aim we 
plan to treat NCOA4 WT and KO mice with Ionizing radiation (IR) and increasing 
doses of cisplatin. 
 
 
5.3 Role of NCOA4 in RET/PTC-induced tumorigenesis. 
 
 In RET/PTC oncogenes, the oncogenic activation of RET is fostered by the 
presence of coiled-coil domains in RET fusion genes mediating RET TK 
dimerization, kinase activation and signaling. It should be noted, however, that 
oncogenic rearrangements involving two genes, such as RET/PTC ones, may 
follow a "two-hits model" in which the activation of a proto-oncogene (RET) is 
coupled to the loss-of-function of a tumor suppressor gene (Figure 18). Data shown 
in this Dissertation, suggest that RET/PTC3 could follow such a two-hits model. 
Indeed, by leading to genome instability, NCOA4 disruption may determine the 
loss of a care-taker mechanism, thereby leading to release from genome stability 
control, DNA damage and genomic instability. We propose that loss of such 
NCOA4 function may be involved in RET/PTC3 driven oncogenesis in papillary 
thyroid carcinoma. 
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Figure 18: Two-hit model for RET/PTC3 mediated carcinogenesis  
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6. Conclusions 
 
 Here we show that NCOA4-/- cells are prone to accumulate DNA damage 
and undergo premature senescence as a consequence of the activation of a DNA 
damage response (DDR). Our previous findings suggested a role for NCOA4 in 
negatively regulating DNA replication by hindering the activity of the MCM2-7 
helicase complex (Carlomagno et al, personal communication). Accordingly, here 
we show that NCOA4-/- mouse embryo fibroblasts (MEFs) fail to maintain normal 
replication fork progression, accumulate stalled forks and feature increased origin 
activation. All together these data suggest that NCOA4 depletion causes 
unscheduled activation of MCM2-7 function thereby leading to altered replication 
dynamics and genomic instability. We propose that NCOA4 might be a novel care-
taker tumor suppressor involved in genome integrity maintenance. Loss of such 
funtion may contribute to RET/PTC induced oncogenesis in thyroid carcinoma.  
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Abstract 
Anaplastic thyroid carcinoma (ATC) is a very aggressive thyroid cancer. We previously 
identified an ATC gene expression signature, featuring the overexpression of a set of genes 
involved in cell cycle progression and mitotic spindle checkpoints. Upregulation of Forkhead 
box protein M1 (FOXM1) was part of this signature. FOXM1 is a member of the forkhead 
box family of transcription factors involved in control of cell proliferation, chromosomal 
stability, angiogenesis and invasion. Here, we show that FOXM1 is overexpressed in ATC 
compared to normal thyroid, well-differentiated papillary and poorly-differentiated thyroid 
carcinoma. The FOXM1 isoform predominantly expressed in ATC and ATC-derived cell 
lines was the FOXM1c splicing variant. Up-regulated FOXM1 expression in human ATC 
cells was mechanistically linked to loss-of-function of p53 and of FOXO3a, due to the 
iperactivation of the PI3K-AKT pathway. Knock-down of FOXM1 in ATC cells inibited cell 
proliferation, arrested cells in G2/M, and reduced invasion through matrigel and cell motility 
in a wound healing assay. This phenotype was associated to reduced expression of FOXM1 
target genes, like cyclin B1, Plk1, Aurora B, Skp2 and uPA. All together these findings 
suggest that FOXM1 represents an important player in the establishment of the anaplastic 
phenotype and a potential therapeutic target for this cancer. 
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Introduction 
Anaplastic thyroid carcinoma (ATC) is a rare tumor that accounts for 2% to 5% of all thyroid 
cancers. ATC ranks among the most lethal solid tumors with a mean survival rate of 4 to 12 
months after diagnosis and, though rare, it represents the first cause of death for endocrine 
neoplasia. ATC usually presents between the 6th and the 7th decade of life as a rapidly 
enlarging neck mass that extends locally and tends to disseminate to regional nodes and 
distant sites. Multimodal therapy, including surgery, chemotherapy and radiotherapy does not 
significally change the natural course of the disease (Kondo et al. 2006; Smallridge et al. 
2009). 
ATC shares genetic alterations with well-differentiated papillary (PTC) or follicular 
(FTC) thyroid carcinoma, namely point mutation in RAS and BRAF (Nikiforova et al. 2003; 
Garcia Rostan et al. 2003). On the other hand, point mutation or gene amplification of 
PI3K3CA or AKT and loss of PTEN are more frequently found in ATC than well-
differentiated carcinomas (Frisk et al. 2002; Garcia-Rostan et al. 2005; Wu et al. 2005; 
Santarpia et al. 2007; Ricarte-Filho et al. 2009; Saji & Ringel 2010). Accordingly, intercross 
of transgenic mice expressing oncogenic RAS with PTEN null mice gave rise to highly 
aggressive ATC (Miller et al. 2009). Moreover, while well differentiated thyroid carcinomas 
are rarely associated with p53 mutation (less then 10%), the great majority of ATC features 
p53 mutations (67% to 88%) or disfunction induced by mechanisms such as upregulation of 
negative p53 regulators like HMGA1, ∆Np73 or HDM2 (Kondo et al. 2006; Pierantoni et al. 
2007; Malaguarnera et al. 2007; Smallridge et al. 2009; Nikiforov et al. 2011). Therefore, 
deregulation of PI3K3CA/AKT and p53 pathways may foster ATC development. 
At a variance from well-differentiated thyroid tumors, ATC has a high proliferation 
rate and a marked aneuploidy (Wreesmann et al. 2002). Recently, we identified a gene 
expression signature associated with the ATC phenotype, featuring the upregulation of a panel 
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of genes involved in the G2 and M phases of the cell cycle (Salvatore et al. 2007). This 
signature overlapped with "proliferation" and “chromosomal instability” signatures which 
were correlated with mitogenic and aneuploid phenotype of aggressive human cancer types 
from various tissues (Cartel et al. 2006). 
Forkhead box protein M1 (FOXM1) is a member of the forkhead box family of 
transcription factors (Korver et al. 1997). It promotes cell cycle progression by affecting both 
the G1/S and the G2/M transitions and it is an important regulator of chromosomal stability 
(Laoukili et al. 2005). Accordingly, FOXM1 regulates the expression of a large number of 
G2/M specific genes, such as Cyclin B, Plk1, Nek2 and CENP-F. Interestingly, most of these 
genes were part of the ATC signature (Salvatore et al. 2007) and one of them, Plk1, was 
shown to be promising therapeutic target for ATC (Nappi et al. 2009).  FOXM1 deletion was 
associated with mitotic spindle defects and cell death through mitotic catastrophe (Wonsey & 
Follettie 2005) and compounds targeting FOXM1 transcriptional activity induced apoptosis in 
cancer cell lines, thereby suggesting it may represent a potential therapeutic cancer target for 
several cancers (Hegde et al. 2011). FOXM1 has been also shown to regulate the transcription 
of genes involved in angiogenesis and invasion, thus acting as a master regulator of 
metastasization (Raychaudhuri & Park 2011). Accordingly, FOXM1 downregulation reduced 
invasion and migration of pancreatic and breast cancer-derived cell lines (Wang et al. 2007; 
Ahmad et al. 2010). FOXM1 overexpression has been observed in several human cancers, 
including basal cell carcinoma (Teh et al. 2002), glioblastoma (Liu et al. 2006) and 
hepatocellular (Kalinichenko et al. 2004), breast (Wonsey and Follettie 2005), prostate (Kalin 
et al. 2006) and gastric cancer (Li et al. 2009) and it is often correlated to high proliferative 
and invasive phenotype and a dismal prognosis.  
Recently, Ahmed and co-workers reported that FOXM1 was up-regulated in a fraction 
(28.4%) of PTC and that chemical or genetic FOXM1 block reduced PTC cell invasiveness 
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and survival parallel to decreased metalloproteinases (MMP-2 and MMP-9) expression 
(Ahmed et al. 2011). We reasoned that FOXM1 over-expression could be an important event 
in fostering the anaplastic phenotype, leading to increased cell proliferation and invasiveness 
of ATC. Here we show that FOXM1 is upregulated in ATC compared to well-differentiated 
thyroid tumours and mediates the mitogenic program of ATC cells. We also show that 
FOXM1 expression in ATC cells is sustained by the PI3K/AKT pathway as well as by the 
loss-of-function of the p53-p21(CIP1/WAF1)-pRb axis. Finally, FOXM1 knock-down in 
ATC cells reduced proliferation, survival and invasion of ATC cells. These results suggest 
that ATC cells remain addicted to FOXM1 and that FOXM1 targeting may represent a 
strategy for the treatment of ATC.   
Materials and methods 
Tissue samples and immunohistochemistry. Tumors and normal thyroid tissue samples for 
immunohistochemical analysis were retrieved from the files of the Pathology Department of 
the Hospital Central de Asturias (Oviedo University, Asturias, Spain) and of the Hospital 
Clinico Universitario de Santiago de Compostela (Santiago de Compostela University, 
Galicia, Spain). Tumors and normal thyroid tissue samples (n.45) for RNA extraction and RT-
PCR were retrieved from the files of the Department of Surgery, University of Pisa (Italy). 
Case selection was based on the histological findings and on the availability of adequate 
material for RNA extraction. All histological diagnoses were reviewed by two blinded 
pathologists (G. G-R and C. U) according to the latest recommendations about diagnostic 
features of PTC, PDC and ATC (Hedinger et al. 1989; DeLellis et al. 2004; Volante et al. 
2007). PDC (poorly differentiated carcinomas) were defined as malignant tumors of follicular 
cells displaying predominant solid/trabecular/insular growth patterns, high grade features such 
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as mitoses (>3-5 mitoses x 10 HPF) and/or necrosis and convoluted nuclei, with or without 
concurrent differentiated components of the follicular or papillary type. ATC (anaplastic 
thyroid carcinomas) were defined as tumors displaying admixtures of spindle, pleomorphic 
giant, and epithelioid cells, high mitotic activity, extensive coagulative necrosis with irregular 
borders, and infiltration of vascular walls often accompanied by obliteration of the vascular 
lumina. Processing of samples and of patient information proceeded in agreement with review 
board approved protocols. Formalin-fixed and paraffin-embedded 3–5-µm thick tumor 
sections were deparaffinized, placed in a solution of absolute methanol and 0.3% hydrogen 
peroxide for 30 min, and treated with blocking serum for 20 min. The slides were incubated 
with rabbit polyclonal anti-FOXM1 antibody (H-300, Santa Cruz Biotechnology, USA) and 
processed according to standard procedures. Negative controls by omitting the primary 
antibody were included. Cases were scored as positive when unequivocal brown staining was 
observed in the nuclei of tumor cells. Immunoreactivity was expressed as the percentage of 
positively stained target cells in four intensity categories [-, no staining; +, low/weak; ++ 
moderate/distinct; +++, high/ intense]. Score values were independently assigned by two 
blinded investigators (FB and CU) and a consensus was reached on all scores used for 
computation.  
 
RNA extraction and reverse transcription-PCR. Total RNA was isolated with the RNeasy 
Kit (Qiagen, Crawley, West Sussex, UK). The quality of the RNAs was verified by the 2100 
Bioanalyzer (Agilent Technologies, Waldbronn, Germany); only samples with RNA integrity 
number (RIN) value > 7 were used for further analysis. One µg of RNA from each sample 
was reverse-transcribed with the QuantiTect® Reverse Transcription (Qiagen). For 
quantitative RT-PCR, primers pairs and PCR conditions are available upon request. PCR 
reactions were done in triplicate and fold changes were calculated with the formula: 2 - (sample 1 
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∆Ct - sample 2 ∆Ct) , where ∆Ct is the difference between the amplification fluorescent threshold of 
the mRNA of interest and the mRNA of the β-actin used as an internal reference. 
Semiquantitative RT-PCR was performed to detect the specific FOXM1 splicing isoforms. 
The following primers were used:  
Fox-F2 (5'-GCGACTCTCGAGCATGGAGAATTGTCACCTG-3') and Fox-R2, (5'-
GCGCTACTCGAGTTCGGTTTTGATGGT-3'), encompassing A1 exon;  
Fox-F3 (5'-GGGCGCACGGCGGAAGATGAA-3') and Fox-R3 (5'-
CCACTCTTCCAAGGAGGGCTC-3'), encompassing A2 exon.  
Semiquantitative RT-PCR was applied to study FOXM1 target genes, as follows:  
Plk1-F: 5'-ATCACCTGCCTGACCATTCCACCAAGG-3'; 
Plk1-R: 5'-AATTGCGGAAATATTTAAGGAGGGTGATCT-3' (annealing temperature: 
60°C);  
cyclin B1-F: 5'-AAGGCGAAGATCAACATGGC-3'; 
cyclin B1-R: 5'-AGTCACCAATTTCTGGAGGG-3' (annealing temperature: 56°C);  
aurora B-F: 5'-CCTATCGCCGCATCGTCAAG-3' ; 
aurora B-R: 5'-GCAGCACCCTCCGAGAGTTG-3' (annealing temperature:  60°C);  
Skp2-F: 5'-AGAGGTGGTATCGCCTAGCGTCT-3'; 
Skp2-R: 5'-AGGGTACCATCTGGCACGATTCCA-3' (annealing temperature: 56°C);  
uPA-F: 5'-AGCGACTCCAAAGGCAGCAATGA-3'; 
uPA-R: 5'-AGGGTCGCCTCCGGTTGTCT-3' (annealing temperature: 56°C) 
 
Cell cultures. P5 3N cells were provided by F. Curcio (Università di Udine, Udine, Italia) in 
2003. 8505C and CAL62 cells were purchased from DSMZ (Deutsche Sammlung von 
Mikroorganismen und Zellkulturen GmbH, Braunschweig, Germany) in 2006. SW1736 and 
HTH74 cells were obtained from N.E. Heldin (University Hospital, Uppsala, Sweden) in 
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2005. OCUT-1, TTA1 and ACT-1 cells were provided by N. Onoda (Osaka University of 
Medicine, Osaka, Japan) in 2005. All the cells were DNA profiled by short tandem repeat 
analysis and shown to be unique and identical to those reported in Schweppe et al., 2008 
(Schweppe et al. 2008). P5 3N were grown as previously described (Curcio et al. 1994). The 
thyroid cancer cell lines were grown in Dulbecco's modified Eagle's medium (DMEM) 
(Invitrogen, Groningen, The Netherlands) containing 10% fetal bovine serum. LY294002 was 
from Calbiochem (Merck Chemicals Ltd. Nottingham UK) and used at 10 µM final 
concentration. MEK inhibitor PD98059 was from Cell Signaling and used at 50 µM final 
concentration. 
 
Protein studies. Protein extraction and immunoblotting was carried out according to standard 
procedures. Anti-FOXM1 antibody (H-300) was from Santa Cruz Biotechnology; monoclonal 
anti alfa-tubulin was form Sigma-Aldrich (St Louis, MO). Secondary anti-mouse and anti-
rabbit antibodies coupled to horseradish peroxidase were from Santa Cruz Biotechnology. 
 
Plasmids, siRNA and transfection. FOXM1 siRNA smart pool was purchased from 
Dharmacon (Lafayette, CO, USA). The siCONTROL Non-targeting Pool (#D-001206-13-05) 
was used as a negative control. Cells were transfected with 100 nM siRNA using Dharmafect 
3 siRNA reagent following manufacturer’s instructions. The HA-FOXM1b plasmid was 
purchased from Origene Technologies (Rockville, MD); HA-FOXM1c was a kind gift of Dr. 
KM Yao (University of Hong Kong).  
 
Invasion Assay. In vitro invasiveness through Matrigel was assayed using transwell cell 
culture chambers. Briefly, 8505c confluent cell monolayers were harvested with 
trypsin/EDTA and centrifuged at 800Xg for 10 min. The cell suspension (1X105 cells/well) 
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was added to the upper chamber of transwells on pre-hydrated polycarbonate membrane filter 
of 8 µM pore size (Costar, Cambridge, MA, USA) coated with 35µg Matrigel (BD 
Biosciences). The lower chamber was filled with complete medium. Cell dishes were 
incubated at 37 °C in 5% CO2 and 95% air for 24 h. Non-migrating cells on the upper side of 
the filter were wiped off and migrating cells on the reverse side of the filter were stained with 
0.1% crystal violet in 20% methanol for 15 min, counted and photographed. Each experiment 
was repeated three times. 
 
Wound healing assay. For wound healing assays, 8505c cells were grown up to 80% 
confluency; a wound of approximately 300 µm width was inflicted to the cell monolayer with 
a sterile pipette tip. The culture medium was changed to remove nonadherent cells. The 
progress of wound closure (healing) was monitored with microphotographs of ×10 
magnification taken with the Leica DM IL light microscope (Leica Microsystems, Wetzlar, 
Germany) immediately and 24 hours after the wound. The experiment was repeated three 
times. 
 
Luciferase assays. Cells were transfected with 500 ng of the reporter plasmid DNA 
(6XCDX2), together with (when required) p53 wild type, p21 (CIP1/WAF1), E2F4 (kindly 
donated by M. Crescenzi, Istituto Superiore di Sanità, Rome), AKT-K178M and FOXO-3a by 
using LipofectAMINE reagent (Invitrogen, Groningen, The Netherlands) according to 
manufacturer's instructions. A plasmid expressing the enzyme Renilla luciferase (pRL-null) 
was used as internal control. In all cases, the total amount of transfected plasmid DNA was 
normalized by adding empty vector DNA. Forty-eight hours after transfection, Firefly and 
renilla luciferase activity were assayed using the Dual-Luciferase Reporter System (Promega 
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Corporation), and the Lumat LB9507 luminometer (EG Berthold). Each experiment was done 
in triplicate. 
 
Statistical analysis.  The two-tailed unpaired Student's t test was used for statistical analysis. 
All P values were two sided and differences were significant when P was less then 0.05. All 
statistical analysis were carried out using the GraphPad Instat software program (version 
3.06.3). 
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Results 
Increased FOXM1 expression in ATC and ATC-derived cell lines. We studied the 
expression of FOXM1 in normal thyroids and thyroid carcinomas by immunostaining a set of  
35 normal thyroids, 51 PTC, 246 PDC and 113 ATC samples. Nuclear positivity was 
classified as low (+), medium (++) and high (+++), based on the  percentages of nuclear 
positive cells. Results are reported in Table 1 and representative pictures are shown in Fig. 1. 
FOXM1 was not detectable in normal thyroid cells; consistent with a previous report (Ahmed 
et al. 2011) 25.4% of PTC and 30.8% PDC show weak/moderate stain. Noteworthy, FOXM1 
nuclear expression was strongly increased in ATC (compared to both PTC and PDC: p 
<0.001), with 42.2% of the samples scoring weak/moderate and 22% showing an intense stain 
(Table 1). 
We performed qRT-PCR analysis on RNA extracted from normal thyroids, PTC and 
ATC samples (15 each) to verify whether FOXM1 up-regulation was at the RNA level. 
FOXM1 mRNA expression was significantly higher in ATC samples compared to normal 
thyroid (p< 0.001) and PTCs (p< 0.001) (Fig. 2A).  
FOXM1 gene is located on chromosome 12p13.3 and it consists of nine exons, two of 
which (A1 and A2) are alternatively spliced giving rise to three differentially espressed 
isoforms: FOXM1a (containing both A1 and A2 exons), FOXM1c (containing only A1) and 
FOXM1b (lacking both A1 and A2) (Fig. 2B). Only FOXM1b and FOXM1c are active as 
transcription factors, because of the lack of the inhibitory sequence encoded by exon A2 
which renders FOXM1a variant transcriptionally inactive and endowed with dominant 
negative effects (Ye et al. 1997). We applied RT-PCR and primers designed to amplify the 
regions containing A1 and A2 exons, generating large or small PCR fragments depending on 
the presence or not of the targeted exon, to address the relative expression of the three 
isoforms in normal and tumour thyroid tissues (9 samples for each category). FOXM1b and 
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FOXM1c plasmids were used to generate PCR products as molecular weight controls. ATC 
samples predominantly expressed FOXM1c (Fig. 2C). Noteworthy, FOXM1c was reported to 
be the FOXM1 variant that more strongly triggers proliferation and invasion of cancer cells 
(Kim et al. 2006). 
 
Deregulation of the p53/p21/E2F and PI3K/AKT/FOXO axis promote FOXM1 
overexpression in ATC cells. We investigated the mRNA and the protein levels of FOXM1 
in a panel of ATC cell lines. A primary culture of normal thyrocytes, P5-4N, was used as 
control. ATC cell lines expressed high levels of FOXM1 mRNA (Fig. 3A) and protein (Fig. 
3B) as compared to normal cells. As for tissue samples, ATC cell lines expressed FOXM1c 
isoform (Fig. 3A). 
 Then, we asked which ATC-associated molecular pathways may trigger FOXM1 up-
regulation. FOXM1 has been recently identified as a target of p53-mediated repression, 
secondary to p21CIP1/WAF1-mediated pRb de-phosphorylation and E2F transcription factor 
down-regulation (Barsotti & Prives 2009; Pandit et al. 2009). This event is critical for the 
maintenance of a stable G2 arrest in response to DNA damage. To address whether in ATC 
cells FOXM1 overexpression depend on p53 loss-of-function, we transfected two ATC-
derived cell lines, 8505C and HTH74, with plasmids coding for p53 wildtype, 
p21(CIP1/WAF1) and E2F4 (a negative regulator of the E2F family) together with a firefly 
luciferase reporter to monitor FOXM1 transcriptional acivity (6XCDX2) (Kim et al. 2006). 
As shown in Fig. 4A, adoptive overexpression of p53 wt, p21(CIP1/WAF1) and E2F4 
decreased FOXM1 activity, compared to cells transfected with the empty vector (p<0.001). 
Consistently, FOXM1 mRNA levels as measured by qRT-PCR were reduced in p53 wt-, 
p21(CIP1/WAF1)- and E2F4-transfected cells (Fig. 4B). These findings suggest that p53 loss 
is a molecular event driving the high FOXM1 transcription levels in ATC, this eventually 
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unleashing cell cycle progression (see below) from the cell cycle checkpoints and thus 
facilitating chromosomal instability, a common feature of ATC. 
The phosphatidylinositol-3-kinase (PI3K)/AKT pathway is a key regulator of 
proliferation, apoptosis and motility and is hyperactivated in several cancer types. Thyroid 
cancer features constitutive activation of the PI3K/AKT pathway due to PI3K3CA 
amplification or mutation, AKT mutation or PTEN downregulation (Saji & Ringel 2010). 
These genetic lesions are more prevalent in ATC than in well-differentiated thyroid lesions 
suggesting a role for PI3K/AKT pathway in the progression of thyroid malignancies (Saji & 
Ringel 2010). FOXO3a transcription factor is negatively controlled by AKT and, in turn, 
FOXM1 expression has been reported to be negatively regulated by FOXO3a in breast cancer 
(McGovern et al. 2009). Thus, we hypothesized that the PI3K/AKT/FOXO3a pathway may 
influence FOXM1 expression in ATC. To address this possibility, we transfected ATC cells 
with plasmids coding for dominant negative AKT mutant (K178M) or FOXO3a together with 
the FOXM1 activity reporter. AKT(K178M) and FOXO3a transfection strongly reduced 
FOXM1 activity in ATC cells (Fig. 4A). Same results were obtained by treatment with the 
chemical PI3K inhibitor, LY294002. LY294002 also reduced FOXM1 expression levels (Fig. 
4B). Importantly, chemical blockade of the MAPK pathway by the MEK inhibitor PD98059 
did not recapitulate this event, suggesting that FOXM1 up-regulation is specifically sustained 
by the activation of the PI3K/AKT pathway in ATC (Fig. 4).  
 
Down-regulation of FOXM1 expression by siRNA inhibited ATC cell growth and in 
vitro invasion. We knocked down FOXM1 expression by siRNA in 8505C and HTH74 and 
monitored cell counts in triplicate at 48 hours. FOXM1 siRNA but not scrambled control 
caused growth inhibition in both the cell lines tested (P<0.001) (Fig. 5A), parallel to FOXM1 
mRNA knock-down (see below Fig. 5D). 
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ATC features a higly invasive and metastatic phenotype. FOXM1 promotes the 
transcription of genes involved in extracellular matrix degradation and motility, thereby 
acting as a master regulator of metastasization (Raychaudhuri & Park 2011). Thus, we 
monitored cell motility (wound closure assay) and invasion (transwell chamber assay) upon 
FOXM1 knock-down. FOXM1 depletion significantly impaired the capability of ATC cells to 
close the wound (p< 0.001) (Fig. 5B) and to invade through Matrigel (p< 0.001) (Fig. 5C) 
when compared to the scrambled control.  
 Finally, we tested whether pro-mitogenic and –invasive effects of FOXM1 were 
mediated by the transcriptional program induced by FOXM1. Indeed, transcriptional effects 
of FOXM1 includes up-regulation of genes involved in cell proliferation and invasion 
(Laoukili et al. 2005). As shown in Fig 5D, FOXM1 downregulation in ATC cells blunted the 
expression of mRNAs related to cell-cycle (Skp2, cyclin B1, aurora B, and Plk1) as well as 
invasion (UPA). Noteworthy, some of these FOXM1 targets have been previously reported to 
be up-regulated in ATC (Ito et al. 2002; Chiappetta et al. 2007; Sorrentino et al. 2005; 
Wiseman et al. 2007; Nappi et al. 2009). 
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Discussion 
At a variance from well differentiated thyroid carcinoma that is treatable with surgery and 
radioactive iodine ablation, ATC is one of the most aggressive human malignancies and it 
represents the first cause of death for thyroid cancer. Our understanding of the molecular 
mechanisms leading to the highly aggressive mitogenic and invasive ATC phenotype is still 
very limited (Smallridge et al. 2009). FOXM1 oncogenic factor is a master regulator of a 
transcriptional program including genes mediating cell proliferation, motility, invasion and 
metastasization and it was indeed included in the set of genes upregulated in ATC identified 
through our previous gene expression profile screening (Salvatore et al. 2007). This prompted 
us to explore FOXM1 function in ATC.  
In this study, we show that FOXM1 expression is strongly upregulated in ATC. 
FOXM1 overexpression in ATC tissue samples and cell lines was detected at the protein as 
well as at the mRNA levels suggesting increased transcription as the main mechanism 
responsible for its overexpresssion. Recently, FOXM1 expression has been reported to be 
negatively controlled by p53 and FOXO3a anti-oncogenic transcriptional factors (Barsotti & 
Prives 2009; Pandit et al. 2009; McGovern et al. 2009). In turn, impaired activity of both 
these tumor-suppressors is part of the molecular features of ATC, that indeed include p53 
loss-of-function, in turn releasing E2F factors from the negative control exerted by the 
p21(CIP1/WAF1)/pRb axis, as well as PI3K3CA/AKT gain-of-function mutations, in turn 
mediating a phosphorylation-dependent FOXO3a block (Smallridge 2009; Saji & Ringel 
2010). Accordingly, here we show that release from these negative constraints contributes to 
FOXM1 up-regulation in ATC cells (Fig. 6). Importantly, we show that this pathway is 
amenable of therapeutic targeting by PI3K chemical inhibitors, drugs that have been recently 
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proposed as potential therapeutic tools in preclinical models of thyroid cancer (Liu et al. 
2011a; Liu et al. 2011b; Xing et al. 2010; Jin et al. 2011; Jin et al. 2009).   
 We found that FOXM1c was the main splicing variant strongly upregulated in ATC 
and FOXM1c has been reported to be the isoform endowed with more potent mitogenic and 
pro-invasive effects (Kim et al. 2006). Finally, by applying RNAi, we show that ATC cells 
depend on FOXM1 expression for both proliferation and in vitro motility and invasion. 
Mechanistically, FOXM1 ablation downregulated the expression of a set of genes that in turn 
are candidate mediators of these functions. These findings support a model whereby FOXM1 
up-regulation may contribute to the locally invasive, metastatic and mitogenic phenotype of 
ATC; in turn, release of ATC cells from the normal cell cycle checkpoints may also 
contribute to the chromosomal instability that characterizes this cancer (Fig. 6). 
 Our data represent an extension of the findings recently reported by Ahmed and 
colleagues (2011), who, studying differentiated thyroid carcinomas, demonstrated that 
FOXM1 was upregulated in a fraction (28.4%) of PTC and correlated with aggressive PTC 
variants (tall-cell) and expression of molecular markers of invasiveness, such as different 
metalloproteases. Overall it is feasible that FOXM1 is a mediator of thyroid cancer 
aggressiveness and therefore involved in most ATC as well as in that fraction of differentiated 
carcinomas featuring an aggressive behaviour. More importantly, Ahmed and collegues 
proved that a natural compound, thiostrepton, that reduces FOXM1 transcriptional activity 
and protein level (Radhakrishnan et al 2006; Kwok et al 2008) impair thyroid cancer cell 
growth and invasion. All together, these findings suggest that FOXM1 is a molecular 
determinant of thyroid cancer malignant phenotype and may be exploited as a molecular 
marker of aggressiveness as well as a molecular target in approaches aimed at inhibiting 
directly its transcriptional activity or indirectly the pathways sustaining its expression (Fig. 6). 
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Figure legends 
Figure 1. Immunohistochemical analysis  of FOXM1 expression in human thyroid tissue 
samples   Representative captions of a normal thyroid (negative), PTC and PDC (weakly 
positive: +) and ATC (strongly positive: +++) samples. Original magnification: left (x4),  
right (x40) 
 
Figure 2. FOXM1 is overexpressed at the mRNA level in human anaplastic thyroid 
carcinoma samples   A) Quantitative RT-PCR showing increased FOXM1 expression in 
ATC samples compared to normal thyroids as well as to PTC samples (15 samples for each 
category). Values are expressed as fold changes of tumor samples with respect to the average 
expression in normal samples measured with ∆Ct method after normalization for actin mRNA 
levels (***, p < 0.001). B) Schematic representation of the 3 altervatively spliced FOXM1 
variants and the PCR primers used to detect the presence of spliced exons A1 and A2. C) RT-
PCR to show relative expression of levels the three FOXM1 isoforms in normal thyroids, PTC 
and ATC (9 samples for each category). Plasmids encoding FOXM1b and FOXM1c were 
used as PCR templates to generate molecular weight controls for the presence or the absence 
of exon A1 (primers F2/R2) or A2 (primers F3/A3). Arrows indicate expected migration for 
RT-PCR products containing (variants FOXM1a and FOXM1c) or lacking exon A1 
(FOXM1b) or for RT-PCR products containing (FOXM1a) or lacking exon A2 (FOXM1b 
and FOXM1c). 
 
Figure 3. FOXM1 is overexpressed at the mRNA and protein level in ATC cells   A) 
Semiquantitative RT-PCR showing increased levels of FOXM1c in ATC cells compared to 
normal thyrocytes (P5) (see legend to Figure 2). Levels of 18S rRNA were measured for 
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normalization. B) Western Blot analysis showing increased protein expression of FOXM1 in 
ATC cells compared to P5 control. Tubulin was used for normalization. These results are 
representative of at least three independent experiments. 
 
Figure 4. FOXM1 in ATC cells is controlled by the p53/p21/pRb/E2F and 
PI3K/Akt/FOXO3a pathways   A) The indicated ATC cells were co-transfected with the 
indicated expression vectors (or the empty vector as control) together with 6XCDX2 
containing 6 copies of the FOXM1 binding site fused to firefly luciferase. Alternatively, as 
indicated cells were treated for 48 h with the PI3K inhibitor LY294002 or the MEK inhibitor 
PD98059. Cells were co-transfected with renilla luciferase for normalization. Normalized 
luciferase levels are reported as average results of three independent experiments are reported 
with 95% confidence intervals. Reporter activity  in empty vector-transfected cells was 
arbitrary set at 10; (***, p < 0.001). B) FOXM1 mRNA expression levels were measured in 
the indicated ATC cells 72 h after transfection with the indicated plasmids or treatment with 
LY294002. The average results of three independent experiments are reported together with 
95% confidence interval. FOXM1 expression in mock-transfected cells was arbitrary set at 
1.0; (***, p < 0.001). 
 
Figure 5. Effect of FOXM1 silencing on ATC cell growth, migration and invasion   A) 
ATC cells were transfected with either FOXM1-siRNA or the scrambled control or left un-
transfected. Cells were harvested at 48 hours and counted. Values represent the average of 
triplicate experiments with bars indicating 95% confidence intervals; (***, p < 0.001). B) 
8505C cells, transfected with either FOXM1-siRNA or the scrambled control, were plated at 
confluence and scratch wounds were inflicted. After 24h, cell plates were photographed and 
cells closing the wound were counted. The avearage results of three experiments are reported 
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with bars representing 95% confidence intervals; (***, p < 0.001). C) 8505C cells, transfected 
with either FOXM1-siRNA or the scrambled control, were plated in transwells coated with 
Matrigel and their migration through Matrigel was measured by staining migrated cells with 
Giemsa. The avearage results of three experiments are reported with bars representing 95% 
confidence intervals; (***, p < 0.001). D) RNA was extracted from 8505C cells, transfected 
with either FOXM1-siRNA or the scrambled control or left untransfected and 
semiquantitative RT-PCR assays were performed to  detect expression levels of the indicated 
mRNAs. 
 
Figure 6. A model for FOXM1 role in thyroid cancer. Schematic representation of the 
molecular pathways linked to FOXM1 up-regulation in ATC (+ and – refer to activating or 
inhibitory signal, respectively) and gene targets whose expression is stimulated by FOXM1. 
This pathway can be therapeutically targeted at multiple levels; as show here and in the 
Ahmed (2011) study, these levels include FOXM1 itself and PI3K. 
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Table 1. FOXM1 expression by immunohistochemistry in human thyroid samples. 
Sample Staining intensity* 
 (-)  (+) (++) (+++) 
Normal thyroid 100% (35/35) 0% (0/35)  0% (0/35)   0% (0/35) 
PTC 74.5% (38/51) 19.6% (10/51) 5.8% (3/51) 0% (0/51)   
PDC 67% (165/246) 24.3% (60/246) 6.5% (16/246) 2% (5/246) 
ATC 25.6% (29/113) 23% (26/113) 29.2%(33/113) 22.1% (25/135) 
 
*(-) < 5% of cells positive for nuclear FOXM1 expression;  
(+) 5-10% of positive cells;  
(++) 20-40% of positive cells;  
(+++) >50% of positive cells. 
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ABSTRACT 
Background. Thyroid cancer is the most frequently occurring malignancy of the endocrine 
system, whose incidence is increasing worldwide. Even though recent years have been 
characterized by significant advances in understanding the molecular basis of thyroid 
carcinogenesis, leading to the identification of RET and BRAF kinases as major molecular 
targets in these tumors, still further studies are needed to characterize tumor-initiating genetic 
events and to identify additional mediators of tumorigenesis and of resistance to conventional 
therapies. Methods. We performed an high-throughput screening of the entire human kinome 
by transfecting a library of synthetic small interfering RNA (siRNA) in the TPC1 thyroid 
cancer cell lines, harboring rearrangement of RET-PTC1, in order to identify novel protein 
kinases required to sustain viability of thyroid carcinoma cells. Results. Our data show that 
knock-down of 21 kinases reduced significantly the viability and the proliferation of thyroid 
cancer cell lines. Among them, we identified several members of the Ephrine Receptor family 
(EPHA2, EPHA4 and EPHB2) as regulators of different biological features of thyroid cancer 
cells such as invasion and migration. Conclusions. The identification of EPHs as mediators of 
thyroid carcinogenesis sheds new light on the molecular mechanisms regulating thyroid 
transformation and offers novel therapeutic approaches against this malignancy.  
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INTRODUCTION 
The past two decades have witnessed significant progress in understanding molecular 
mechanisms regulating cancer pathogenesis. Thus, actual efforts are focusing on development 
of anti-cancer drugs that target proteins involved in carcinogenesis and kill tumor cells while 
sparing normal cells. Among these drugs, small molecules targeting kinases are proving 
effective against well-characterized cancers, as many tumors are associated with increase in 
activity of specific kinases caused by mutational activation, or changes in expression due to 
gene amplification or translocation (Futreal et al., 2004; Venter et al., 2001; Manning et al., 
2002). In a recent study, 23% (120/518) of kinase genes were estimated to function as cancer 
genes (Greenman et al., 2007), as they mediate most of the signal transduction events in cells 
by phosphorylation of specific substrates, modifying their activity, cellular location, and/or 
association with other proteins.  
Thyroid cancer is one of the best examples of characterization of the genetic lesions 
involved in tumor development and progression and of successful therapeutic approaches 
with specific molecular inhibitors targeting activated proteins. Rearrangements involving 
RET together with point mutations in the BRAF kinase cover about 70% of Papillary Thyroid 
Carcinoma (PTC) cases (Santoro et al., 1992; García-Rostán et al., 2003; Kimura et al., 2003; 
Soares et al., 2003; Nikiforova et al., 2003a; Nikiforova et al., 2003b; Frattini et al., 2004; 
Elisei et al., 2008a).  
Several compounds able to target the RET and the BRAF kinases are under 
investigation and some of them have already reached the clinical approval (Santoro and 
Carlomagno 2006; Schlumberger et al., 2009; Sherman, 2009) such as Vandetanib (Zactima, 
ZD6474) (Astra Zeneca, Wilmington, DE) that has been recently approved (April 2011) from 
the U.S. Food and Drug Administration (FDA) to treat adult patients with late-stage 
(metastatic) medullary thyroid cancer (MTC) who are ineligible for surgery and who have 
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disease that is growing or causing symptoms.  
Although most of the genetic lesions involved in thyroid cancer are known, still there 
is a certain number of PTC (about 30% of cases) where no mutations have been identified yet. 
In addition, many PTC tumors undergo development of resistance against small molecular 
inhibitors, due to mutation in the kinase target of the drug or due to the activation of 
compensatory kinases, that rescue cancer cell proliferation; therefore combination therapies 
targeting multiple signaling pathways may offer more effective therapeutic strategies. 
siRNA screening of the kinome in cancer cells can be exploited to identify molecular 
mediators of tumorigenesis and to highlight compensating kinases, leading  to development of 
multi target inhibitors able to overtake the mechanism of resistance to drug treatment (Berns 
et al., 2007; Westbrook et al., 2005; MacKeigan et al., 2005). We have used a high-
throughput siRNA screening to characterize functional differences in kinase requirements in 
human thyroid cells and to find kinases whose roles in proliferation and survival differ in 
tumor cells as compared to normal cells. Through this screening, we identified 21 “down 
hits”, e.g. kinases whose knock-down reduced by 30% or more TPC1 cell viability. Most of 
these kinases were essential not only for the viability of TPC1 but also other thyroid cancer 
cell lines with different genetic backgrounds (RAS or BRAF mutations) but not for normal 
thyroid cells. Our down-hits include components of multiple signaling pathways. In 
particular, we identified several members of the EPH (ephrin receptors) family, namely 
EPHA2, EPHA4 and EPHB2, as over-expressed and functionally active in various thyroid 
cancer cell lines. The identified EPHs were also up-regulated in human thyroid tumor 
specimens and their specific knock-down impaired the ability of cancer cells to invade the 
matrigel and close the wound.  
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METHODS 
Cell Lines, Cell Culture and Tissue Samples 
TPC-1 and BCPAP are cell lines derived from papillary thyroid carcinomas and express the 
RET-PTC1 and BRAF-V600E oncogenes respectively; CAL62, 8505C and SW1736 are 
derived from undifferentiated- anaplastic carcinomas expressing K-RAS or BRAF-V600E 
oncogenes as described in supplemental table 1 (Table S1). All thyroid cancer cell lines were 
grown in Dulbecco’s modified Eagle’s medium supplemented with 10% FBS (Invitrogen, 
Carlsbad, CA, USA), L-glutamine and penicillin/streptomycin (Sigma Aldrich, St Louis, MO, 
USA) (Cerutti et al., 1996; Ohta et al., 2001; Basolo et al., 2002). Nthy-ori 3-1 (ECACC, 
Wiltshire, UK) represents a normal human thyroid follicular epithelial cell line that has been 
immortalized by transfection with a plasmid encoding for the SV40 large T gene, grown in 
RPMI-1640 medium supplemented with 10% FBS.  Human primary cultures of normal 
thyroid cells (P5) were obtained from F. Curcio and cultured as previously described (Curcio 
et al., 1994). All cells were expanded briefly in culture and cryopreserved in multiple 
replicate vials. This cell bank was tested by ELISA assay (Mycoplasma detection Kit, Cat # 
11296744001, Roche, Indianapolis, IN, USA) and found to be free of mycoplasma. To 
authenticate the cell lines, short tandem repeat genotyping was performed. All cells were 
maintained in a humidified incubator at 37 C and 5% CO2. A thyroid tumor tissue bank 
containing a large number of samples (about 300, equally divided among the different 
subtypes) snap-frozen in liquid nitrogen and maintained at -80°C has been made available 
through the group of F. Basolo (University of Pisa, Italy). For all of them, formalin-fixed 
paraffin-embedded material is available. For all cases, clinico-pathological parameters such as 
age, gender, size, extrathyroidal extension, lymphonode and distant metastases were recorded. 
The use of these archival tissues in this study was approved by the Ethics Committee of the 
University of Pisa. 
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High-Throughput siRNA screening 
For primary high-throughput screening, the TPC1 cells were seeded into black, transparent 
bottom, 384/well plates (BD Biosciences, Heidelberg, Germany) using an automatic 
MultiDrop dispenser (Thermo Labsystems, Philadelphia, PA, USA). All wells were filled 
with 1,000 cells/well in a volume of 100 µl of DMEM supplemented with 2.5% FBS without 
antibiotics. The cells were then transfected with the human kinome siRNA set v 2.0 (Qiagen, 
Germantown, MD, USA). Each well contained a specific siRNA targeting one of 646 distinct 
genes. Two siRNAs for each target were used, as well as positive controls (e.g. MAPK-
siRNA, PLK1-siRNA), negative controls (scrambled, GFP, buffer) and untransfected cells. 5 
µl of 2 micromolar siRNA (10 pmol) was transferred from the stock plate using the robotic 
liquid handler and mixed to transfection solution, prepared with 0.2 µl of HyPerfect cell 
culture reagent (Qiagen) diluted in 10 µl of Optimem medium (Invitrogen). Following 10 
minutes incubation, the transfection mix was delivered to each well and incubated at room 
temperature for 1 hour. 72 hours after transfection, 10 µl of Cell Titer Blue reagent (CellTiter 
Blue Assay, Promega, Madison, WI, USA) diluted 1:1 in cell culture medium were added to 
each well, to measure the amount of metabolite which is generated by dye reduction in viable 
cells. Plates were incubated at 37 °C for 6 hours with 5% CO2 and then transfered to room 
temperature for overnight incubation, at dark. Cell viability was measured with an EnVision 
Multilabel plate reader at an excitation wavelength of 530 nm and emission wavelength of 
590 nm (Perkin Elmer, Waltham, MA, USA). For each well data were calculated as a ratio on 
an average of control wells present in each plate, to minimize the effects due to transfection 
toxicity. The results were expressed as log2 and siRNA effective in reducing cell vitality by at 
least 30% (loess log ≤-0.67) were considered as negative hits. The primary screening was 
repeated in duplicate and the results are attached as supplemental informations (Table S2). 
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Secondary siRNA screen 
To confirm the primary screening results, we obtained an independent set of 2 siRNAs for 
each of the 49 identified hits (with exception of two pseudo-genes: LOC392265 and 
MGC4796) (Table S3). The catalogue number list of siRNA used is attached as Supplemental 
table 4. From this analysis 80.8% (38) of the 47 tested genes were significantly reducing cell 
viability with the new siRNAs, although only those hits (26) that were reducing cell viability 
by at least 30%, compared to the control, and with at least 3 (out of 4) different siRNAs, 
passed our confirmation screening. Among these genes, after a preliminary test in normal 
cells, we identified some hits that were significantly (p ≤0.05) affecting viability also of 
normal cells (8 genes out of 26). Because our aim was to find kinases that could be important 
for cancer cells, as mediators of tumorigenesis and as potential therapeutical targets, we 
excluded from further studies those hits that were affecting also normal cells, limiting our 
analysis to 18 hits. Moreover, because the Ephrine Receptor Family (EPH) was the best 
represented group in our list, we reduced the cut off to fish for more member of this protein 
group and we identified two proteins (EPHA4, EPHB2), located just below the chosen cut off 
(EPHA4 loess log = -0.3; EPHB2 loess log= -0.4), that we included in our further studies.  
Our final list contained therefore 20 down hits, that we targeted with siRNA in a broader 
panel of thyroid cells (BCPAP, 8505C, SW1736, Nthy-ori and P5), as a validation screening. 
For each of the used cell line, siRNA transfection conditions had been previously set up by 
using the KDalert GAPDH kit (Ambion, Applied Biosystem, Carlsbad, CA, USA) that 
measures the efficiency of GAPDH silencing with specific siRNA. The secondary and the 
validation screenings were repeated three independent times. 
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Quantitative RT-PCR 
The goal of the validation screen was to prioritize the identified hits for further studies. In 
order to verify the specificity of the siRNAs used in our study, we performed a Quantitative 
RT-PCR analysis in cancer (TPC1) and normal (Nthy-ori) cells, confirming that the used 
duplex were knocking down their specific target genes. Moreover we tested the relative 
expression for every identified gene in a broader panel of thyroid cancer cells, compared to 
normal cells.  For evaluation of mRNA expression, each cell line was grown to 70% 
confluency, total RNA was extracted with RNeasy mini kit (Qiagen) and subjected to on-
column DNase digestion with the RNase-free DNase set (Qiagen) according to the 
manufacturer’s instructions. RNA (1µg) was reverse transcribed using a high-capacity reverse 
transcriptase kit (Quantitect Reverse® Transcription Kit, Qiagen). Reaction occurred at 42°C 
for 15 minutes, 99°C for 5 minutes, and subsequent cooling at 5°C for 5 minutes. cDNA 
amplification was performed using the GeneAmp RNA PCR Core Kit system starting from 
2.5 µl of RT product in a reaction volume of 25 µl according to the manufacturer’s 
instructions. Primers were designed by using a software available at http://www-
genome.wi.mit.edu/cgi-bin/primer/primer3_www.cgi and synthesized by the Ceinge (Naples, 
Italy). Quantitative (real-time) reverse transcription polymerase chain reactions (qRT-PCR) 
were performed by using the SYBR Green PCR Master mix (Applied Biosystems) in the 
iCycler apparatus (Bio-Rad Laboratories, Berkeley, CA, USA). Fluorescent threshold values 
were measured in triplicate and fold changes were calculated by the formula: 2-(sample 1 ΔCt - 
sample 2 ΔCt), where ΔCt is the difference between the amplification fluorescent threshold (Ct) of 
the mRNA of interest and the Ct of the ß actin mRNA used as housekeeping gene. The list of 
primers used is attached as Supplemental Table 5 (Table S5). Each result derives from three 
independent experiments. 
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Protein Extraction and Immunoblot.  
Protein extraction and immunoblotting experiments were performed according to standard 
procedures. Briefly, cells were harvested in lysis buffer (50 mM HEPES, pH 7.5, 150 mM 
NaCl, 10% glycerol, 1% Triton X-100, 1 mM EGTA, 1.5 mM MgCl2, 10 mM NaF, 10 mM 
sodium pyrophosphate, 1 mM Na3VO4, 10 µg aprotinin/ml, 10 µg leupeptin/ml) and clarified 
by centrifugation at 10,000 g at 4°C. Protein concentration was estimated with a modified 
Bradford assay (Bio-Rad). Lysates of equal protein concentration (30 µg for total cell lysates 
and 1 mg for immunoprecipitation) were separated with sodium dodecyl sulfate-
polyacrylamide gel electrophoresis (SDS-PAGE) and transferred to Hybond C Extra 
nitrocellulose membranes (GE Healthcare, Munich, Germany). Membranes were incubated in 
blocking solution containing 5% nonfat dry milk for 1 hour at room temperature. Incubation 
with primary antibodies was performed overnight at 4°C, followed by incubation for 1 hour at 
room temperature with HRP-conjugated anti-mouse or anti-rabbit secondary antibodies 
(dilution 1:3000) from Amersham Biosciences (Piscataway, NJ, USA). Immunocomplexes 
were detected with the enhanced chemiluminescence kit (ECL; Amersham Biosciences). 
Anti-EphA2 antibody (dilution 1:1000 for WB and 1:100 for IP) and anti-phospho-tyrosine 
(dilution 1:1000) antibodies were from Millipore (Schwalbach, Germany) (05-480 and 05-
321, respectively); anti-EphA4 antibody (dilution 1:500 for WB and 1:50 for IP) was from 
Invitrogen (371600); anti-EphB2 antibody  (dilution 1:1000 for WB and 1:100 for IP) was 
from R&D Systems (Minneapolis, MN, USA); anti phospho-MAPK (dilution 1:1000) and 
anti phospho-AKT (dilution 1:1000) were from Cell Signaling Technologies (Danvers, MA, 
USA) (4370 and 4850 respectively). Monoclonal anti–α-tubulin (dilution 1:10 000) was from 
Sigma-Aldrich (T-9026). All experiments were performed at least three independent times. 
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Proliferation and survival assays 
To test whether siRNA transfection would affect cell proliferation, S-phase entry was 
evaluated by BrdU incorporation, Cell Proliferation ELISA BrDu (Roche). Briefly, cells were 
cultured in 96-multiwell plate black, flat bottom (BD Biosciences) in a volume of 100 µl/well. 
After 72 hours cells were labeled with 10 µM of BrDu labeling solution and incubated at 
37°C for additional 2 hours. Cells were then fixed for 30 minutes at room temperature with 
200 µl/well of FixDenat buffer, and incubated with 100 µl/well of anti-BrDu-POD 
(peroxidase) for 90 minutes at room temperature. After three washes, substrate solution was 
added, plates were kept on a shaker for 3 minutes at room temperature and light emission was 
read using a microplate luminometer with photomultiplier technology, DL Ready 
BERTHOLD Technologies Centro (Beckman, Brea, CA, USA). To measure apoptotic cell 
rate, the Apo-ONE Homogeneous Caspase-3/7 Assay (Promega) was performed after 
siRNA transfection as previously described. Blank, e.g. untransfected cells, and negative 
control, e.g. medium without cells, were performed as well. 100 µl of Apo-ONE 
Homogeneous Caspase-3/7 Reagent were added to each well. The fluorescence values were 
proportional to the amount of caspase-3/7 cleavage activity present in each sample and they 
were measured with an EnVision Multilabel plate reader (Perkin Elmer). All the experiments 
were performed in triplicates. 
 
Wound healing assay  
For wound healing assays, TPC1 cells transfected with siRNA targeting EPHs and scrambled 
control were grown to form cell monolayers of 80% confluency in which a wound of 
approximately 300µm width was inflicted with a sterile pipette tip. The culture medium was 
exchanged to remove non-adherent cells. The progress of wound closure (healing) was 
monitored with microphotographs of X10 magnification taken with the Leica DM IL light 
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microscope (Leica Microsystems, Wetzlar, Germany) immediately and 12 hours after the 
wound. The experiments were repeated three independent times. 
 
Invasion Assay 
In vitro invasiveness through Matrigel was assayed using transwell cell culture chambers 
according to described procedures. Briefly, TPC1 confluent cell monolayers were harvested 
with trypsin/EDTA and centrifuged at 800Xg for 10 min. The cell suspension (1X105 
cells/well) was added to the upper chamber of transwells on pre-hydrated polycarbonate 
membrane filter of 8 µM pore size (Costar, Cambridge, MA, USA) coated with 35µg 
Matrigel (BD Biosciences). The lower chamber was filled with complete medium. Cell dishes 
were incubated at 37 °C in 5% CO2 and 95% air for 24 h. Non-migrating cells on the upper 
side of the filter were wiped off and migrating cells on the reverse side of the filter were 
stained with 0.1% crystal violet in 20% methanol for 15 min, counted and photographed. 
Each experiment was repeated three times. 
 
Statistical analysis 
Experimental data are summarized as the mean values with 95% confidence intervals (CIs). 
All statistical analyses were performed using a two-tailed Student’s  t  test (GraphPad Prism 
3.0, GraphPad Software, San Diego, CA, USA), and differences were considered to be 
statistically significant at a value of  P  less than .05.  
Cell viability values were log-transformed and then subtracted by the median value of the 
experimental and negative control wells. These values were then divided by the standard 
deviation of the plate well values. The raw data were quantile-normalized and analyzed with 
the R/Bioconductor software (Gentleman RC, Carey VJ, Bates DM, Bolstad B, Dettling M, 
Dudoit S, Ellis B, Gautier L, Ge Y, Gentry J, Hornik K, Hothorn T, et al. Bio- conductor: 
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open software development for computational biology and bioinformatics. Genome Biol 
2004;5:R80.).  
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RESULTS 
High-throughput screening of human kinases involved in TPC1 cells viability. 
To establish the role of all known protein kinases in thyroid carcinogenesis we designed a 
functional assay using the human papillary thyroid carcinoma cell line TPC1 harboring 
rearrangement of RET-PTC1 oncogene. Cells were silenced with a library containing 646 
synthetic siRNAs targeting all human protein kinases as well as a number of kinase-related 
and associated proteins. To reduce the off-target effect of siRNAs, the library has been 
designed to contain two independent duplex targeting the same transcript. The transfection 
was done by using 10 pmol of siRNA (see methods for details). To monitor transfection 
efficiency, each plate contained cytotoxic siRNAs targeting genes that are positive regulators 
of proliferation in all cells (e.g. polo like kinase 1-PLK1 and mytogen activated protein kinase 
1-MAPK1), and negative control siRNAs targeting green fluorescente proteine (GFP) or 
scrambled sequences as well as buffer and un-transfected cells.  
 
Identification of primary hits. 
72 hours after transfection of siRNAs we performed a cell titer blue assay to identify genes 
whose knock-down would affect TPC1 cells viability. Primary hits were defined as genes 
that, when silenced, reduced viability (normalized on negative control) by at least 30% (loess 
log ≤ -0.67). According to our data, siRNA-targeted downregulation of 7.5% (49 candidates 
out of 646 tested) of the kinome library resulted in significant reduced cell viability of TPC1 
cells (Figure S1, Table S2 and Table S3). Samples that did not reproduce in at least two 
biological replicates, or those of dubious spots, were excluded from further analysis. To 
validate the screening results we conducted a secondary confirmation test with an independent 
set of 2 siRNAs targeting a distinct mRNA region of the 49 identified kinases. From this list 
we excluded two pseudo-genes (MGC4796 and LOC392265) and we added two other genes 
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(EPHA4 and EPHB2), belonging to the most represented family in our list, the Ephrin 
Receptor Family (EPHs), located just below our chosen cut off (EPHA4 loess log = -0.3; 
EPHB2 loess log= -0.4). With these new siRNAs targeting our 49 down hits, we performed 
the confirmation screening in TPC1 cells, by using the same conditions as for the primary 
screen. Confirmed down hits were those genes whose knock-down (mean of different 
siRNAs) would significantly (p ≤0.05) affect cell viability by at least 25% as compared to the 
control (loess log ≤-0.5). This analysis led to the identification of 28 hits (Table S3). Because 
our study was aimed to discover new mediators of tumorigenesis and novel potential 
therapeutic targets in thyroid cancer, we performed a preliminary test in normal thyroid cells 
and we excluded those kinases (8 out of 28) that were affecting viability of normal and cancer 
cells indistinctly (CIB3, IHPK3, ITPKA, MAPK7, MARCKS, PAK2, STK33, TESK1). Our 
final list contain therefore 20 kinases (Table S3). They include logical candidates, like 
signaling kinases (FYN and AKT2), together with some novel kinases that have not 
previously been described to play a role in thyroid carcinogenesis. Among them the EPHR 
family is the best represented, with 6 different members in our list. Although we could 
exclude off target effects of duplex because we had confirmed our results by using different 
siRNAs for each gene, still we wanted to verify whether the oligos we used were specifically 
down-regulating their target transcripts. To this aim, we performed a quantitative RT-PCR in 
papillary thyroid cancer (TPC1) and normal thyroid cell lines (Nthy-ori 3-1), upon silencing 
of each of the identified kinase. Our data showed that all targets were significantly depleted 
by their specific siRNAs in both tested cell lines (Figure S2, S3), suggesting that the observed 
effects were due to specific gene silencing.  
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Validation screen. 
To test the effect of our identified kinases in other thyroid cancer cell lines, we extended the 
analysis to a panel of genetically different cell lines of papillary (BCPAP), anaplastic (8505C, 
Cal62) and normal phenotype (Nthy-ory 3-1 and P5) (Table S1). The optimal transfection 
conditions for each cell line (number of cells, amount of siRNA and amount of transfection 
reagent) were previously defined by using the GAPDH Alert kit (Ambion), monitoring 
efficiency of GAPDH knock-down by specific siRNA. As shown in figure 2, most of the 
tested gene silencing significantly reduced the viability of all thyroid cancer cell lines while 
sparing normal cells. Few exceptions were represented by two genes that were affecting TPC1 
cells exclusively (LIMK1 and MAP3K6), suggesting their possible connection to the presence 
of the RET-PTC1 rearrangement, and by other genes such as EPHA5, HCK, MAP3K7IP1, 
PKN1 and PRKD2 that were required for the viability only of PTC cells (TPC1 and BCPAP), 
but not of ATC cells (8505C and CAL62), suggesting their link to more differentiated 
(papillary) cancer histotype. 
 
Characterization of the biological effects of kinase knock-down in thyroid cells. 
To further characterize the reduced cell viability caused by the knock-down of our negative 
hits in thyroid cells, we performed growth curve analysis, BrdU incorporation as well as 
cleaved caspase-3 measurement assay upon siRNA transfection in TPC1 as well as Nthy-ori 
3-1 normal cells. Our data show that in TPC1 cells all siRNAs had a significant (p ≤0.05) 
cytostatic effect, evaluated as diminished percentage of BrdU incorporation (Figure 3 upper 
panel), while proliferation of normal Nthy-ory cells was not affected by gene knock-down 
(Figure 3 lower panel). The reduced BrdU incorporation was paralleled by a decreased 
number of cancer cells when performing growth curve experiments (Figure S4, S5). On the 
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other hand, no significant cytotoxic effect was observed in cancer or normal cells when 
measuring caspase 3 cleavage (Figure S6 or data not shown).  
 
Identification of Ephrin receptors and their ligands in thyroid cancer cells and human 
samples. 
Among the identified genes affecting thyroid cancer cell growth, we focused our attention on 
the Ephrin Receptors (EPHR), as six different members of this family were among the most 
prominent down hits in our primary screening (EPHA2, A4, A5, A7, B2 and B6) (Figure 1, 
Table S2, Table S3). To investigate the role of EPHR in thyroid cancer cells and to better 
understand the mechanisms of the reduced cell proliferation observed with EPHR siRNAs in 
TPC1 cells, we first tested whether the EPHR identified among our down hits would be 
differently expressed in cancer cells with respect to normal cells. By using several thyroid cell 
lines of different histotype and genotype we performed a quantitative RT-PCR (Q-RT-PCR) 
and demonstrated that all the 6 EPHRs present among our negative hits were expressed in 
thyroid cell lines. Moreover, when comparing the relative expression in cancer as compared 
to normal (Nthy-ori) cells, we found that some of them (EPHA2, EPHA4 and EPHB2) were 
significantly (p<0.05) over-expressed in transformed cells as compared to the normal control 
cell line (Figure 4A, left panels). To verify whether EPHs could also be present in human 
tumors, we tested the expression of EPHA2, EPHA4 and EPHB2 in papillary thyroid samples 
(PTC) and normal thyroids (NT). Our results, shown in figure 4A, right panels, demonstrate 
that also thyroid tumor samples have significant (p ≤ 0.01) up-regulation of EPHA2, EPHA4 
and EPHB2. These data support recent evidences suggesting strong involvement of 
EPHR/ephrins in tumorigenesis and correlating their expression levels to invasiveness, 
metastatization and reduced patient survival rates (Pasquale, 2005).  
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EPHRs are promiscuous tyrosine kinase receptors, able to bind to transmembrane (ephrins B) 
or GPI-soluble (ephrins A) ligands. They also mediate the signal transduction either in a 
paracrine way between two juxtaposed interacting cells, or in an autocrine manner in between 
the same cells (Pasquale 2005). We therefore screened our panel of thyroid cell lines for the 
expression of all the known ephrin ligands (EFNs). Our analysis revealed that among all the 
ligands, only a few (EFNA1, EFNA4, EFNB2) showed significantly (p< 0.01) higher 
expression in cancer as compared to normal cells (Figure 4B, left panels). Interestingly, these 
ligands can bind to the same EPHs identified from our screening (EPHA2, EPHA4, EPHB2). 
As for the receptors, also the three ligands were up-regulated in PTC tumor samples as 
compared to normal thyroid (Figure 4B, right panels).  
Because EPHs are tyrosine kinase receptors, they undergo phosphorylation upon activatin. To 
evaluate the activation of these proteins in thyroid cancer, we studied the EPHA2, EPHA4 
and EPHB2 protein expression and phosphorylation status by immunoprecipitation and 
Western blot analysis. Our data, shown in figure 5A, demonstrate overall increased total 
amount of EPHs in TPC1, BCPAP, SW1736 and 8505C cancer cells compared to normal 
Nthy-ory cells. Moreover, our screening cell line, TPC1, express high levels of tyrosine 
phosphorylated proteins, however when looking at the phosphorylation status in other cell 
lines, we observed differences among the cells; for instance,  BCPAP cells seem to activate 
mainly EPHA2, while SW1736 cells express high levels of phosphorylated EPHB2 (Figure 
5A). According to the EFN expression level results, the differences in activation could be due 
to the aboundance of specific ligands (EFNA1 for BCPAP and EFNB2 for SW1736), but 
more detailed studies are needed in order to understand the dynamic of EPHs-EFNs 
interaction in thyroid cancer cells.  
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Silencing of EPHRs affects migration and invasiveness of thyroid cancer cells. 
To finally study whether the knock-down of the EPHs would affect any of the known 
pathway controlling thyroid cancer cell growing and metastasizing properties, we performed 
EPHR siRNA transfection in TPC1, BCPAP and NTHY cells and determined the impact on 
mitogenic and invasive properties. By performing Western blotting experiments, we observed 
that in the interfered cells the activation of the most prominent oncogenic pathways (such as 
MAPK and AKT) was impaired (Figure 5B lower panels). To further characterize the 
efficiency of protein silencing we tested the same lysates for EPHRs expression, finding that 
the receptors were significantly reduced in the presence of their specific siRNA (Figure 5B 
upper panels). To then move to study the biological properties of the interfered cells, we 
verified whether knock-down of EPHRs would be able to impair cell migration into a 
“wound” that is created in a cell monolayer and to affect cell invasion of matrigel. Figure 5C 
shows how in TPC1 cells interfered with siRNAs targeting EPHA2, EPHA4 and EPHB2, 
there is a reduced ability to close the wound at 12 hours. Figure 5D shows instead how the 
same siRNA have also ability to impair matrigel invasion of TPC1 cells, supporting the 
hypothesis that EPHR may have a role in promoting not only mitogenesis but also gain of 
invasive and angiogenic properties in thyroid cancer cells. 
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DISCUSSION 
Elucidation of the complex signaling pathways governing cancer cell growth and survival has 
allowed the rational design of targeted inhibitors. Still, a major challenge is that of 
determining which target to inhibit in each cancer type. The dependence of cancer cells on 
specific genetic lesions (“oncogene addiction”) is under deep investigation, as these lesions 
are susceptible of pharmacological intervention (Luo et al., 2009). However, cancer cells can 
also be addicted to proteins that, though non mutated per se, still are crucial for cancer (but 
not for normal) cell viability. This phenomenon has been called “non-oncogene addiction” 
(Luo et al., 2009). Thus, as an example, RAS mutated cancer cells can in principle be 
eradicated by identifying proteins (other than RAS) to which they are addicted to. The 
identification of such Achilles’ heels remains a formidable challenge. Moreover, also in those 
cases in which cancer-causing oncoprotein can be effectively targeted (for example BCR-
ABL in CML), resistance may develop. In some cases, the resistance is mediated by 
secondary mutations in the oncoprotein that impairs drug binding; in other cases, resistance is 
caused by the activation of alternative pathways with which cancer cells escape the treatment 
(Gramza et al., 2009; Milojkovic et al., 2009). 
RNAi technology has provided a powerful approach to tackle these tasks, because it allows 
searching for proteins to which cancer cells are addicted to or that mediate cancer cell 
resistance (Luo et al., 2009). We applied an RNAi-based screen to identify protein kinases to 
which thyroid cancer cells may are addicted to. We focused our attention on protein kinases 
(and associated proteins) because of their frequent involvement in human cancer (in thyroid 
cancer in particular) and because of their “druggability”. Initially, we conducted the screening 
in the TPC1 cell line, expressing the RET/PTC1 rearrangement. Then, we extended the study 
to other thyroid cancer cell lines bearing BRAF or RAS oncogenes. At the end, we have 
identified a set of 20 genes that, when silenced, impaired the viability of the various thyroid 
 20 
cancer cells. Importantly, sensitivity to knock-down of these genes was not cell line-specific 
and, therefore, not oncogene-specific (RET/PTC, BRAF, RAS). Indeed, on average, all the 4 
cancer cell lines were equally susceptible to their blockade.  
These findings anticipate that BRAF mutant thyroid cancers may be susceptible to the 
inhibition of most of our down hits, an important concept because BRAF mutations are 
recognized as risk factors for thyroid cancer to progress to radioiodine refractory disease 
(Xing, 2007). Inhibition of most of our 20 genes may exert efficacy also in RAS mutant 
thyroid cancers; this is also important because, as mentioned above, RAS oncoproteins have 
been difficult to be targeted directly. Moreover, several of the used cancer cell lines bear p53 
mutations. Therefore, efficacy of our siRNAs was not negatively affected by p53 mutations; 
this is another important point given the role that p53 mutation exerts on cancer cell resistance 
to pharmacological therapy (Wiman, 2010). Finally, the two non tumorigenic thyroid cell 
types were in general refractory to the effects of the identified siRNAs, a fact that warrants a 
good therapeutic window for approaches aimed at inhibiting them in thyroid cancer.  
None of our identified hits has been previously directly involved in thyroid cancer; exceptions 
were AKAP9 that was found rearranged with BRAF in radiation-associated PTC (Ciampi et 
al., 2005) and GRK4 that was found overexpressed in thyroid nodules (Voigt et al., 2004).  
Although our hits are involved in several pathways and cellular functions, the list was 
enriched for: i) EPHR; ii) SRC family kinases (FYN, HCK); iii) proteins involved in the p38 
MAPK pathway (MAP3K6, MAP3K7IP1, MAPKAPK2) or other MAPK cascades 
(RPS6KA6 in the ERK; MAP3K6 in the JNK); iv) proteins involved in the PI3K/mTOR 
signaling (AKT2). Involvement of these cascades in thyroid cancer is well established. 
Moreover, both PI3K and ERK are key effectors of RET-derived oncogenes (Melillo et al., 
2005; Lodyga et al., 2009). Also SRC family kinases were previously involved in RET/PTC 
signal transduction (Melillo et al., 1999) and as targets for kinase inhibitors in thyroid cancer 
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(Schweppe et al., 2009). Finally, JNK and p38MAPK were activated by RET/PTC (Chiariello 
et al., 1998) and p38 targeting was effective in reducing proliferation of TPC1 cells (Mariggiò 
et al., 2007). Blockage of the 20 hits quite homogenously affected cell proliferation but not 
cell survival. This suggests that they are primarily involved in sustaining proliferation. 
However, this does not exclude that specific hits may also exert additional functions. In fact, 
EPH receptors, for instance, were important also for cancer cell migration and invasion. RTK 
receptors of the EPH family were the largest group (8/21, 40%) among the hits identified. 
Indeed, four members of the A family (EPHA2, EPHA4, EPHA5, EPHA7) and two of the B 
family (EPHB2 and EPHB6), were included among them. All of them (with the exception of 
EPHA5, that was required for TPC1 and BCPAP only) were required for the viability of all 
thyroid cancer cells. Three of them (EPHA2, EPHA4 and EPHB2) were over-expressed in 
most of the neoplastic cell lines as compared to normal thyroid cells and were constitutively 
phosphorylated in different cancer cell lines but not in NTHY cells. Knock-down of EPHA2, 
EPHA4 and EPHB2 not only reduced proliferation and affected MAPK and AKT activation, 
but also impaired cell motility and invasiveness of TPC1 cells. Finally, EPHA2, and to a 
lower extent EPHA4 and EPHB2, were over-expressed in PTC and ATC comparing to 
normal thyroid specimens. Mechanism of overexpression and activation of EPH in thyroid 
cancer cells remain to be addressed. Intriguingly, EPH expression is stimulated by the RAS-
RAF-ERK axis (Macrae et al., 2005); being virtually always activated in thyroid cancer 
(through RET, RAS or BRAF), this pathway may explain EPH overexpression in thyroid 
cancer cells. EPHB receptors bind promiscuously to the 3 transmembrane ephrins B (EFN-B), 
while EPHA receptors bind promiscuously to the 5 GPI-linked ephrins A (EFN-A). 
Interestingly, EFNA1, major ligand for EPHA2, EFNA4, ligand for EPHA4 and EFNB2, 
ligand for EPHB2 were also overexpressed in TPC1 and other thyroid cancer cells. EPH-EFN 
complexes emanate bidirectional signaling: forward signals that depend on EPH tyrosine-
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kinase activity, and reverse signals depending on SRC family kinases associated to the 
cytosolic side of EFN (Pasquale, 2010). Forward signaling controls many functions including 
cell migration, invasion, proliferation ad survival. Among them, perhaps, the most typical 
EPH-mediated effect is the generation of a “repulsive” inter-cellular force that leads to cell-
cell detachment and scattering (Pasquale, 2005). Importantly, such a migration-promoting 
role was exerted by EPHA2, EPHA4 and EPHB2 in thyroid cancer cells.  
Our conclusion from these observations is that in thyroid cancer EPHA2, EPHA4 and EPHB2 
are overexpressed and constitutively phosphorylated; moreover, their knock-down impair cell 
proliferation and inhibits migration and invasiveness. Therefore, these EPHs behave as bona 
fide oncogenes, and their inhibition with small molecule inhibitors has the potential to 
improve treatment of those cancers that are dependent on these molecules for their growth and 
invasiveness. However, whether these effects are opposite to those that EPH may mediate in 
normal thyrocytes and the biochemical mechanism for such a subversion need to be further 
investigated as well as more studies are required to clarify the EPH-EFN interaction in 
thyroid tumor as well as in tumor microenviroment (endothelial cells and pericytes) where it 
has been described to promote angiogenesis (Pasquale, 2010).  
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Table 1: List of identified down hits.  
Symbol Gene name GenbankID 
AGC protein kinase C family  
AKT2 v-akt murine thymoma viral oncogene homolog 2 NM_001626 
CIT citron (rho-interacting, ser/thre kinase 21) NM_007174 
PKN1 protein kinase N1 NM_002741 
PRKACB protein kinase cAMP dependent, catalitic, beta NM_182948 
RPS6KA6 ribosomal protein S6 kinase, 90kDa, polypeptide 6 NM_014496 
Atypical   
SMG1 PI-3-kinase-related kinase SMG-1 NM_014006 
CAMK calcium/calmodulin-dependent protein kinases  
CAMKIINα calcium/calmodulin-dependent protein kinase  NM_018584 
CIB3 calcium and integrin binding family member 3 NM_054113 
STK33 serine/threonine kinase 33 NM_030906 
CK1   
CSNK1G2 casein kinase 1, gamma 2 NM_001319 
CMGC   
CDK4 cyclin-dependent kinase 4 NM_000075 
HIPK1 homeodomain interacting protein kinase 1 NM_152696 
PLK3 polo-like kinase 3  NM_004073 
KAP Kinase-associated protein  
AKAP9 A kinase (PRKA) anchor protein (yotiao) 9 NM_005751 
MAP2K1IP1 mitogen-activated protein kinase kinase 1 interacting protein 1 NM_021970 
MAP3K7IP1 mitogen-activated protein kinase kinase kinase 7 interacting protein 1 NM_006116 
Other   
AAK1 AP2 associated kinase 1 NM_014911 
AK3 adenylate kinase 3 NM_013410 
CDKN2A cyclin-dependent kinase inhibitor 2A  NM_000077 
DGKB diacylglycerol kinase, beta 90kDa NM_004080 
GRK4 G protein-coupled receptor kinase 4 NM_182982 
IHPK3 inositol hexaphosphate kinase 3 NM_054111 
ITPKA inositol 1,4,5-trisphosphate 3-kinase A NM_002220 
NEK3 NIMA (never in mitosis gene a)-related kinase 3 NM_002498 
PIP5K1C phosphatidylinositol-4-phosphate 5-kinase, type I, γ NM_012398 
SORCS3 sortilin-related VPS10 domain containing receptor 3  NM_014978 
TK1 thymidine kinase 1, soluble NM_003258 
UCKL1 uridine-cytidine kinase 1-like 1 NM_017859 
ULK4 unc-51-like kinase 4 NM_017886 
STE MAPK cascade family  
MAP3K6 mitogen-activated protein kinase kinase kinase 6 NM_004672 
MAP4K1 mitogen-activated protein kinase kinase kinase kinase 1 NM_007181 
MAPK7 mitogen-activated protein kinase 7 NM_002749 
MAPKAPK2 mitogen-activated protein kinase-activated protein kinase 2 NM_004759 
MARCKS myristoylated alanine-rich protein kinase C substrate NM_002356 
PAK2 p21 (CDKN1A)-activated kinase 2 NM_002577 
PXK PX domain containing serine/threonine kinase NM_017771 
STK10 serine/threonine kinase 10 NM_005990 
TK tyrosine kinases  
EPHA2 EPH receptor A2 NM_004431 
EPHA4 EPH receptor A4 NM_004438 
EPHA5 EPH receptor A5 NM_004439 
EPHA7 EPH receptor A7 NM_004440 
EPHB2 EPH receptor B2 NM_017449 
EPHB6 EPH receptor B6 NM_004445 
FYN FYN oncogene  NM_002037 
HCK hemopoietic cell kinase NM_002110 
TKL tyrosine kinases like  
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ACVR1B Ser/ Thr protein kinase receptor R2 precursor  NM_004302 
ACVRL1 Ser/ Thr protein kinase receptor R3 precursor,  NM_000020 
LIMK1 LIM domain kinase 1 NM_002314 
TESK1 testis-specific kinase 1 NM_006285 
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FIGURE LEGENDS 
Figure 1: Confirmation screening in TPC1 cells. 
TPC1 cells were transfected with two independent siRNAs, targeting different regions of the 
49 identified genes. Results of cell titer blue are shown. Our confirmed hits were those 
siRNAs that reduced viability of at least 25% (loess log ≤-0.5, shown as dotted line). The 
values shown are the means of two siRNAs transfections and the bars represent the upper and 
lower 95% confidence intervals for three independent experiments. ∗P= .05. 
 
Figure 2: Validation screening in thyroid cell lines. 
Several thyroid normal (Nthy-ori 3-1 and P5) and cancer cell lines (BCPAP, CAL62 and 
8505C) were transfected with siRNAs targeting our identified 20 down hits. The values 
represent cell titer blue incorporation, expressed as Loess Log of cell viability. Values of three 
independent experiments with upper and lower 95% confidence intervals are shown. ∗P= .05. 
 
Figure 3: Effect of siRNAs on cell proliferation. 
TPC1 and NTHY were transfected with siRNAs targeting our 20 hits and S-phase entry was 
monitored by using luminescence. Proliferation obtained from scrambled transfected cells 
was normalized as 100%, and the values shown are the means and upper 95% confidence 
intervals for three independent experiments. ∗P= .05.  
 
Figure 4: Expression analysis of EPHs in human thyroid cell lines and samples. 
EPHA2, EPHA4 and EPHB2 expression level was analyzed in a panel of thyroid cancer cell 
lines of different genotype and hystotype (see also Table S1). The bar graphs illustrate the ß-
actin normalized EPHs (A) and ephrines (B) mRNA levels in cancer cells relative to those of 
normal cells and in patient samples relative to those of normal thyroid tissues. Data shown are 
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the mean values and upper 95% confidence intervals of the intensity levels from three 
independent PCR amplifications. ∗P= .05. ∗∗P= .01. 
 
Figure 5, A: EPHs protein and phosphorylation levels. EPHA2, EPHA4 and EPHB2 
immunoprecipitation show higher levels in cancer cells compared to normal cells (upper 
lane); moreover, although with differences among the cell lines, cancer cells express more 
phosphorylated protein (middle lane).  Protein have been normalized on tubulin expression 
levels (lower lane). B: Knock-down of EPHs impairs activation of MAPK and AKT signaling 
pathways. TPC1 and NTHY have been transfected with siRNA against EPHA2, EPHA4 and 
EPHB2 receptors. After testing efficiency of silencing with specific EPH antibodies, we 
probed the same lysates for phosphorylation (activation) of MAPK and AKT. Our data show 
that all the three EPHs are somehow affecting MAPK and AKT activation , as their silencing 
impairs the phosphorylation of both pathways. Normalization has been performed using 
tubulin antibody. C: EPHs control migration and invasion of thyroid cancer cells. Wounds of 
300 µM width were set in a 80% confluent monolayer of TPC1 scrambled or EPHA2, EPHA4 
and EPHB2 interfered. The vertical dotted lines indicate the margins of wound. 
Representative micrographs are shown. Magnification = ×10. Scale bar = 200 µM. Closure of 
the wound 12 at hours was measure and scrambled transfection was used as control. The 
means and 95% confidence intervals (error bars) from three independent experiments are 
presented. P values were calculated using two-sided Student t test. ∗∗P= .01. D: Cell 
migration was analyzed using Boyden chamber assay and expressed as percentage of solvent-
treated TPC1 scrambled interfered cells. The means and 95% confidence intervals (error bars) 
from three independent experiments are presented. P values were calculated using two-sided 
Student t test. ∗P= .05. ∗∗P= .01. 
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FIGURES 
Figure 1: Confirmation screening in TPC1 cells. 
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Figure 2: Validation screening in thyroid cell lines. 
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Figure 2: Validation screening in thyroid cell lines (cont’nd). 
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Figure 3: Effect of siRNAs on cell proliferation. 
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Figure 4: Expression analysis of EPHs in human thyroid cell lines and samples. 
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Figure 4: Expression analysis of EPHs in human thyroid cell lines and samples (cont’nd) 
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Figure 5: EPHs protein and phosphorylation levels  
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Figure 5: EPHs protein and phosphorylation levels (cont’nd).  
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Figure 5: EPHs protein and phosphorylation levels (cont’nd).  
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Figure 5: EPHs protein and phosphorylation levels (cont’nd).  
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Table S2: List of used cells lines 
Cell line Type Oncogene 
BCPAP PTC Braf V600E 
CAL62 ATC KRAS 
NTH-ory 3-1 NT - 
P5 NT - 
SW1736 ATC Braf V600E 
TPC1 PTC RET/PTC1 
8505C ATC Braf V600E 
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Table S3: List of used siRNA 
 siRNA1 siRNA2 siRNA3 siRNA4 
AAK1 SI02224579 SI02224586 SI00108717 SI00108724 
ACVR1B SI02622046 SI00288127 SI03070977 SI03117107 
ACVRL1 SI02659972 SI00000154 SI02758392 SI04894687 
AK3 SI02224453 SI02224460 SI03084305 SI03102253 
AKAP9 SI00080948 SI03024854 SI02223963 SI02223970 
AKT2 SI00299166 SI00287672 SI00299173 SI00287679 
CAMKIINalpha SI02224873 SI02224880 SI00112882 SI00112889 
CDK4 SI00604744 SI00001428 SI00299789 SI00299803 
CDKN2A SI02659503 SI02664396 SI02664403 SI00299817 
CIB3 SI02225223 SI02225230 SI02647666 SI02647673 
CIT SI02224243 SI00095088 SI00095074 SI04438840 
CSNK1G2 SI00605171 SI00605178 SI03073217 SI03105690 
DGKB SI02225265 SI02225272 SI03043103 SI03050551 
EPHA2 SI02223508 SI04434990 SI00300181 SI00300188 
EPHA4 SI04435018 SI04435025 SI02223522 SI02223529 
EPHA5 SI00063686 SI00063672 SI02223536 SI00287511 
EPHA7 SI00063707 SI03091851 SI02223543 SI02223550 
EPHB2 SI02642626 SI02224796 SI02224789 SI04026330 
EPHB6 SI00063805 SI00063826 SI02665292 SI02758441 
FYN SI02654729 SI02659545 SI00605451 SI03095218 
GRK4 SI02649920 SI02622501 SI02622508 SI03032092 
HCK SI02627807 SI02665320 SI02659986 SI02665327 
HIPK1 SI00288001 SI00288008 SI03054233 SI04903899 
IHPK3 SI02659846 SI02659853 SI04441318 SI00148092 
ITPKA SI00605500 SI00605507 SI00034482 SI00034489 
LOC392265 SI00538776    
LIMK1 SI00036057 SI00605542 SI00605549 SI00036064 
MAP2K1IP1 SI02225027 SI02225034 SI00131845 SI00131859 
MAP3K6 SI00066955 SI04438042 SI00288218 SI00288225 
MAP3K7IP1 SI04900049 SI02660329 SI02758903 SI04952311 
MAP4K1 SI00095130 SI04438854 SI02224250 SI02224257 
MAPK7 SI00606039 SI02629445 SI00606046 SI03024924 
MAPKAPK2 SI00068033 SI00068012 SI02223697 SI00288246 
MARCKS SI00605584 SI00605591 SI00036603 SI04897060 
MGC4796 SI00287910 SI00287917 SI00141687 SI00141694 
NEK3 SI02225293 SI02225300 SI04897193 SI04897193 
PAK2 SI00039802 SI00605710 SI00301077 SI00301084 
PIP5K1C SI02224376 SI00099953 SI02758966 SI00099967 
PKN1 SI00042350 SI00605962 SI00605955 SI00042357 
PLK3 SI02223466 SI00059388 SI02223473 SI00059395 
PRKACB SI03063228 SI03022740 SI02225468 SI02225461 
PXK SI02224817 SI02224824 SI00119609 SI00119616 
RPS6KA6 SI00106603 SI04379592 SI00287609 SI02659748 
SMG1 SI02640148 SI00102753 SI02622333 SI00102767 
SORCS3 SI00108983 SI02641100 SI00108990 SI00108997 
STK10 SI02224047 SI02224054 SI04713569 SI04713576 
STK33 SI02660210 SI02660203 SI02660217 SI00139741 
TESK1 SI02224117 SI02224124 SI04379522 SI00086919 
TK1 SI00049931 SI02223193 SI02223200 SI02223200 
UCKL1 SI00288484 SI00288491 SI04439939 SI04439939 
ULK4 SI04901631 SI04025490 SI02812061 SI02812068 
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Table S4: List of primers used for QPCR 
 REVERSE  FORWARD 
AAK1 GGGTTTTGGTTGGGGAAC AAGAGGGCCACTGTTCAGC 
ACVR1B GGCAGCTGATATTCTTCATGG ATATTGGGAGATTGCTCGAAGA 
ACVRL1 CTGCTCCGAAGGAGGTTG CCACCTCTGCAACCACAA 
AK3 GCTTTCTGGCTTCTTTGTGG TCTCATTCAGCGTGAGGATG 
AKAP9 CTTTGTCGAAACTGGGCAAG GGAGGACGAGGAGAGACAGA 
AKT2 ACACACCCCAGCTGCCCTCA CGCCAAGCCCAACCACTCTGG 
CAMKIINalpha GAGGCCAGCAACAGATTCTC GGAGGGACACCACTACCTGA 
CDK4 AGGGAGACCCTCACGCCAGC CTCTGCGTCCAGCTGCTCCG 
CDKN2A AAAACCCTCACTCGCGGCGG GTGCGTGGGTCCCAGTCTGC 
CIB3 TCACGGAAAACATGTCCAAA CTCGTGCCCCTCGACTATAC 
CIT CAGAAGGAGGTGGAGCTGAA CTTGCTCCAAACTTCGCTTT 
CSNK1G2 AGTTCAACGCCTGGTTTTTG CTTCGAGAAGCCCGACTATG 
DGKB CTCCTGAAGTGGGCAGAGTC GGACTGCATTGTGTTTGGTG 
EPHA2 CCAGGCAGGCTACGAGAA GGCTCTCAGATGCCTCAAAC 
EPHA4 TCCAAGTTCACAGATGTCTCGTTGAC TCTATGCCCTGCACCCGTCCA 
EPHA5 TCTGGAGGACGTGCCTTCTCCT TGACAGTGCGTGAATCCAAT 
EPHA7 GGTCAGATGGAGCCCTGTAA AAGCAGGCTACCAGCAAAAA 
EPHB2 CCAGCAGAACTTGCATCTTG TCTTTGGAGGGCCTGGAT 
EPHB6 CGGAACTCCTGCTCTATTGC TGCTGGTGAATAGCCACTTG 
FYN CATCTTTTCGGCCAAGTTTT CAGCAATTATGTGGCTCCAG 
GRK4 CACAATCACTTCGGTCCTCA GAGGCACATTGAATTCTTGGA 
HCK GCAATCTGGGCTGAGAAGTC TGGCAGTGAAGACGATGAAG 
HIPK1 TTTTGTGAAGCTATTGATATGTGGT GCAAGCCTTGTGTTTGTGAA 
IHPK3 GAGCATACGGTGTGCAAGC AGAGGTGCACTGTGACGGTA 
ITPKA TACATGTCCTTCCGCAGCTT GTGTGCTCGACTGCAAAATG 
LOC392265   
LIMK1 TGTCCTTGGCAAAGCTCACT GGGGCATCATCAAGAGCA 
MAP2KIP1 TGTCAGATAGAGATGGAGTACCTGTT AAACCAGGTCGCAAAGCAT 
MAP3K6 CGGGGGAGATGTTGGAGT TCTCCTTGATGGCGATGC 
MAP3K7IP1 CTGAGCCAACCCCAGAGA GGAGCTTGCTGCAGAGTGA 
MAP4K1 GCCACCAAGATGCTCAGTC CCGGGATTCTTCAGTTTGTC 
MAPK7 GGTCGCTTTCCATCAGGTC AAATGGCGGACACAATTCC 
MAPKAPK2 TCTCGTACACATCCACGATCC GAGGACCCAGGAGAAATTCG 
MARCKS TTTACCTTCACGTGGCCATT ATGGGTGCCCAGTTCTCC 
MGC4796 TCCGCTTCATTCTCAGCTCT AGCATGACCACAGACCCATT 
NEK3 TATTAGGGTGTTTCATTTTGGCTA GCCATGAAAGAAATAAGGCTTC 
PAK2 GATAACGGTTTGGCCAGTTTC AAGGGGTTCAGCCAAAGAAT 
PIP5K1C CTGGGTCGGGGGCTGCATAGA CACCGACATCTACTTTCCCACCG 
PKN1 CTCTTCGATGCGCAGCTC CACATCCGCATGCAACT 
PLK3 GTGGTCCCCGTAGAAGTTCA CTACATGGAGCAGCACCTCA 
PRKACB CTTTGGCTAGAAACTCTTTCACG TGACCCCTTCTTGCCATC 
PXK GGGCCAAGGTCAGCCCAGCTTA GAACCAAAGTGGGAGGTGGTGGA 
RPS6KA6 GCAACTCAAACTGTGCAGGA CGGCGAGGTAAATGGTCTTA 
SMG1 GCACTATCAGTTCTGGGTTGCCAGT TAATGAGCCGCAGAGCCCCGG 
SORCS3 TTCCTCTCAGGTCCACATCC ACGCGTGGGATTTACTTCAC 
STK10 CTTCGGCAAGGTTTACAAGG TCAATCTCCACGATGTAGTCCTC 
STK33 TGTAATTGGCATCAGGGACA CTTCGGTGAGACCAACCAAT 
TESK1 GGTGCTGGGTTCCAGGTT AACTCTGGTGGGGGATGACT 
TK1 AATGGCTTCCTCTGGAAGGT AGACACTCGCTAACAGCAGCA 
UCKL1 GGTAAGCTGGTTGTTCTGGA TTCAGGACTGCGTCGTACAG 
ULK4 ACCCCTCACAACTTCTGGTG GGCAAAAGTGGAAGGTGAAA 
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Supplementary Figures 
 
 
Figure S1: Plot of screening data. 
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Figure S2, S3: All used siRNAs silence their specific targets. Gene expression of the 20 
down hits has been tested in TPC1 (S2) and NTHY (S3) cells transfected with their siRNAs 
compared to control, scrambled transfected, cells. Hystograms express fold reduction 
compared to control. Error bars represent upper 95% confidence intervals from three 
independent experiments. ∗P= .05. ∗∗P= .01. 
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Figure S2, S3: All used siRNAs silence their specific targets. Gene expression of the 20 
down hits has been tested in TPC1 (S2) and NTHY (S3) cells transfected with their siRNAs 
compared to control, scrambled transfected, cells. Hystograms express fold reduction 
compared to control. Error bars represent upper 95% confidence intervals from three 
independent experiments. ∗P= .05. ∗∗P= .01. 
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Figure S4, S5: Knock-down of our down hits reduce number of thyroid cancer cells but not 
of normal cells. Cell count was performed 72 hours after transfection of siRNA in TPC1 (S4) 
and NTHY (S5) cells. Error bars represent upper 95% confidence intervals from three 
independent experiments. ∗P= .05. ∗∗P= .01. 
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Figure S4, S5: Knock-down of our down hits reduce number of thyroid cancer cells but not 
of normal cells. Cell count was performed 72 hours after transfection of siRNA in TPC1 (S4) 
and NTHY (S5) cells. Error bars represent upper 95% confidence intervals from three 
independent experiments. ∗P= .05. ∗∗P= .01. 
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Abstract
RET/papillary thyroid carcinoma (RET/PTC) oncoproteins
result from the in-frame fusion of the RET receptor tyrosine
kinase domain with protein dimerization motifs encoded by
heterologous genes. Here, we show that RET/PTC stimulates
the B-catenin pathway. By stimulating PI3K/AKT and Ras/
extracellular signal–regulated kinase (ERK), RET/PTC pro-
motes glycogen synthase kinase 3B (GSK3B) phosphorylation,
thereby reducing GSK3B-mediated NH2-terminal B-catenin
(Ser33/Ser37/Thr41) phosphorylation. In addition, RET/PTC
physically interacts with B-catenin and increases its phospho-
tyrosine content. The increased free pool of S/T(nonphospho)/
Y(phospho)B-catenin is stabilized as a result of the reduced
binding affinity for the Axin/GSK3B complex and activates the
transcription factor T-cell factor/lymphoid enhancer factor.
Moreover, through the ERK pathway, RET/PTC stimulates
cyclic AMP–responsive element binding protein (CREB)
phosphorylation and promotes the formation of a B-catenin-
CREB-CREB-binding protein/p300 transcriptional complex.
Transcriptional complexes containing B-catenin are recruited
to the cyclin D1 promoter and a cyclin D1 gene promoter
reporter is active in RET/PTC–expressing cells. Silencing of
B-catenin by small interfering RNA inhibits proliferation of
RET/PTC–transformed PC Cl3 thyrocytes, whereas a constitu-
tively active form of B-catenin stimulates autonomous
proliferation of thyroid cells. Thus, multiple signaling events
downstream from RET/PTC converge on B-catenin to stimu-
late cell proliferation. [Cancer Res 2009;69(5):1867–76]
Introduction
Papillary thyroid carcinoma (PTC) features chromosomal
aberrations that result in the fusion of the tyrosine kinase domain
of the RET receptor with the NH2 terminus of heterologous
proteins, thereby generating the RET/PTC oncoproteins (1).
Although there is large variation according to the geographic area
and the detection method, the fraction of PTC samples positive for
RET/PTC oncogenes is estimated to be 20% to 40%; this fraction
increases up to 80% in PTC developed in radiation-exposed
individuals (1). RET/PTC1 (H4-RET) and RET/PTC3 (NCOA4-RET)
are the most prevalent variants (1). Fusion with protein partners
that have protein-protein interaction motifs provides RET/PTC
kinases with dimerizing interfaces, thereby resulting in ligand-
independent dimerization and constitutive kinase activation.
Autophosphorylation of RET Y1062 plays a particularly important
role in cell transformation (2). Accordingly, when phosphorylated,
Y1062 acts as the binding site for several protein tyrosine binding
proteins, namely, Shc, IRS1/2, FRS2, and DOK1/4/5 (2). This
mediates recruitment of growth factor receptor binding protein
2/son of sevenless homologue complexes (2–5) and Gab-family
adaptors (2, 6–8) leading to Ras/RAF/extracellular signal–regulated
kinase (ERK) and PI3K/AKT signaling (9–11). Moreover, RET/PTC
depends on the phosphorylation of Y1062 for recruitment at the
inner surface of the cell membrane (2–5).
RET/PTC–mediated transformation requires the Ras/RAF/ERK
cascade (11–13). In line with this observation, oncogenic
conversion of a member of the RAF family, BRAF, is frequently
detected in PTC (1, 14). In addition, deregulation of the PI3K
signaling, through activation of PI3K and AKT serine/threonine
kinase or loss of PTEN phosphatase, is prevalent in thyroid cancer
(15, 16). PI3K signaling is mitogenic for thyrocytes (15, 16).
h-Catenin is a multifunctional protein that plays an important
role in signal transduction. In normal resting cells, h-catenin is
mainly localized to the adherens junctions, whereas free cytosolic
h-catenin is recruited to a ‘‘destruction’’ complex that includes
the scaffolding protein Axin, the tumor suppressor adenomatous
polyposis coli (APC), and glycogen synthase kinase 3h (GSK3h).
This complex facilitates the NH2-terminal serine/threonine phos-
phorylation of h-catenin by GSK3h, thereby targeting h-catenin for
degradation by the ubiquitin-proteasome (17). When the pathway
is activated, as it occurs in the presence of Wnt ligands, h-catenin
is stabilized. Stabilization of h-catenin results in its nuclear
accumulation and interaction with T-cell factor/lymphoid enhanc-
er factor (TCF/LEF) or other transcription factors and in activation
of genes required for cell proliferation (e.g., c-Myc and cyclin D1 ;
ref. 18). PI3K/AKT induces Ser9/21 GSK3h phosphorylation and
inhibition of GSK3h-mediated phosphorylation of h-catenin (19).
p90RSK, a Ras/ERK downstream kinase, also phosphorylates and
inhibits GSK3h thereby leading to h-catenin up-regulation (17, 20,
21). In this pathway, ERK associates with a docking motif, FKFP
(residues 291–294), of GSK3h and phosphorylates it at Thr43 to
prime it for subsequent phosphorylation at Ser9/21 by p90RSK (22).
Up-regulation of h-catenin occurs in a variety of cancers, namely,
colorectal, breast, and ovarian cancers (17, 18). Mutations that
activate h-catenin occur late in thyroid tumor progression, being
detected in undifferentiated (anaplastic) thyroid carcinomas (23).
Increased free h-catenin pools have been observed in thyroid
carcinomas secondary to reduced E-cadherin expression (24). It
has been recently reported that oncogenic point mutants of RET
(2A-RET and 2B-RET), which are associated with medullary thyroid
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cancer, phosphorylate h-catenin on Y654 thereby promoting
h-catenin escape from APC/Axin/GSK3h–mediated destruction
(25). This prompted us to investigate the functional connection
between RET/PTC and the h-catenin signaling cascades.
Materials and Methods
Cell lines. HEK293T cells were grown in DMEM supplemented with
10% FCS (Invitrogen). The human thyroid cancer cell lines, derived from
papillary (TPC-1 and BCPAP) or anaplastic (OCUT-1 and 8505C) thyroid
carcinoma, were grown in DMEM containing 10% fetal bovine serum (FBS).
8505C were from DSMZ (Deutsche Sammlung von Mikroorganismen
und Zellkulturen GmbH). OCUT-1 were a gift of K. Hirakawa and N. Onoda
(Osaka, Japan). TPC-1 harbors a RET/PTC1 rearrangement; BCPAP, OCUT-1,
and 8505C harbor a BRAF V600E mutation (26). Normal human thyrocytes
were isolated from normal thyroid tissue obtained from a patient who
underwent thyroid surgery and cultivated in RPMI supplemented with 20%
FBS. PC Cl3 (hereafter called ‘‘PC’’) is a differentiated thyroid follicular cell
line derived from 18-mo-old Fischer rats. PC cells were cultured in Coon’s
modified Ham’s F-12 medium supplemented with 5% calf serum and a
mixture of six hormones, including thyrotropin (10 milliunits/mL),
hydrocortisone (10 nmol/L), insulin (10 Ag/mL), apo-transferrin (5 Ag/mL),
somatostatin (10 ng/mL), and glycyl-histidyl-lysine (10 ng/mL; Sigma).
RET/PTC–expressing PC cells have been described previously (11). To obtain
PC cells stably expressing the RET/PTC(4F) or RET/PTC(3F) mutants,
transfections were done by the calcium phosphate coprecipitation technique
as described previously (11) and mass populations of several 10 cell clones
were isolated for each transfection by G418 selection. Equal levels of
expression of RET/PTC mutants were confirmed by immunoblotting.
Transient transfections were carried out with the Lipofectamine reagent
according to the manufacturer’s instructions (Life Technologies).
Cell growth and staining. For growth curves, 0.5  105 cells were
seeded in triplicate and counted at the indicated time points. DNA synthesis
rate was measured with the 5¶-bromo-3¶-deoxyuridine (BrdUrd) Labeling
and Detection kit from Boehringer Mannheim. Briefly, cells were seeded
on glass coverslips, pulsed for 1 h with BrdUrd ( final concentration of
10 Amol/L), fixed, and permeabilized. Coverslips were incubated with anti-
BrdUrd mouse monoclonal and rhodamine-conjugated secondary anti-
bodies (Jackson ImmunoResearch Laboratories) and mounted in Moviol
on glass slides. Cell nuclei were identified by Hoechst 33258 ( final
concentration, 1 Ag/mL; Sigma) staining. The fluorescent signal was
visualized with an epifluorescent microscope (Axiovert 2, Zeiss; equipped
with a 100 lens) interfaced with the image analyzer software KS300 (Zeiss).
At least 100 cells were counted in five different microscopic fields; results
were average fractions of BrdUrd-positive cells F SD.
Tissue samples. Archival frozen thyroid tissue samples from 12 patients
affected by PTC (T1–T12) and 2 normal thyroids (N1–N2) were retrieved
from the files of the Pathology Department of the University of Pisa. The
study was approved by the Institutional Ethics Committee. Sections (4 Am
thick) of paraffin-embedded samples were stained with H&E for histologic
examination to ensure that the samples met the diagnostic criteria required
for the identification of PTC (enlarged nuclei with fine dusty chromatin,
nuclear grooves, single or multiple micro/macro nucleoli, and intranuclear
inclusions; ref. 27). According to a previous characterization, three of these
PTC samples had a RET/PTC1 rearrangement (T2, T7, and T12) and six had
a BRAF V600E mutation (T1, T4, T5, T6, T8, and T10; ref. 11). Snap-frozen
tissue samples were kept in liquid nitrogen for storage at 80jC until
protein extraction was done.
Plasmids. Unless otherwise specified, RET/PTC3 is the RET/PTC form
used in this study. The RET/PTC3 constructs were cloned in pBABE and
pCDNA3.1 (Invitrogen). They encode the short (RET-9) RET/PTC3 spliced
form and are described elsewhere (11). For simplicity, we numbered the
residues of RET/PTC proteins according to the corresponding residues in
unrearranged RET. Briefly, RET/PTC(K) is a kinase-dead mutant carrying
the substitution of the catalytic lysine (residue 758 in full-length RET) with a
methionine. RET/PTC(4F) is a mutant in which the four autophosphor-
ylation sites (Y826, Y1015, Y1029, and Y1062) of the COOH-terminal tail
are mutated to phenylalanines; in RET/PTC(3F), the Y1062 has been added
back. Plasmids encoding the dominant-negative Ras(N17), MEK(DN), and
AKT(DN); the constitutively active Ras(V12), BRAF(V600), and h-catenin
(S374A); and the TCF/LEF reporter system are described elsewhere (28).
Antibodies and compounds. Anti-RET is an affinity-purified polyclonal
antibody raised against the tyrosine kinase protein fragment of human RET.
Anti–h-catenin (610153) and anti–E-cadherin (610181) were purchased
from Becton Dickinson (BD Transduction Laboratories). Anti–phospho-
p44/42 mitogen-activated protein kinase [MAPK; recognizing MAPK
(ERK1/2) when phosphorylated either individually or dually on Thr202
and Tyr204], anti–p44/42 MAPK, anti–phospho-AKT (specific for AKT
phosphorylated at Ser473), anti-AKT, anti–phospho-Ser21/9 GSK, anti-GSK,
and anti–phospho-h-catenin (Ser33/37/Thr41) were purchased from Cell
Signaling. Anti-tubulin was from Sigma. Monoclonal anti–phospho-
h-catenin (Y654) antibody was from Abcam. Anti–cyclic AMP-responsive
element binding protein (CREB), anti–phospho-S133 CREB (06-519), and
anti-Tcf4 (05-511) were from Upstate Biotechnology, Inc. Anti–CREB-
binding protein (CBP), anti-p300, anti-SP1, and anti–c-Myc antibody were
from Santa Cruz Biotechnology. Secondary antibodies coupled to
horseradish peroxidase were from Amersham Pharmacia Biotech. Cyclo-
heximide was purchased from Sigma and used at 10 Ag/mL final
concentration. LY294002 was from Calbiochem (Merck Chemicals Ltd.)
and used at 10 Amol/L final concentration. MAPK/ERK kinase (MEK)-1/2
inhibitor UO126 was from Cell Signaling and used at 10 Amol/L final
concentration.
Protein studies. Immunoblotting experiments were done according to
standard procedures. Protein concentration was estimated with a modified
Bradford assay (Bio-Rad). Immune complexes were detected with the
enhanced chemiluminescence kit (Amersham Pharmacia Biotech). Signal
intensity was analyzed with the Phosphorimager (Typhoon 8600, Amersham
Pharmacia Biotech) interfaced with the ImageQuant software. For
immunoprecipitations, total lysates were incubated with 2 Ag antibody
for 2 h at 4jC. Antibody-antigen complexes were collected with 30 AL of
protein G-Sepharose or protein A-Sepharose beads overnight at 4jC with
gentle rotation. The samples were centrifuged, washed, eluted in sample
buffer, and run on SDS-polyacrylamide gel. Nuclear extraction was done
as described elsewhere (29). Briefly, cells were harvested in lysis buffer
[10 mmol/L Tris-HCl (pH 7.9), 10 mmol/L KCl, 1.5 mmol/L MgCl2, 1 mmol/L
DTT, 1 mmol/L phenylmethyl-sulfonylfluoride (PMSF), supplemented with
60 mmol/L NaF, 60 mmol/L h-glycerophosphate, and protease inhibitors
(aprotinin, leupeptin, and pepstatin; 40 mg/mL)] and lysed by shearing with
15 passages through a 26-gauge needle mounted in a 1-mL syringe. Nuclei
were recovered by centrifugation at 3,000  g for 10 min. Nuclear proteins
were extracted in 50 mmol/L Tris-HCl (pH 7.5), containing 0.3 mol/L
sucrose, 0.42 mol/L KCl, 5 mmol/L MgCl2, 0.1 mmol/L EDTA, 20% glycerol,
2 mmol/L DTT, 0.1 mmol/L PMSF, 60 mmol/L NaF, 60 mmol/L h-
glycerophosphate, leupeptin, and aprotinin. Cytosolic fractions were recov-
ered after membrane fraction removal by 100,000  g ultracentrifugation.
Pull-down assay. The GST-RET/PTC3 and GST-RET/TK plasmids were
generated by PCR amplification of full-length RET/PTC3 or the isolated RET
component of the RET/PTC3 protein (RET residues 718–1072) and fusion to
the glutathione S-transferase (GST) coding sequence into the pEBG vector
(kindly provided by S. Meakin, Laboratory of Neural Signaling, Cell Biology
Group, The John P. Robarts Research Institute, London, Ontario, Canada;
ref. 30). GST-RET/PTC3 and GST-RET/TK fusion proteins were purified
from transiently transfected cell lysates using glutathione-Sepharose
according to standard procedures. HEK293T cells were serum starved for
18 h and lysed in an ice-cold buffer. Protein lysates (2 mg) were incubated
overnight with 30 Ag of GST-RET/PTC3 and GST-RET/TK fusion proteins.
Pellet beads were collected by centrifugation (14,000  g ) and washed with
lysis buffer. The beads were resuspended in 2 Laemmli buffer and
subjected to Western blotting.
Reporter assay. To evaluate the TCF/LEF transcriptional activity, we
used a pair of luciferase reporter constructs, TOP-FLASH and the negative
control FOP-FLASH (Upstate Biotechnology). TOP-FLASH contains three
copies of the TCF/LEF binding site (AAGATCAAAGGGGGT) upstream of
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the thymidine kinase minimal promoter; FOP-FLASH contains a mutated
TCF/LEF binding site (AAGGCCAAAGGGGGT). Cells were transiently
transfected by one of these reporters together with pRL-TK (encoding the
Renilla luciferase) in triplicate, as instructed by the manufacturer (Promega
Corporation). Luciferase activity was measured 48 h after transfection with
the Dual-luciferase reporter assay system (Promega). TCF/LEF activity was
determined by the TOP-FLASH/FOP-FLASH ratio after normalization for
Renilla luciferase activity. Light emission was quantified with a Berthold
Technologies luminometer (Centro LB 960). Data were represented as
average fold change F SD with respect to the negative control.
RNA silencing. Predesigned duplex small interfering RNA (siRNA)
against rat h-catenin (190086, 190087, and 190088) were provided by
Ambion. The scrambled oligonucleotide was synthesized by Proligo, and
the sequence was 5¶-AGGAUAGCGUGGAUUUCGGUTT-3¶. The day before
transfection, cells were plated in six-well dishes at 30% to 40% confluency.
Transfection was done using 5 Ag of duplex RNA and 6 AL of Oligofectamine
reagent (Invitrogen). Cells were harvested at 48 h posttransfection or
counted at different time points for evaluating cell growth.
Chromatin immunoprecipitation. Chromatin was extracted from
RET/PTC– or empty vector–transfected HEK293T cells. Chromatin
immunoprecipitation assay was done by using the chromatin immunopre-
cipitation assay kit (Upstate Biotechnology), following the manufacturer’s
instructions. Chromatin was fixed by directly adding formaldehyde (1%, v/v)
to the cell culture medium. Nuclear extracts were isolated and then
Figure 1. RET/PTC stabilizes h-catenin and promotes its nuclear accumulation. A, immunofluorescence for h-catenin in PC cells transiently transfected with
RET/PTC. Note the increase of nuclear staining in transfected cells. Hoechst stain was used to visualize cell nuclei; parallel transfection with green fluorescent protein
showed that f20% of the cells expressed exogenous DNA (data not shown). B, nuclear translocation of h-catenin on RET/PTC expression. HEK293T cells were
transfected with RET/PTC or the indicated mutants [mock transfected (Control )]. PC-RET/PTC cells or parental PC were also used. Subcellular fractions were obtained
and nuclear extracts (50 Ag) probed with anti–h-catenin. The purity of the fractions was assessed by verifying the absence of SP1 in the cytosolic fraction and of
RET/PTC in the nuclear fraction. Total h-catenin levels were also measured in unfractionated extracts. Columns, mean percentage of nuclear h-catenin with respect to
total levels from five independent determinations; bars, SD. Reported P values were calculated by Student’s t test. C, HEK293T cells transiently expressing RET/PTC
or a control vector were treated with cycloheximide for different time points. Lysates (30 Ag) were run on SDS-PAGE, and h-catenin levels were determined by
immunoblot.
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fragmented through sonication. Transcription factor–bound chromatin was
immunoprecipitated with h-catenin, CREB, or TCF antibodies; cross-linking
was reversed; and the isolated genomic DNA amplified by quantitative
PCR using primers spanning either the CRE site (Fig. 4D) or the TCF/LEF
binding site (data not shown) of the human cyclin D1 promoter:
CRE-forward , 5 ¶-AACGTCACACGGACTACAGG-3 ¶; CRE-reverse,
5¶-TGTTCCATGGCTGGGGCTCTT-3¶; TCF-forward, 5¶-GAGCGCATGC-
TAAGCTGAAA-3¶; TCF-reverse, 5¶-GGACAGACGGCCAAAGAATC-3¶.
Figure 2. RET/PTC induces the dissociation of the h-catenin degradation complex. A, HEK293Tcells were transfected with a myc-tagged Axin together with RET/PTC
or the indicated mutants. Protein complexes containing Axin were recovered by immunoprecipitation (1 mg) with anti-myc tag and blotted against h-catenin or
S/T-phosphorylated h-catenin (phospho-Ser33/37/Thr41). Myc-Axin and RET/PTC protein levels in total cell lysates are shown for normalization. B and C,
phosphorylation levels of GSK3h, h-catenin (phospho-Ser33/37/Thr41), AKT, ERK, and RET (Y905) were measured by immunoblot of total cell lysates (50 Ag)
harvested from HEK293T (B) or PC (C ) cells expressing the indicated RET/PTC variants or treated with the indicated compounds. GSK3h antibodies may recognize
both GSK-3a (51 kDa) and GSK3h (46 kDa) proteins; *, GSK3h migration (C ). D, nuclear accumulation of h-catenin (measured as in Fig. 1B ) in HEK293T cells
transfected with RET/PTC and treated or not with chemical PI3K or MEK inhibitors. Representative data of at least three independent experiments.
Cancer Research
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Fluorescent threshold values (C t) were measured in triplicate for
immunoprecipitated samples as well as for an aliquot of the input DNA.
Results were calculated by the following formula: 2[DC t/C t input DNA],
where DC t is the difference between the C t of the specific antibody-
immunoprecipitated DNA and the C t of mock-immunoprecipitated DNA.
Results are average F SD of triplicate samples.
Statistical analysis. Student’s t test was used for statistical analysis. All
P values were two sided and differences were significant when P < 0.05.
Results
RET/PTC promotes the nuclear accumulation of B-catenin.
Thyroid follicular PC cells transiently transfected with RET/PTC
accumulated nuclear h-catenin, a hallmark of h-catenin activation
(Fig. 1A). By biochemical fractionation, although total h-catenin
levels were increased on RET/PTC expression, nuclear h-catenin
levels were proportionally increased to a greater extent, thereby
accounting for the increase in the nuclear h-catenin fraction in
HEK293T or PC cells [7-fold (P < 0.001) or 3.6-fold (P < 0.01),
respectively] on transient or stable RET/PTC expression (Fig. 1B).
h-Catenin nuclear accumulation depended on RET/PTC kinase
activity because it was reduced by a kinase-dead mutant (K). The
residual, albeit not significant, activity of PTC(K) might depend
on RET kinase rescue operated by other tyrosine kinases, such
as epidermal growth factor receptor, as recently shown (31).
Moreover, h-catenin accumulation depended on RET/PTC auto-
phosphorylation because it was not exerted by a RET/PTC mutant
(PTC-4F) whose major autophosphorylation sites (Y826, Y1015,
Y1029, and Y1062) were mutated to phenylalanine (Fig. 1B). Y1062
was essential because nuclear accumulation of h-catenin was
restored when tyrosine Y1062 was added back to the 4F mutant
(PTC-3F; P < 0.01; Fig. 1B). There was no detectable difference
in the mRNA levels of h-catenin between RET/PTC–positive and
RET/PTC–negative cells, which suggests that the increase in
h-catenin occurred at the posttranscriptional level (data not
shown). Accordingly, the half-life of h-catenin increased in RET/
PTC–expressing cells (>24 hours) versus control HEK293T
(f12 hours; Fig. 1C).
RET/PTC targets the Axin-GSK3B-B-catenin complex. The
pathway leading to h-catenin activation involves a series of events
that result in the dissociation of h-catenin from Axin, a scaffold
protein that forms a large molecular complex with APC, Dsh, and
GSK3h (17, 18). Transient RET/PTC expression in HEK293T cells
decreased the amount of h-catenin coprecipitating with myc-
tagged Axin; this effect depended on Y1062, as shown when we
used the PTC-4F mutant (Fig. 2A). Secondary to the assembly of
the Axin-GSK3h-h-catenin complex, phosphorylation of h-catenin
by GSK3h in NH2-terminal Ser33, Ser37, and Thr41 promotes its
ubiquitin-dependent proteolytic degradation (19–22). RET/PTC
expression in HEK293T reduced amounts of S/T-phosphorylated
h-catenin coprecipitating with Axin (Fig. 2A). Moreover, transient
RET/PTC expression in HEK293T (Fig. 2A and B) and stable
expression in PC (Fig. 2C ) reduced overall S/T h-catenin
phosphorylation by immunoblot, an effect that depended on
RET/PTC kinase and Y1062 (Fig. 2B). h-Catenin phosphorylation is
affected by GSK3h. In turn, the activity of GSK3h can be blocked
by both AKT- (19) and ERK pathway–mediated phosphorylation
at Ser9 (22). RET/PTC stimulates both the PI3K/AKT and the
ERK pathways by recruiting several adaptors to phosphorylated
Y1062 (2). RET/PTC–triggered phosphorylation of AKT and
ERK paralleled the phosphorylation of GSK3h-Ser9 and the
consequent reduction of phospho-S/T h-catenin (Fig. 2B and C).
PTC-4F had a significantly reduced activity with respect to wild-
type RET/PTC (Fig. 2B). In addition, PTC-3F (although expressed
at lower levels) had a reduced effect on GSK3h phosphorylation,
suggesting that COOH-terminal tyrosines other than Y1062 may
participate to this pathway. LY294002, a PI3K inhibitor, partially
impaired GSK3h phosphorylation and increased h-catenin S/T
phosphorylation; these effects were associated with a reduction in
AKT phosphorylation (Fig. 2B). In addition, treatment with U0126,
a MEK inhibitor, reduced phosphorylation of GSK-3h and partially
rescued phospho-S/T h-catenin (Fig. 2B). Finally, treatment with
LY294002 or U0126 reduced nuclear accumulation of h-catenin
(Fig. 2D).
RET/PTC increases B-catenin phosphotyrosine content. h-
Catenin interacts directly with the oncogenic tyrosine kinases c-src
Figure 3. RET/PTC interaction with
h-catenin. A, protein lysates (2 mg) from
mock-transfected or RET/PTC–transfected
HEK293T cells were immunoprecipitated
with anti–h-catenin and probed with
tyrosine-phosphorylated h-catenin
(pY654), RET, or E-cadherin antibodies.
Expression levels in total cell lysates are
shown for normalization. B, full-length
RET/PTC3 and the isolated RET
component of the RET/PTC3 (deprived of
the NCOA4 region) protein were produced
as GST-fusion proteins and used to pull
down h-catenin from HEK293T protein
lysates. Immunoblot was stained with
anti–h-catenin; recombinant RET proteins
input is also reported.
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(32), c-MET (33), RON (34), c-erbB-2 (35), and BCR-ABL (36),
thereby resulting in h-catenin phosphorylation on tyrosine
residues. More importantly, Gujral and colleagues (25) recently
reported that MEN2-associated RET point mutants bind to
h-catenin and phosphorylate it on tyrosine 654. We tested
whether this mechanism was also used by RET/PTC. In HEK293T
cells, RET/PTC coimmunoprecipitated with h-catenin (Fig. 3A),
and on RET/PTC expression, tyrosine-phosphorylated h-catenin
(pY654) increased; overall increased h-catenin levels may partially
account for these effects (Fig. 3A). The binding of h-catenin to
RET/PTC paralleled its dissociation from E-cadherin (Fig. 3A).
Moreover, recombinant GST-RET/PTC3 and GST-RET/TK proteins
were able to pull down h-catenin from HEK293T cell lysates,
showing an interaction, either direct or mediated by intermediate
protein(s), between the RET component of RET/PTC and h-catenin
(Fig. 3B).
RET/PTC stimulates TCF/LEF– and CREB-mediated cyclin
D1 transcription. Nuclear h-catenin forms complexes with
members of the TCF and LEF family of DNA-binding proteins,
and this process results in activation of target gene promoters.
RET/PTC stimulated the activity of a luciferase TCF/LEF–
dependent reporter gene system (TOPflash) in both HEK293T
and PC cells (P < 0.01; Fig. 4A). The mutant TOPflash reporter
(FOPflash), bearing a mutated TCF/LEF site, was used to subtract
background. This activity depended on the integrity of the RET/
PTC kinase and of the Y1062 multidocking site (P < 0.05; Fig. 4A,
left). Again, other tyrosines besides Y1062 likely played a role
because the PTC-3F mutant was impaired with respect to wild-
type RET/PTC (Fig. 4A, left). TOPflash expression was partially
reduced by treatment with LY294002 and U0126 and by the
coexpression of dominant negative mutants for Ras (N17), MEK
(MEKDN), and AKT (AKTDN; P < 0.05). Constitutively active BRAF
(V600E) and Ras (V12) stimulated the TCF/LEF reporter in
HEK293T cells, although to a lesser extent than RET/PTC. A
transcriptionally active form of h-catenin (S374A) served as a
positive control (Fig. 4A).
Besides TCF/LEF, h-catenin recruits the activated form (serine
133 phosphorylated) of CREB, thereby resulting in a transcrip-
tionally active complex, which in turn binds CBP/p300 (37–40).
TCF/LEF and CREB collaborate in regulating the transcription of
TCRa (41) and WISP-1 (42). Finally, RET signaling through Y1062
and Ras/ERK increases S133 phospho-CREB levels (2). To
determine whether RET/PTC affected the binding of CREB to
h-catenin, we immunoprecipitated h-catenin from PC cells in the
presence or absence of RET/PTC and probed the immunocom-
plexes with anti-CREB and anti-CBP/p300 antibodies. Expression
of RET/PTC significantly increased the amounts of h-catenin
bound to CREB and CBP/p300 (Fig. 4B). Chemical blockade of
MEK by U0126 reduced this association, and this effect was
paralleled by a reduction in CREB phosphorylation on Ser133 and
ERK phosphorylation (Fig. 4B). In a mirror experiment, RET/PTC
expression increased not only TCF/LEF-h-catenin (Fig. 4C,
bottom) but also CREB-h-catenin protein complexes (Fig. 4C,
top). In HEK293T cells, formation of both complexes was reduced
when kinase-dead and 4F mutants were used (Fig. 4C, right).
Instead, by immunoprecipitating CREB and staining with TCF/
LEF, we did not detect TCF/LEF-CREB interaction, suggesting that
h-catenin–containing TCF/LEF and CREB complexes are distinct
(Fig. 4C, middle).
Cyclin D1 promoter contains adjacent TCF/LEF (at 81 bp) and
CREB (at 58 bp) binding sites (40). We used chromatin
immunoprecipitation to measure h-catenin, TCF/LEF, and CREB
binding to the region of the cyclin D1 promoter that contains CREB
and TCF/LEF binding sites. For PCR, we used two primer pairs
spanning the CRE (Fig. 4D) and TCF (data not shown) sites,
respectively. With both primer sets, binding of h-catenin, TCF/LEF,
and CREB to the cyclin D1 promoter was greatly increased on
RET/PTC expression (P < 0.05; Fig. 4D). Because the binding sites
for CREB and TCF/LEF are just a few nucleotides apart on the
cyclin D1 promoter, this experiment left open possibilities that
the two h-catenin–containing (CREB and TCF/LEF) complexes can
be either identical or distinct; however, the lack of coimmunopre-
cipitation in Fig. 4C favors the possibility that the two complexes
are distinct.
RET/PTC–mediated mitogenic signaling depends on B-
catenin. In PC cells, RET/PTC–mediated increase in h-catenin
activity was paralleled by accumulation of the TCF/LEF and CREB
target protein cyclin D1 and, more weakly, c-Myc (Fig. 5A). We
knocked down h-catenin by RNA interference in parental and
RET/PTC–expressing PC cells. As shown in Fig. 5A , h-catenin–
specific siRNA, but not the scrambled control, reduced the
expression of h-catenin by >50% in both PC and PC-PTC cells.
Moreover, h-catenin siRNA reduced cyclin D1 and, more weakly,
c-Myc levels in RET/PTC–expressing cells. h-Catenin RNA
interference reduced hormone-independent proliferation of PC-
PTC cells (Fig. 5B, bottom), whereas a constitutively active form of
h-catenin (S374A) stimulated hormone-independent growth of PC
cells (Fig. 5B, top). We generated mass populations of PTC-4F– and
PTC-3F–expressing PC cells. On hormone deprivation, we counted
S-phase cells on a 1-hour BrdUrd pulse after transient transfection
with scrambled or h-catenin specific siRNA. Similarly to wild-type
PTC, PTC-3F–expressing, but not PTC-4F–expressing, cells incor-
porated BrdUrd in the absence of hormones in a h-catenin–
dependent manner (P < 0.01). Taken together, these findings show
that h-catenin is a mediator of the RET/PTC mitogenic signaling
in thyrocytes.
Finally, to study the h-catenin pathway in human PTC samples,
we measured levels of GSK3h-Ser9 and S/T h-catenin phosphor-
ylation compared with normal thyroid samples (n = 2) in a small
set of PTC (n = 12) samples (three RET/PTC positive, six BRAF
V600E positive, and the remainder RET/PTC and BRAF negative).
Reduced levels of h-catenin S/T phosphorylation was visible in
virtually all the tumor samples; increased levels of GSK3h-Ser9
phosphorylation and total h-catenin were detectable inf75% and
50% of them, respectively (Fig. 5D, left). Similarly, thyroid
carcinoma cell lines positive either for RET/PTC1 (TPC-1) or for
BRAF V600E (BCPAP, 8505C, and OCUT-1) showed reduced levels
of S/T h-catenin and increased GSK3h-Ser9 phosphorylation
when compared with a primary culture of normal thyrocytes
(Fig. 5D, right).
Discussion
Here we describe the functional interaction between the RET/
PTC and the h-catenin signaling pathways. h-Catenin activation
by RET/PTC occurred through several coordinated mechanisms
(Fig. 6). As previously reported by Gujral and colleagues (25) for
point mutant RET, RET/PTC induced the tyrosine phosphorylation
of h-catenin, thereby mobilizing the fraction of h-catenin
associated to E-cadherin and increasing its free cytosolic pool.
RET/PTC-mediated activation of PI3K/AKT and Ras/ERK contrib-
uted to promote h-catenin stabilization through inactivation of
Cancer Research
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Figure 4. RET/PTC–mediated activation of TCF/LEF and CREB transcription factors. A, HEK293T (left) and PC-PTC cells (right ) were transfected with the indicated
plasmids together with the TOPflash reporter and, when indicated, treated with the chemical inhibitors. Luciferase activity was expressed as fold increase with respect to
mock-transfected cells. Columns, average results of three independent assays; bars, SD. Reported P values were calculated by Student’s t test. B, cellular lysates
(1 mg) from PC and PC-PTC cells, treated or not with U0126, were immunoprecipitated with anti–h-catenin and probed with CREB and CBP/p300 antibodies. The
CREB antibody may also recognize, besides CREB (43 kDa), CREM (30 kDa) and activating transcription factor-1 (38 kDa); *, CREB migration. Phosphorylation of
CREB (S133) and ERK (MAPK) was measured in total cell lysates by immunoblot. Tubulin was used for normalization. C, lysates from PC or PC-PTC cells (left ) and
HEK293T cells transiently expressing the indicated RET/PTC constructs (right ) were immunoprecipitated with CREB and TCF antibodies and probed for h-catenin
or TCF antibodies, as reported. D, chromatin immunoprecipitation (ChIP) was done in HEK293T cells transfected with RET/PTC or the empty vector (control ).
Processed DNA was immunoprecipitated with TCF, h-catenin, or CREB antibodies and subjected to real-time PCR (bar graphs ) with amplimers spanning the CRE site
of the cyclin D1 promoter. Columns, mean of triplicate samples; bars, SD. Fluorescent threshold values (C t) were measured for immunoprecipitated samples as well
as for an aliquot of the input DNA. Reported P values were calculated by Student’s t test. Semiquantitative PCR (ethidium bromide stain) was also done with the
same primers by using 1 AL of the DNA and 25 cycles of amplification. Amplification of the expected fragments in the input samples indicated equal input; mock PCR
was done without template.
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Figure 5. h-Catenin contributes to autonomous growth of RET/PTC–expressing thyroid cells. A, h-catenin was knocked down by transient transfection with specific
siRNA (si b-catenin ) in parental or RET/PTC–expressing PC cells. As a control, cells were treated with scrambled siRNA (si scrambled ). Protein levels were measured
by immunoblot with the indicated antibodies. B, proliferation in the absence of hormones of parental, constitutively active h-catenin (S374A) or h-catenin siRNA
transiently transfected PC or PC-PTC cells was measured by cell counts. Points, mean of triplicate samples; bars, SD. Reported P values were calculated by Student’s
t test. C, mass populations of PTC-4F– and PTC-3F–expressing PC cells were generated by stable transfection and marker selection. On hormone deprivation
and transfection with scrambled or h-catenin–specific siRNA (as in A), cells were pulsed (1 h) with BrdUrd, and BrdUrd-positive cells were analyzed by
immunofluorescence. At least 100 cells were counted in five different microscopic fields. Columns, mean fractions of BrdUrd-positive cells; bars, SD. Reported P values
were calculated by Student’s t test. D, phosphorylation levels of GSK3h and h-catenin (phospho-Ser33/37/Thr41) were measured by immunoblot of total cell
lysates (50 Ag) harvested from PTC (T1–T12) and normal thyroid (N1–N2 ) tissue samples (left ) or thyroid carcinoma and normal human primary cells (NT ; right ).
GSK3h antibodies may recognize both GSK-3a (51 kDa) and GSK3h (46 kDa) proteins; *, GSK3h migration.
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GSK3h. However, neither pathway was probably sufficient because
chemical blockade of either one reduced but did not abrogate
h-catenin accumulation. Finally, RET/PTC signaling favored the
formation of transcriptional complexes containing h-catenin by
triggering ERK-mediated CREB phosphorylation. Ser133-phosphor-
ylated CREB formed a protein complex with CBP and h-catenin,
which participated in the transcription of cyclin D1. TCF/LEF and
CREB binding sites coexist in the promoters of some h-catenin
target genes, such as cyclin D1 (40), TCRa (41), and WISP-1 (42),
and collaborate in their firing. Accordingly, our findings suggest
that downstream of RET/PTC, h-catenin participates in two
distinct transcriptional complexes, one with TCF/LEF and another
one with CREB, and that both are recruited to cyclin D1 promoter.
The particularly important role played by Y1062 in signaling to
h-catenin in the case of RET/PTC with respect to full-length
RET mutants (25) may be explained by differential signaling
mechanisms between the distinct RET oncogenic forms and the
cytosolic localization of RET/PTC that relies on Y1062 to be
recruited to the cell membrane (2–4). Finally, h-catenin expression
is required for RET/PTC–mediated autonomous proliferation of
PC thyrocytes.
It is possible that h-catenin activity cooperates with other
signaling cascades activated by RET/PTC to mediate mitogenic
activity. Cytosolic h-catenin is recruited to a ‘‘destruction’’ complex
that includes APC and GSK3h. Loss of APC tumor suppressor
reduces the activity of the h-catenin destruction complex (17, 21).
Of direct relevance to thyroid tumorigenesis, patients affected
by familial APC [familial adenomatous polyposis (FAP)] and
harboring APC mutations are predisposed to thyroid carcinoma
(43). Furthermore, the RET/PTC oncogene is activated in some
FAP-associated thyroid carcinomas (44). Therefore, our data
support a model whereby two different lesions concomitantly
present in FAP-associated thyroid carcinoma (i.e., RET/PTC
activation and APC loss of function) may converge to enhance
the activity of the h-catenin signaling cascade. On the other hand,
direct h-catenin mutations are restricted to aggressive and
undifferentiated types of thyroid carcinomas (23).
h-Catenin targeting approaches for cancer therapy are currently
being explored. For example, a conditionally replicative adenovirus,
which kills only cells with a hyperactive h-catenin pathway,
significantly inhibited the growth of undifferentiated (anaplastic)
thyroid cancers (45). ICG-001, an inhibitor of the h-catenin/CBP
transcriptional complex, efficiently induced apoptosis of colon
cancer cells (46). Prostaglandin E2 (PGE2) also promotes h-catenin
signaling (28), and PGE2 synthesis inhibitors, nonsteroidal anti-
inflammatory drugs, in an adjuvant or preventive setting are being
tested already in cancer. Our data, together with those reported by
Gujral and colleagues (25), suggest that h-catenin targeting
approaches could have therapeutic potential in thyroid cancer.
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Figure 6. A summary of the pathways
leading to h-catenin induction by RET/PTC.
1 and 2, RET/PTC activates PI3K/AKTand
Ras/MEK/ERK. This leads to GSK3h
phosphorylation, thereby relieving its
negative control on h-catenin, and to an
increase of the free h-catenin protein pool.
2, through ERK activation, RET/PTC
induces S133 phosphorylation of CREB,
which associates in a complex with
h-catenin and CBP/p300 to stimulate
transcription of cyclin-D1. 3, RET/PTC
directly binds h-catenin and increases its
phosphotyrosine content, thereby
decreasing the E-cadherin–bound pool and
increasing the free h-catenin pool. Free
h-catenin enters the nucleus and
participates in at least two different
transcription complexes with CREB/p300
and with TCF/LEF, both ultimately involved
in the regulation of cyclin D1.
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A set ofmiRNAs participates in the cellular senescence
program in human diploid fibroblasts
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Here we show that replicative senescence in normal human diploid IMR90 fibroblasts is accompanied by altered expression
of a set of microRNAs (miRNAs) (senescence-associated miRNAs), with 14 and 10 miRNAs being either up or downregulated
(42-fold), respectively, in senescent with respect to young cells. The expression of most of these miRNAs was also deregulated
upon senescence induced by DNA damage (etoposide) or mild oxidative stress (diethylmaleate). Four downregulated miRNAs
were part of miRNA family-17, recently associated to human cell and tissue aging. Moreover, eight upregulated and six
downregulated miRNAs mapped in specific chromosomal clusters, suggesting common transcriptional regulation. Upon
adoptive overexpression, seven upregulated miRNAs induced the formation of senescence-associated heterochromatin foci and
senescence-associated b-galactosidase staining (Po0.05), which was accompanied, in the case of five of them, by reduced cell
proliferation. Finally, miR-210, miR-376a*, miR-486-5p, miR-494, and miR-542-5p induced double-strand DNA breaks and reactive
oxygen species accumulation in transfected cells. In conclusion, we have identified a set of human miRNAs induced during
replicative and chemically induced senescence that are able to foster the senescent phenotype by prompting DNA damage.
Cell Death and Differentiation advance online publication, 4 November 2011; doi:10.1038/cdd.2011.143
Replicative or cellular senescence, a state of irreversible
arrest of cell division, was first described in cultures of human
fibroblasts.1 Since then, replicative senescence has been
described in various mammalian cells.2 The mechanisms
underlying senescence include telomere shortening, upregu-
lation of the CDKN1A (p21WAF1) and CDKN2A (p16INK4a
and p14ARF) loci, and accumulation of DNA damage.3
Telomeres become progressively shorter at every round
of cell division and this leads to critically short telomere length
sensed as double-strand DNA breaks.4 DNA damage
and DNA-damage response (DDR) could be common events
to cellular senescence programs initiated by telomere
dysfunction and aberrant oncogene activation.5
Senescent cells are marked by lack of DNA replication;
expression of senescence-associated b-galactosidase
(SA-b-gal); accumulation of discrete nuclear foci that are
termed senescence-associated heterochromatin foci
(SAHFs); and senescence-associated DNA-damage foci
(SDFs). SAHFs are detected by preferential binding of DNA
dyes, such as 40,6-diamidino-2-phenylindole (DAPI), and the
presence of certain heterochromatin-associated histone
modifications (trimethyl-Lys9 Histone H3). SDFs are nuclear
foci containing proteins that are associated to DNA damage
(Ser139-phosphorylated histone H2AX -g-H2AX- and p53-
binding protein-1-53BP1).6
Senescent cells show striking changes in gene expression,
including upregulation of cell-cycle inhibitors (p21WAF1 and
p16INK4a) and secreted proteins involved in microenviron-
ment remodeling (IL-6),7 and downregulation of genes that
facilitate cell-cycle progression (c-FOS, cyclin-A, cyclin-B,
PCNA)8 or that are involved in cell-cycle execution (FOXM1,
UBE2C, TYMS).9 Mechanisms underlying the gene express-
ion program that is associated to senescence are still poorly
understood.
MicroRNAs (miRNAs) are short (20–24nt) non-coding
RNAs that are involved in post-transcriptional regulation of
gene expression. miRNAs are transcribed as part of primary
transcripts (pri-miRNAs). The pri-miRNA is cleaved by the
Drosha ribonuclease-III to produce an approximately 70-nt
stem–loop precursor miRNA (pre-miRNA), which is further
cleaved by the cytoplasmic Dicer ribonuclease to generate
maturemiRNA and antisensemiRNA star (miRNA*) products.
The mature miRNA is incorporated into an RNA-induced
silencing complex (RISC), which recognizes target mRNAs
and most commonly results in translational inhibition or
destabilization of the target mRNA.10
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Being potent regulators of gene expression, we hypothe-
sized that miRNAs were involved in the gene expression
program associated to cellular senescence. This hypothesis
was supported by recent results obtained by Hackl et al.11
showing that miRNAs of family 17 were downregulated in
aged tissues and cells. Moreover, senescence in human
lung (WI-38) fibroblasts was accompanied by upregulation
of miR-152, miR-410, miR-431, and miR-493, and down-
regulation of miR-155, miR-20a, miR-25, and miR-15a;
knockdown of miR-155 or miR-20a enhanced IR-induced
senescence.12,13
In this study, we profiled miRNA expression in human
senescent fibroblasts (IMR90). We identified 24 miRNAs that
were either up- or downregulated in senescent cells. Upon
adoptive overexpression, most of the upregulated miRNAs
reduced DNA synthesis rate, and induced SA-b-gal staining
and SAHFs. Five of them induced a robust DNA damage that
likely sustains the senescent phenotype.
Results
Altered expression of a set of miRNAs accompanies
replicative senescence in IMR90 fibroblasts. At PDL58,
more than 70% IMR90 cells stained positively for SA-b-gal,
whereas less than 1% of PDL33 cells stained positively
(Supplementary Figure 1). Moreover, PDL58 cells had an
expression profile consistent with a senescent phenotype,
expressing about three-fold higher levels of p21WAF1 and
p16INK4a proteins; higher levels of IL6 mRNA; and reduced
levels of cell-cycle-related mRNAs such as cyclin-A,
thymidylate synthase (TYMS), cyclin-selective ubiquitin
carrier protein (UBE2C), and forkhead box-M1 (FOXM1)
with respect to PDL33 cells (Supplementary Figure 1). We
profiled miRNA expression in senescent PDL58 with respect
to PDL33 IMR90 cells by qRT-PCR. A total of 148 miRNAs
were detected (Cto39 cycles) in at least one of the two
samples; 18 miRNAs were upregulated and 51 were
downregulated (42-fold) in senescent versus young cells
(Supplementary Table 1).
To validate these results, independent preparations of
PDL58 and PDL33 IMR90 cells were obtained and the
expression of all the highest ranked 18 up- and 14 down-
regulated miRNAs was investigated in triplicate by qRT-PCR.
Results are reported in Table 1. Fourteen (fold changes:
2.7–8.9) and 10 (fold changes: 0.42–0.13) miRNAs were
significantly (Po0.001) up- or downregulated in PDL58
versus PDL33 cells, respectively (Table 1).
These findings indicate that senescence of IMR90 is
associated to altered expression of a set of miRNAs (hereafter
referred to as ‘senescence-associated miRNAs’).
DNA damage and oxidative stress deregulate
the expression of senescence-associated miRNAs.
Treatment with etoposide,15 a topoisomerase inhibitor used
to induce DNA damage, or DEM,9 a glutathione depletor
able to cause a mild oxidative stress, were applied to
chemically induce cellular senescence. When IMR90 cells
were exposed to DEM (100 mM) for 10 days or treated with
etoposide (20mM) for 24 h and further cultured for 11 days,
62 and 80% SA-b-gal-positive IMR90 cells, respectively,
were detected. This was accompanied by gene expression
changes consistent with a senescent phenotype
Table 1 Expression change of senescence-associated miRNAs in IMR90 cells
miRNA
Chromosomal
locationa Familya
Fold changes
(PDL58/PDL33) S.D. P-value
Upregulated
miR-486-5p 8p11.21 486 8.9 0.009 o0.0001
miR-210 11p15.5 210 7.9 0.9 o0.0001
miR-30e-5p 1p34.2 30 6.5 0.9 o0.0001
miR-376a* 14q32.31 368 5.9 0.7 0.0001
miR-126* 9q34.3 126 5.3 1.4 o0.0001
miR-494 14q32.31 154 4.5 1.6 o0.0001
miR-379 14q32.31 379 4.4 1.1 o0.0001
miR-654 14q32.31 654 4.3 1.4 o0.0001
miR-542-5p Xq26.3 542 3.8 1 o0.0001
miR-23b 9q22.32 23 3.7 0.6 0.0022
miR-134 14q32.31 134 3.4 1 o0.0001
miR-369-3p 14q32.31 154 3.3 0.4 o0.0001
miR-656 14q32.31 154 3.3 1 o0.0001
miR-485-5p 14q32.31 485 2.7 0.5 o0.0001
Downregulated
miR-20a 13q31.3 17 0.13 0.01 0.0002
miR-155 21q21.3 155 0.14 0.04 0.0034
miR-17-5p 13q31.3 17 0.15 0.02 0.0060
miR-199b-5p 9q34.11 199 0.21 0.09 0.0002
miR-15b 3q25.33 15 0.23 0.16 0.0008
miR-92b 13q31.3; Xq26.2 25 0.27 0.04 0.0001
miR-296-5p 20q13.32 296 0.27 0.2 0.0061
miR-19bc 13q 31.3; Xq26.2 19 0.28 0.1 0.0016
miR-93 7q22.1 17 0.35 0.04 o0.0001
miR-106b 7q22.1 17 0.42 0.17 0.01
aThe information were obtained from miRBase (http://www.mirbase.org/). bmiR-92 includes two identical sequences (miR-92a-1 and miR-92a-2) encoded by two
different loci. cmiR-19 includes two identical sequences (miR-19b-1 and miR-19b-2) encoded by two different loci.
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(Supplementary Figure 2). RNA was extracted from DEM-
and etoposide-treated IMR90 cells, and the expression of the
24 senescence-associated miRNAs was studied in triplicate
by qRT-PCR. Results are reported in Table 2. About 90% of
the senescence-associated miRNAs were de-regulated
(albeit with smaller fold changes than during replicative
senescence) upon chemically induced senescence
(Po0.05). In detail, DEM-mediated senescence was
associated with the upregulation (range: 1.26–3.25) of 13
of the 14 (with the exception of miR-542-5p) upregulated
senescence-associated miRNAs (Po0.05) (Table 2),
whereas etoposide-mediated senescence was associated
with the upregulation (range: 1.21–3.22) of 12 (with the
exception of miR-654 and miR-494) of them (Po0.05)
(Table 2). Moreover, both DEM-treated (range: 0.84–0.2)
as well as etoposide-treated (range: 0.7–0.29) cells showed
downregulation of all the 10 downregulated senescence-
associated miRNAs (Po0.05) (Table 2).
These findings indicate that DNA damage and oxidative
stress alter the expression of senescence-associated
miRNAs in IMR90 cells, thereby suggesting that DNA damage
and oxidative stress, occurring during replicative senescence,
may contribute to the altered expression of senescence-
associated miRNAs.
A set of miRNAs promotes a senescent phenotype in
IMR90 cells. We sought to establish whether upregulation of
senescence-associated miRNAs was causally related to
senescence. Thus, the nine highest ranked upregulated
miRNAs (Table 1) were adoptively upregulated (in the form of
synthetic pre-miRNAs) by electroporation in young PDL33
IMR90 cells and their capability of inducing senescence-
associated markers was assessed. Negative control was
represented by scrambled pre-miRNA-transfected PDL33
IMR90 cells. Positive control was represented by PDL55
(or 58) IMR90 cells. Seven out of the nine miRNAs induced a
significant (Po0.05) increase of SAHF-positive nuclei
(range: 10–24% of the cells) detected by both DAPI
staining and 3meH3K9 immunofluorescence with respect
to the scrambled control (Figures 1a and b). This was
accompanied by a 4- to 18-fold increase of SA-b-gal-positive
cells (Po0.05) (Figure 1c). miR-654 did not cause any
significant increase of SAHF-positive and SA-b-gal-positive
cells; instead, we noted a robust cytotoxic effect exerted by
this miRNA, assessed as percentage of dead cells upon
transfection (data not shown). miR-654 was not studied
further.
Senescent cells are arrested in the G1 phase of the cell
cycle. Therefore, we tested whether expression of the highest
ranked upregulated miRNAs was also able to reduce BrdU
incorporation into newly synthesized DNA. Electroporation of
five of them (miR-210, miR-376a*, miR-486-5p, miR-494, and
miR-542-5p) in PDL33 IMR90 cells caused a significant
(Po0.001) reduction (2- to 3-fold) of BrdU incorporation
(Figure 2a). Moreover, these five miRNAs also caused a
parallel reduction (approximately 30–60%) in cell number
(P40.05) (Figure 2b). miR-126* did not exert any detectable
effect, and miR-379 and miR-30e-5p caused only negligible
reduction of BrdU incorporation and cell proliferation
(Po0.05) (Figures 2a and b). Negative control was
represented by scrambled miRNA-transfected cells (Figures
2a and b).
Altogether, these findings show that seven senescence-
induced miRNAs are able to induce SAHF/SA-b-gal positivity,
with five of them (miR-210, miR-376a*, miR-486-5p, miR-494,
and miR-542-5p) causing a robust reduction of cell prolifera-
tion and DNA synthesis rate.
miR-210, miR-376a*, miR-486-5p, miR-494, and miR-542-
5p enhance DNA damage. DNA damage and DDR are
Table 2 Expression change of senescence-associated miRNAs in IMR90 cells treated with DEM or etoposide
DEM Etoposide
miRNA Fold variationa S.D. P-value Fold variationa S.D. P-value
miR-486-5p 1.55 0.118 0.0018 3.22 0.07 o0.0001
miR-210 1.69 0.12 o0.0001 1.5 0.2 0.0001
miR-30e-5p 3.25 0.57 0.0008 1.82 0.03 o0.0001
miR-376a* 2.87 0.89 o0.0001 1.7 0.27 0.0023
miR-126* 2.35 0.28 0.0004 2.05 0.15 0.0001
miR-494 2.14 0.2 0.0011 0.93 0.04 0.2652
miR-379 1.52 0.06 0.0001 1.39 0.08 0.0070
miR-654 2.29 0.53 0.0046 1.16 0.8 0.5177
miR-542-5p 1.128 0.14 0.5818 1.22 0.04 0.0224
miR-23b 1.94 0.12 0.0002 1.42 0.18 0.0105
miR-134 1.52 0.12 0.0032 1.67 0.002 o0.0001
miR-369-3p 1.44 0.13 0.0036 1.61 0.03 o0.0001
miR-656 1.26 0.06 0.0181 1.21 0.04 0.0137
miR-485-5p 2.33 0.08 0.0001 1.36 0.11 0.0420
miR-20a 0.419 0.002 o0.0001 0.29 0.03 o0.0001
miR-155 0.2 0.002 o0.0001 0.32 0.014 o0.0001
miR-17-5p 0.51 0.01 o0.0001 0.43 0.04 0.0086
miR-199b-5p 0.55 0.06 0.069 0.37 0.02 o0.0001
miR-15b 0.33 0.016 o0.0001 0.33 0.02 0.0013
miR-92 0.43 0.08 0.0018 0.37 0.01 0.0003
miR-296-5p 0.72 0.005 0.0007 0.7 0.02 0.0059
miR-19b 0.39 0.14 0.0125 0.33 0.04 0.0002
miR-93 0.45 0.02 0.0006 0.46 0.06 0.0009
miR-106b 0.84 0.01 o0.0001 0.65 0.07 0.0396
aWith respect to untreated cells.
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involved in senescence.5 Therefore, we asked whether
the five senescence-associated miRNAs, that were able to
reduce proliferation rate and promote a senescent
phenotype, were able to induce DNA damage. To this aim,
we used neutral COMET assay to monitor double-strand
DNA breaks. Etoposide-treated and scrambled miRNA-
transfected cells were used as positive or negative
controls, respectively. Tail moments were calculated and
percentages of nuclei showing different tail moments were
determined. The results shown in Figure 3 demonstrate that
all the five miRNAs, but not the scrambled control, caused
significant (Po0.05) increase in the percentage of cells with
tail moment 44, consistent with induction of double-strand
DNA breaks (Figure 3).
Finally, we evaluated whether adoptive miRNA expression
induced the formation of gH2AX foci in cell nuclei. Senescent
cells and etoposide-treated cells were used as positive
controls, whereas scrambled miRNA-transfected cells were
used as negative controls. Figure 4 shows that miR-210 and
miR-494, but not the scrambled control, induced the formation
of gH2AX foci in more than 25% of cell nuclei (Po0.01). miR-
376a*, miR-486-5p, and miR-542-5p increased the number of
gH2AX foci-positive nuclei only modestly (Po0.05) (Figure 4).
These findings suggest that senescence-associated
miRNAs facilitate the establishment of a senescent state by
promoting DNA damage and in some cases through increase
of a DDR marker.
Role of oxidative stress and the mTOR-signaling
pathway in miRNA-induced cellular senescence.
Increased intracellular oxygen radicals can elicit DDR
and senescence.5 Therefore, we investigated whether over-
expression of senescence-associated miRNAs was able to
cause intracellular accumulation of superoxide anion, by flow
cytometry upon cell staining using the oxidation-sensitive DHE
fluorescent probe. The results reported in Figure 5 demonstrate
that overexpression of all five miRNAs (miR-210, miR-376a*,
miR-486-5p, miR-494, and miR-542-5p) caused a significant
Figure 1 Senescence-associated miRNAs induce SAHFs and SA-b-gal. The nine highest ranked upregulated pre-miRNAs were electroporated in triplicate in PDL33
IMR90 cells. After 7 days cells were fixed and examined by immunofluorescence for a-trimethyl-Lys9 Histone (SAHF) or counterstained with DAPI (a and b), and stained for
SA-b-gal (c). (a and b) Counts of at least 300 cells were averaged and expressed as percent of cells±S.D. with SAHF foci. Representative pictures are shown in panel b. (c)
Cells were stained for SA-b-gal. Counts of at least 300 cells were averaged and expressed as fold change±S.D. with respect to the scrambled control. Experimental points
with *Po0.05, **Po0.01, or ***Po0.001 respectively
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(Po0.05) increase in DHE-positive cells with respect to the
scrambled control. Of note, miR-210 was previously reported to
induce the generation of ROS.18,19 Furthermore, it appears of
interest that miR-494, which caused the highest levels of ROS
generation, also caused the highest level of DNA damage as
shown by the COMET assay (Figure 3).
The mammalian target of rapamycin (mTOR) pathway
was demonstrated to drive senescence in cells treated with
several factors, including oxidative agents.20–22 Thus, initially,
we asked whether miRNA transfection caused any change in
mTOR pathway activation, by measuring the phosphorylation
of the ribosomal S6 protein (S6); S6 is phosphorylated by
p70-S6 kinase (p70S6K), which, in turn, is activated by
mTOR.23 IMR90 cells featured high levels of S6 phosphoryla-
tion, and adoptive overexpression of any of the five miRNAs
(miR-210, miR-376a*, miR-486-5p, miR-494, and miR-542-
5p) did not cause detectable change in the levels of phospho-
S6 (Supplementary Figure 3). Then, we tested whether
inhibition of mTOR by the macrolide antibiotic rapamycin
affected cell senescence (SA-b-gal) induced by miRNA
transfection. Treatment with rapamycin caused a detectable
reduction of SA-b-gal-positive cells upon transfection with the
five miRNAs, a reduction that was statistically significant
(Po0.05) in the case of four of them (Table 3). Rapamycin’s
effects on SA-b-gal stain were not accompanied by significant
reduction of g-H2AX foci (Table 3).
Altogether, these findings suggest that the senescent
phenotype induced by miR-210, miR-376a*, miR-494, and
miR-542-5p depends on the activity of the mTOR pathway.
Discussion
Here we have identified a set of 24 miRNAs either up- or
downregulated in senescent human diploid fibroblasts.
Figure 3 Senescence-associated miRNAs induce DNA damage. The indicated pre-miRNAs were electroporated in PDL33 IMR90 cells. After 4 or 7 days cells were
harvested and comet tails were generated by electrophoresis. Slides were stained with SYBER Green and DNA migration was analyzed by fluorescence microscopy. Tail
moment was determined and nuclei were divided in classes based on the value of the tail moment (as shown in the representative images of cells transfected with pre-miR-494
at the bottom). The percentage of damaged cells for each class is indicated within the bar graphs. A minimum of 100 cells per experiment were analyzed. Experimental points
with *Po0.05, **Po0.01, or ***Po0.001 respectively
Figure 2 Senescence-associated miRNAs reduce cell proliferation. The nine
highest ranked upregulated pre-miRNAs were electroporated in triplicate in PDL33
IMR90 cells. (a) After 48 h cells were incubated with BrdU for 24 h and fixed.
Coverslips were incubated with an anti-BrdU and secondary fluorescein-conjugated
antibody, counterstained with Hoechst-33258, and counted by immunofluores-
cence. Counts of at least 300 cells were averaged and expressed as fold
change±S.D. with respect to the scrambled control. (b) After 96 h cell numbers
were counted and expressed as fold change±S.D. with respect to the scrambled
control. Experimental points with *Po0.05, **Po0.01, or ***Po0.001 respectively
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Of note, 8 (chromosome 14q32.31) upregulated and 6
(4 on chromosome 13q31.3 and 2 on chromosome 7q22.1)
downregulated miRNAs mapped in specific chromosomal
clusters, suggesting that their expression might be co-
regulated. We have also shown that the expression of most
of the senescence-associated miRNAs was modified in DEM-
or etoposide-induced senescence, in the same direction
as in replicative senescence. This suggests that oxidative
stress and DNA damage are among the factors that mediate
senescence-associated miRNA expression changes.
However, the effects of DEM and etoposide were smaller
than those measured upon replicative senescence, suggest-
Figure 4 Senescence-associated miRNAs induce gH2AX foci. The indicated
pre-miRNAs were electroporated in triplicate in PDL33 IMR90 cells. After 7 days
cells were fixed and examined by immunofluorescence for a-H2AX phosphorylated
on Ser139 (gH2AX). Coverslips were washed and incubated with an Alexa-488 goat
anti-rabbit antibody and counterstained with DAPI. Counts of at least 300 cells were
averaged and expressed as percent of cells±S.D. with gH2AX foci. Representative
images are shown in panel b. Experimental points in panel (a) are indicated with
with **Po0.01, or ***Po0.001 respectively
Figure 5 Senescence-associated miRNAs lead to oxidative stress. IMR90 cells
(PDL33) were electroporated with the indicated pre-miRNAs. After 72 h cells were
incubated with 0.1mM DHE at 37 1C for 30 min. Intracellular fluorescence was
examined by flow cytometry. Fluorescence intensity of 10 000 cells was analyzed in
triplicate and expressed as percentage of stained cells±S.D. As positive controls,
PDL33 cells treated with the mitochondrial inhibitor rotenone (5 mM for 2 h) and
senescent PDL55 cells were used. Experimental points with *Po0.05, **Po0.01,
or ***Po0.001 respectively
Table 3 Effects of mTOR inhibition by rapamycin on miRNA-induced
senescence and DDR
Pre-miRNA
SA-b-gal
staining
upon
rapamycin
(% change)a P-value
cH2AX
staining
upon
rapamycin
(% change)b P-value
Pre-miR-control 16.2 0.4711 +2.56 0.8520
Pre-miR-210 43 0.0498 2.34 0.0808
Pre-miR-376a* 37.6 0.0052 2.75 0.2354
Pre-miR-486-5p 15.3 0.2526 +7.69 0.5734
Pre-miR-494 46.2 0.0050 6.59 40.999
Pre-miR-542-5p 38.9 0.0262 +6.38 0.9360
aStarting 24 h after transfection with the indicated miRNAs, cells were treated
for 3 days with 10 nM rapamycin or vehicle, and then stained for SA-b-gal.
Counts of at least 300 cells were averaged and expressed as percentage of
SA-b-gal-stained cells. Reduction in the percentage of positive cells upon
rapamycin treatment is reported. bStarting 24 h after transfection with the
indicated miRNAs, cells were treated for 3 days with 10 nM rapamycin or
vehicle, and then examined by immunofluorescence for gH2AX. Counts of at
least 300 cells were averaged and expressed as percent of cells with gH2AX
foci. Change in the percentage of positive cells upon rapamycin treatment
is reported.
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ing that either the contribution of other factors or the conditions
of chemical treatments were not sufficient to achieve a robust
change of miRNA expression.
We have also shown that adoptive expression of five
upregulated miRNAs (miR-210, miR-376a*, miR-486-5p,
miR-494, and miR-542-5p) induced a senescent phenotype
(with SAHFs, SA-b-gal staining, and reduced cell proli-
feration). Overexpression of these five miRNAs was also
associated with double-strand DNA breaks in a neutral
COMET assay and, for two of them (miR-210 and miR-494),
appearance of a DDR marker (gH2AX foci). Thus, over-
expression of the five miRNAs favored DNA damage, and not
solely DDR (gH2AX), which can also occur in the absence of
DNA damage (pseudo-DDR).24 Finally, we showed that the
mTOR pathway was an essential driver of senescence
induced by senescence-associated miRNAs as SA-b-gal
staining was significantly reduced by treatment with rapa-
mycin.20–22 Of note, our preliminary observations, by studying
the expression levels of the senescence-inducing miRNAs
in human skin broblasts from young (age 17–25) or old
(age 89–94) donors, show that the highest expression levels
of miR-376a* and miR-494 were found in one old donor cell
line, and expression of miR-486-5p was on average two-fold
higher in old with respect to young cells.
Overall, these findings suggest a model whereby DNA
damage and oxidative stress, which occur during replicative
senescence, stimulate the expression of a set of miRNAs,
which, in turn, feedback positively to DNA damage and
oxidative stress, thereby sustaining the senescent phenotype
(Supplementary Figure 4). The mechanisms through which
the upregulated miRNAs provoke these effects will deserve
further investigation. However, the model is supported by the
observation that overexpression of the senescence-asso-
ciated miRNAs caused an accumulation of superoxide anion
and by the fact that some known targets of senescence-
associated miRNAs are involved in DNA damage, oxidative
stress, cell-cycle control, and apoptosis. For instance,
miR-210 was found to activate the generation of ROS by
targeting subunits of the electron transport chain (ETC)
complexes I and II.18 Other potential targets of miR-210 in
the same pathway included ISCU (iron–sulfur cluster scaffold
homolog) and COX10 (cytochrome-c oxidase assembly
protein), two factors of the mitochondrial electron transport
chain and the tricarboxylic acid cycle.19 In addition,
forced expression of miR-210 decreased endogenous levels
of RAD52, a key factor in homology-dependent DNA repair
(HR).25 Similarly, miRNA-494 was recently found to be
localized to mitochondria, where it may target genes involved
in ATP synthesis-coupled electron transport.26 Of note,
miR-210 also suppresses cell-cycle progression by targeting
E2F327 and fibroblast growth factor receptor-like-1
(FGFRL1).28 miR-376a* was reported to repress phosphor-
ibosyl pyrophosphate synthetase-1 (PRPS1) involved in DNA/
RNA synthesis as well as threonine and tyrosine kinase (TTK)
essential for mitosis checkpoint.29 miR-494 was upregulated
in cells exposed to the DNA-damaging agent benzo[a]pyrene
(B[a]P) and was found to restrain cell cycle through CDK6
downregulation.30 Finally, miR-542-5p was upregulated in
senescent BJ cells31 and downregulated in neuroblastoma
and other solid tumors.32
Though not investigated in our study, it is tempting
to speculate that also senescence-downregulated miRNAs
contribute to the execution of the senescence program
(Supplementary Figure 4). In our study, several miRNAs
of the miR-17 family (miR-17-5p, miR-20a, miR-106b, and
miR-93) and miR-155 were downregulated both in replicative
and chemically induced senescence. Noteworthy, the miR-17
family33 and miR-15512 have already been involved in cellular
senescence. Hackl et al.11 reported that miRNAs of the miR-
17 family were downregulated in replicative senescence and
in organismal aging models, their decrease correlating with
increased levels of p21WAF1. miRNAs of the miR-17 family
(miR-17-92 cluster) were also upregulated in cancer34–37 and,
by targeting p21WAF1, they were able to confer resistance to
RAS-induced senescence.38 On the other hand, miR-155 was
downregulated in senescent WI-38 cells, causing increased
levels of TP53INP1, a protein acting in the TP53 growth arrest
pathway.12 Another link between miR-155 and cell prolifera-
tion comes from recent data showing that WEE1 (WEE1
homolog—Schizosaccharomyces pombe), a kinase that
blocks cell-cycle progression, is a target of this miRNA.39
In conclusion, we have identified a set of miRNAs, which,
being modulated by senescence-mediating conditions, and
being able to either facilitate DNA damage or regulate the
expression of several senescence mediators, may represent
critical components of the cellular senescence program.
Materials and Methods
Cell cultures. Normal primary human fibroblasts IMR90 were obtained
from American Type Culture Collection (Manassas, VA, USA). IMR90 were
grown in Dulbecco’s modified Eagle’s medium (DMEM) (Invitrogen, Groningen,
The Netherlands) supplemented with 10% (v/v) fetal bovine serum and 1%
penicillin/streptomycin (Invitrogen). Cultures were maintained at 37 1C in a 5% CO2-
humidified atmosphere. The population doubling level (PDL) was calculated by
using the formula DPDL¼ log(nh/ni)/log2, where ni is the initial number of cells and
nh is the final number of cells at each passage. The cells were used at 33 PDL or 58
PDL. More than 70% of PDL58 cells were positive for SA-b-gal. SA-b-gal was
assayed according to Dimri et al.14 Briefly, cells were washed twice with PBS, fixed
with 2% formaldehyde and 0.2% glutaraldehyde in PBS, and washed twice in PBS.
Then, cells were stained overnight in X-gal staining solution (1 mg/ml X-gal, 40 mM
citric acid/sodium phosphate (pH 6.0), 5 mM potassium ferricyanide, 5 mM
potassium ferrocyanide, 150 mM NaCl, 2 mM MgCl2).
Diethylmaleate (DEM) was purchased from Sigma Chemical Co. (St. Louis, MO,
USA) and used at a final concentration of 100mM in complete medium.9 Etoposide
(VP-16; Calbiochem, La Jolla, CA, USA) was used at 20 mM.15 Rapamycin was
obtained from Merck Chemicals Ltd (Nottingham, UK) and used at 10 nM. Rotenone
(Sigma Chemical Co.) was used at 5mM.
miRNA profiling. Total RNA was isolated using the mirVana MiRNA isolation
kit (Ambion, Austin, TX, USA) according to the manufacturer’s instructions.
The RNA was quantified by Nanodrop (Thermo Scientific, Wilmington, DE, USA)
and RNA integrity was analyzed by using the 2100 Bioanalyzer (Agilent
Technologies, Waldbronn, Germany). Global miRNA expression analysis was
performed by using TaqMan Low Density Arrays (TLDA)/Human microRNA Panel
v1.0 (Applied Biosystems, Foster City, CA, USA). This technology detects mature
miRNAs from the Sanger miRBase database. Each card/panel contains a primer–
probe set for 365 human miRNAs. Briefly, for each sample, 100 ng of total RNA was
converted into cDNA by multiplex reverse transcription (RT) using a primer pool
from the Taqman array kit (Applied Biosystems), according to the manufacturer’s
instructions. Then, miRNA levels were measured by quantitative real-time PCR
(qRT-PCR) using the 7900HT Sequence Detection System (Applied Biosystems).
Ct values were determined by using the automatic threshold in RQ manager v1.1
analysis software (Applied Biosystems). Data were analyzed by using the Sequence
Detection System software (v. 2.3) (Applied Biosystems). The endogenous control
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RNU48 was used to normalize the relative expression of each miRNA using the
DDCt method (Applied Biosystems User Bulletin No. 2—P/N 4303859).
Real-time PCR. Total RNA was isolated by using the mirVana MiRNA isolation
kit (Ambion) according to the manufacturer’s instructions. The RNA was quantified
by Nanodrop (Thermo Scientific) and RNA integrity was analyzed by the 2100
Bioanalyzer (Agilent Technologies). The TaqMan MiRNA Assay kit (Applied
Biosystems) was used to detect the expression of mature miRNAs. Briefly, 100 ng of
total RNA was reverse-transcribed (RT) at 16 1C for 30 min, 42 1C for 30 min, and
85 1C for 5 min in a 15-ml reaction volume. 2-ml volume of the RT product was used
for PCR in a final volume of 20ml. The PCR started with an initial denaturation step at
90 1C for 10 min, followed by 40 cycles of 95 1C for 15 s and 60 1C for 1 min. Small
nucleolar RNA RNU6 (Applied Biosystems) was used for normalization. PCRs were
performed in triplicate and fold changes were calculated by the following formula:
2(sample-1DCtsample-2DCt), where DCt is the difference between the amplification
fluorescent thresholds of the miRNA of interest and the RNA of RNU6.
Cell electroporation. PDL33 IMR90 cells were electroporated by using
Microporator MP100 (EuroClone, Milano, Italy) following the manufacturer’s
instructions. Briefly, 1 106cells were electroporated in 100ml of suspension buffer
(Neon transfection kit; Invitrogen) using 100 nM pre-miRNA (Ambion) according to
the manufacturer’s protocol adapted to IMR90 cells (pulse voltage: 1400 V for
10 ms, three pulses). Electroporation efficiency was tested by using the Cy3-labeled
negative control (Ambion) according to the manufacturer’s protocol and was
approximately of 75%. After electroporation, cells were seeded and viable cells were
counted at 96 h.
BrdU assay. For BrdU (5-bromo-2-deoxyuridine) incorporation assay,
electroporated cells were seeded on glass coverslips. Forty-eight hours after
transfection, cells were incubated for 24 h with BrdU (10 mM) and fixed. Coverslips
were incubated with an anti-BrdU and secondary fluorescein-conjugated antibody.
Coverslips were counterstained with Hoechst-33258, rinsed, and mounted in Moviol
on glass slides. The fluorescent signal was visualized with an epifluorescent
microscope (Axiovert 2; Zeiss, Gottingen, Germany), interfaced with the image
analyzer software KS300.
Immunofluorescence. For indirect immunofluorescence, cells were fixed in
4% paraformaldehyde and permeabilized with 0.2% Triton X-100 (5 min on ice), and
then incubated with a-H2AX phosphorylated on Ser139 (gH2AX) (R&D Systems,
Minneapolis, MN, USA) or a-trimethyl-Lys9 Histone H3 (Lake Placid Biologicals,
Lake Placid, NY, USA) for 1 h at room temperature. Coverslips were washed and
incubated with an Alexa-488 goat anti-rabbit antibody (Invitrogen) for 30 min at room
temperature. After 5 min of DAPI counterstaining, coverslips were mounted and
observed with a Zeiss LSM 510 META confocal microscope (Carl Zeiss,
Thornwood, NY, USA). At least 300 cells were counted in triplicate experiments.
COMET assay. The neutral comet assay was performed according to the
manufacturer’s recommendations (Trevigen, Gaithersburg, MD, USA).16 Slides
were incubated for 30 min in lysis buffer and for 40 min in alkaline solution (pH413),
and comet tails were generated by 15-min electrophoresis in TBE buffer at 20 V, at
4 1C. The slides were stained with SYBER Green and DNA migration was analyzed
by fluorescence microscopy (Leica DMS 4000B). Tail moment (TM), defined as the
product of the tail length and the fraction of total DNA in the tail (TM¼ tail
length% of DNA in the tail), was determined by using the software ‘Comet
Assay II’ (Perceptive Instruments, Suffolk, UK). A minimum of 100 cells per
experiment were analyzed. All experiments were performed in triplicate.
ROSmeasurement. Reactive oxygen species (ROS) were measured by using
the oxidation-sensitive fluorescent probe dihydroethidium (DHE; Sigma Chemical),
according to a published procedure.17 Briefly, 72 h after miRNA transfection, cells
were incubated for 30 min at 37 1C with 0.1mM DHE, harvested, and resuspended
in PBS. To determine fluorescence due to formation of superoxide anion, the cell
suspension was subjected to flow-cytometric analysis using a Becton Dickinson
FACSCalibur instrument (Becton Dickinson, San Jose`, CA, USA), after excitation at
488 nm (FL-2 channel). Results from at least 10 000 cells from each sample were
analyzed in triplicate using the CellQuest 3.2.1 software (Becton Dickinson).
Statistical analysis. Statistical analyses were performed by using
the GraphPad InStat software program (version 3.06.3, San Diego, CA, USA).
All P-values were two-sided and differences were significant when Po0.05.
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